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1. INTRODUCTION 
   
Siddha system of medicine is one of the oldest medical systems of India 
existed separately in early times. The system has flourished well in India for many 
centuries. Siddha system of medicine treats all types of diseases, especially the 
chronic diseases, which baffles and eludes even the modern sophisticated medicine. 
This system got its birth by 18 Siddhars headed by Siddha ‘Agasthiyar’. 
Siddhars were popular writers in Tamil in all branches of knowledge and many of 
their works were written in what is called High Tamil. They were men of high culture, 
intellectual and spiritual faculties combined with supernatural powers and intuitive 
intelligence acquired by yogic powers. The prevention and the cure of illness is the 
basic aims of all systems of medicine. 
Majority of the drugs from produce side effects especially on heart and kidney.  
Thus a clear cut cure is not seen in any of these techniques. The patient only gets 
temporary relief with reoccurrence of this disease with more severity. Hence it is not 
only well understood that Siddha drugs are safe without any side effects but its use 
may also helpful in controlling the severity of the disease. 
Among several respiratory diseases affective man, Bronchial asthma is the 
most common disabling syndrome. There are many ranges of drugs for bronchial 
asthma but short lives and produces more side effects, therefore there is a dire need to 
identify effective and safe remedies to treat bronchial asthma. Herbal medicines are 
being used by nearly about 80% of world populations. 
Bronchial asthma increasing in prevalence, which is a global phenomenon. 
Urbanisation, air pollution and environmental tobacco smoke increase the prevalence 
of asthma. A study on 20,000 children under the age of 18 years from 
1979,1984,1989,1994 and 1999 in the city of Bangalore showed a prevalence of 9%, 
10.5%, 18.5%, 24.5% and 29.5% respectively. The increased prevalence correlated 
well with demographic changes of the city (Indian journal of paediatrics, volume 69- 
April 2002) 
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Asthma is one of the major causes of human mortality. Moreover, existing 
drugs are not sufficient and produce numerous side effects. A safer alternative therapy 
is much necessary therefore siddha medicines could be useful. it shows tremendous 
effects over bronchial asthma. 
Thus as per siddha literature my drug Orithazhthamarai will be more effective 
for Bronchial asthma. No research works have be done for Bronchodilator activity in 
this plant. Here I will try to bring out clinical and preclinical evaluation of 
Orithazhthamarai chooranam for Bronchial asthma. 
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2. AIM AND OBJECTIVES 
 
Aim: 
Environment includes everything around us. Environmental diseases are 
closely related to the lung. Most of the air pollutants are invisible and affect the health. 
The air pollutants enter the body through exposed organs, commonest being the lungs. 
In today’s stressful life there is an increased exposure to number of 
immunological agents like allergens, dust, pollens, viruses, chemicals. The significant 
increase in the prevalence of allergic diseases has become a health problem of national 
and world –wide proportions. Bronchial asthma is one of the diseases among them. 
Roughly 10% of population suffers from asthma. Today numbers of synthetic 
antihistaminic drugs are available for symptomatic control of asthma along with their 
quit disturbing side effect.  The available treatment options for upper and lower 
respiratory tract allergic diseases have major limitations owing to low efficacy, 
associated adverse effects and compliance issues. Therefore the world is in search for 
suitable traditional remedies, which can serve mankind from dawn of civilization. In 
order to achieve this aim an attempt was made to establish the scientific validity for 
the bronchodilator and antihistaminic property of Orithazhthamarai chooranam 
(OTC). 
Objectives: 
The main objective of the present study is to high light the efficacy of 
Orithazhthamarai chooranam on Suvasakasam, the following methodology was 
adopted to evaluate drugs in OTC and its standardization studies. 
 Identification of  the drugs in the OTC 
 Preparation of  Orithazhthamarai chooranam as per classical literature 
 Collection of materials from the relevant literature   
 Phyto-chemical  study of Test drug 
 Physico chemical analysis of Test drug 
 Evaluation of the toxicity of Test drug 
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 Evaluation of the Anti-histaminic of Test drug on isolated Guinea pig ileum 
 Evaluation of Broncho dilator activity of test drug in experimental animal 
model 
 Clinical efficacy of Test drug on Suvasakasam (Bronchial asthma) 
 Statistical analysis 
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3. REVIEW OF LITERATURE 
 
3.1. BOTANICAL ASPECT: 
Ionidium suffruticosum (Orithazhthamarai) 
Bentham and Hooker classification: 
Kingdom  :  Plantae  
Division  :  Angiosperms 
Class   :  Dicotyledoneae  
Family   :  Violaceae 
Genus   : Ionidium  
Species  :  Suffruticosum 
Synonyms: 
 Hybanthus enneaspermus 
 Viola suffruticosa 
Vernacular names: 
Tamil   :  Orithazhthamarai, Rathanapurush 
Common name :  Spade flower 
Hindi   :  Ratnapurus 
Telugu   :  Nilacobari 
Malayalam  :  Kalthamara 
Sanskrit  :  Amburuha 
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Plant description:  
 A small suffrutescent perennial herb, 15-3 cm high, with many diffuse or 
ascending branches, glabrous or more or less pubescent. 
 Leaves linear or lanceolate  4- 5cm by3-8 cm, subsessile, entire or with 
serrated margins, stipules gland-tipped, subulate. 
  Flowers red, axillary and solitary. Pedicles shorter than the leaves, 6-12mm 
long, erect, slender; bracts small, above the middle of the pedicle. Sepals 2.5mm long 
lanceolate, very acute,keeled. 
 Petals unequal, the 2 upper ones oblong, slightly longer than the sepals, the 2 
lateral longer falcate, the lowest must larger than the others, having an orbicular or 
oborate limb with a long claw which is curved behind into a short spur. 
 Capsules about 6mm diameter, subglobose seeds ovoid, acute, longitudinally 
striate, yellowish white, about 1.5mm long. 
Medicinal uses: 
 The plant is bitter and acrid, easily digested, removes ‘kapha’ and ‘pitta’, 
asthma, urinary calculi, strangury pain, dysentery, vomiting, burning, wandering of 
the mind, urethral discharges, blood troubles, epileptic fits, cures cough, gives tones to 
breasts, alexeteric (ayumada). 
The plant is reported to posses tonic, diuretic and demulcent properties. 
The root is diuretic and administered as an infusion in gonorrhea and urinary 
affections. Sandals employ the root in bowel complaints of children. 
The leaves and tender stalks are demulcent and used as a decoction or 
electuary in conjunction with oil, they are employed in preparing a cooling liniment 
for the head. In Africa the plant is added to the food of pregnant and parturient 
women; an infusion is also given to children. 
The fruit in combination with other drugs has been recommended as an 
antidote to snake venom (Mhaskar and caius) and is useless in the treatment of 
scorpion sting (Lains and Mhaskar). 
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Chemical constituents: 
  Plant extract contains an alkaloid, aurantiamide acetate, β-sitosterol and 
isoarborinol (Asolkar et al., 1992). Nectar contains high amount of amino acids 
including valine, leucine and glutamic acid (Ghani, 2003). 
Distribution: 
 Agra, Bundelkhand, Bengal, almost throughout the Madras presidency, 
Gujarat, Khandesh, Carnatic, Ceylon. Tropic Asia, Africa and Australia. 
3.2. MATERIA MEDICA (GUNAPADAM ASPECT): 
Orithazhthamarai (Ionidium suffruticosum) 
Synonyms  :   Sooriyagandhi, rathanapurus  
Part used  :  Whole plant 
Suvai   :  Inippu 
Thanmai  :  thatpam 
Pirivu   :  Inippu 
 It is a small perennial herb. It has mucilage in taste. 
Action: 
 Nutritive 
 Aphrodisiac 
 Laxative 
 Diuretic 
 Lactagogue 
 Demulcent 
 Tonic    
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ெபா¢ண 
தா¢ைவ­zடாt| தனேமக{ைத{ ெதாைலt 
ஆதரவா ேமனt கழத¯x-சீதேபா 
சீ¾த{ தாமைரவா ெசய மடவனேம? 
ஓ¾த{ தாமைரைய ­z. 
      (பதா{த ணசி|தாமண) 
It increases the consistency of the semen and regains strength of the body. It 
gives relieves from dysentery. 
©zட¾க ந}ைம ெபா¯|தெவ}றா ேலேடகல 
©zட¾க ந}ைம ©ைனதந-©zட¾க 
நா´திர ¬t நலிtேகல நாவேயா 
நா´திர ¬tப{¢ நா 
      (ேதைரய யமகெவzபா) 
The whole plant with pachaikarpooram and korosanam is mixed with cow’s 
ghee and use externally cures megavettai, wounds and diseases related to head. 
  ர{ைதt க|¢ வாச{ைத~ ேபாtகி 
­ர{ைத ­ட´t தº- ப¯{தºட 
வாடாத§ தின« ைவ{தt ேமக{ைத 
ேயேடக ேகாகனேம. 
It cures fever and bronchial asthma and gives strength to the body and also 
administered for increases body weight due to megam. 
Other uses: 
• When taken every morning as kaayakalpa, increases strength to the 
body. 
• It oxidizes karattukendhi parpam. 
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• Its leaf along with milk if taken regularly for 40 days gives vigor and 
vitality. 
• This gives relief from urinary infections. 
• Flowers are used in bilious affection lung troubles etc. 
Drugs and other preparations which contains Orithazhthamarai: 
 
1. Orithazhthamarai karpam: 
 The body cleansed using an laxative, then finely grinded orithazhthamarai 
paste 4.2g and mixed with 84ml of cows curd and consumed that morning. For next 
consecutive 21 days orithazhthamarai paste should be increased 2.1g daily. From 22nd 
day onwards measurement of orithazhthamarai paste decreased by 2.1g daily and 
consumed.  
It cures megavettai and strengthens the body. 
2.Nayana viyadhi poovirku marunthu 
Ingredients: 
 Athimathuram 
 Ventha mandai odu 
  Orithamarai ver 
 Thuththam 
 Kuthiraippal  
 Vetpula verppattai 
Preparation: 
 The drugs are ground with honey and sieved and used as eye medication. 
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3. Santhanathi urundai 
Ingredients: 
 Izhaitha santhanam 
 Orithazthamarai ver 
 Sanbagapoo 
Preparation: 
 The drugs aare ground with breast milk and made pills and administered with 
breast milk for eye medication. This pill is to be used only after 15 days. 
3. Rathinathi maathirai 
Ingredients: 
 Muthu 
 Thurusu 
 Orithzhthamarai ver 
 Pachai karpooram 
 Thutham 
 Nellivatral 
Preparation: 
 These drugs are ground with juice of Eclipta prostata and made pills then used 
as eye medication with either breast milk or juice of the bark of palm. This pill to be 
used only after 3 years. 
Other preparations: 
 Nayana rogathirku urundai 
 Nayana paduvanuku marunthu 
 Pachai urundai 
 Maha nirkundi thailam 
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3.4. SIDDHA ASPECT OF THE DISEASE 
 IRAIPPIRUMAL (Bronchial asthma) 
Other names: Izhuppu noi, swasakaasam. 
Nature of the disease: 
 The disease does not fall under any particular type and the exact cause is not 
known. It produces chest pain as if the chest is constricted. There will be 
breathlessness with difficulty in inspiration as well as expiration. The expiratory noise 
will sound like musical instruments such as flute, lute and veena. Further, even if 
attempt is made naturally for expectorating the sputum from the chest, it does not 
come out. 
Genesis of the disease: 
Ôகாெப¯t ணºெபா¯ தzண மாற 
  க¯தி¯ம மிகவா|தி ள|த கா² 
மாெச¢ நாேதா² வ²{¢u காvச 
  ம|தன «யநிைலய லக தாuக 
ஏசீத ேபதிவட பாz ©ைகக 
  இலகிய ெநலாதிமணv ைண­y ெசல 
ேமவழிய சிலவ¾§ மிைர~பா ேநா­ 
 «னவக வளப னாேர 
(ைகெய¸{¢~பரதி) 
 
It is considered that the disease may develop due to the following factors: 
1. The body strength is reduced because of unwanted foods and acts. In such 
condition the disease develops when food which can aggravate the activity of 
kapha are taken or by any other act which aggravate the same. 
2. It may also develop as a result of allergy due to grass, plantage, rice and ragi. 
3. By smelling some foul smelling substances which are not good to the body. 
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Prodromal symptoms: 
“மாப வலாவரz மz மி ெந¾ய 
 ேச|¢ வலி{த திணறஃ- தா¬v 
 உ~ப வயறி ´¯வ¢ேவ «றியாv 
 ெச~பைர~© ேநாtகிதைன{ ேத”. 
      (®கி ைவ{திய சி|தாமண) 
 Generally, those who have suffered from this disease chronically can recognize 
the prodromal symptom and also the intensity of the disease allergic to them. The 
patient on smelling the food and air which are allergic to him, will develop watery 
discharge from the nose, sneezing, chest pain as if the chest constricted. Blockage of 
natural respiration, pain at the region of ribs with breathlessness distension of 
abdomen and sweating of body are other symptoms of the disease. 
 In ancient Tamil book, the disease has not been mentioned separately. But it 
has been mentioned as two separate entities, viz. under cough disease as ‘Swasa kasa’ 
and under fire disease as ‘Swasa pitta’. The signs and symptoms of these two have 
also been mentioned. However, other text books have classified the disease as 5 types. 
4 of them are associated with intensity of breath. The description of them as follows: 
Types: 
• Vali iraippu 
• Iya iraippu 
• Iyavali iraippu 
• Mukktra iraippu 
• Melnokku iraippu 
Ôசி²ேப ¾ைர~© திணற ம|தார 
வ¯ேம லிைர~ைப| தி}மாz© 
It is also classified as, 
• Sitriraippu 
 
 
 
PG Gunapadam departmant  Page 13 
 
• Periraippu 
• Thinaraliraippu 
• Manthara iraippu 
• meliraippu 
The description of them as follows: 
Signs and symptoms: 
“td;ikaha;f; Nfhiofl;b ,Ukp tPOk; 
khehfk; NghyNt thq;FQ; Rthrk; 
jpz;ikaha;r; nrUkYz;lh kbf;f bf;FQ; 
rPuz kpyhkNy tapW %Jk; 
ed;ikaha; ehrpaJ jzy;Ngh yhFk; 
eype;Jlk;G tw;wp tUq; FuYq; fk;Kk; 
cz;ikah Az;zhf; fpY}Wq; Nfzp 
Aoe;JNk Rthrfh rj;jp ndhg;Ng”. 
     -a+fp itj;jpa rpe;jhkzp 
 
Vatha asthma disease (Vali iraippu noi): 
 The activity of vatha dhosha gets aggravated due to, intake of food which is 
not digested easily, wandering in the hot sun rays, eating of substances such as tubers. 
As a result of excessive activity of vatha dosha, body strength is reduced. The patient 
may feel a sensation as if nothing is inside the chest. Inspite of all these effects, the 
disease does not cause severe hardship to the patient. The disease is also called as 
‘Soothira suvaasam’. 
Kapha asthma (Iya iraippu noi): 
 The disease is caused by the excessive activity of kapha, foods which 
aggravate the kapha and also on exposure to rain and chill air. The excessive activity 
of kapha in the body also affects in the head, causes nasal obstruction and watery 
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discharge from the nose. But these symptoms will subside within few hours. The other 
clinical features are: 
1. The patient will have a sensation of constriction type of chest pain with 
difficulty in expiration. Sometimes patient may fear that may even die in view 
of his inability to breath. When the patient coughs a bit and mucus is 
expectorated out, he may have relief. If the patient does not cough and there is 
no expectoration of sputum, patient will experience severe difficulty in 
expiration and he may not be even in a position to lie on the bed and stand. 
2. There will be also sweating over the forehead, blackening of face, chillness of 
limbs. The eyes may appear as if swollen due to breathlessness. Dryness of 
tongue, shivering of body, dyspnoea and inability to sleep in the bed are other 
features of the disease. The disease is also known as ‘Thamaraga suvaasam’. 
Vatha kapha asthma (Iyavali iraippu): 
 In this disease, as the kapha and vatha dosha are deranged together, the signs 
and symptoms will be severe. In addition to the signs and symptoms of Iraippu noi, 
the following clinical features may be seen due to the derangement of vatha dosha and 
its association with udhana vaayu: inability breath in and breath out with intermittent 
dyspnoea, distension of due to retention of stool and urine, dryness of tongue, 
congestion eyes with pain, pain at the region of reproductive organs, sweating, 
incoherent talk, feeling sad, occasional behavioral disturbance, giddiness, sensation of 
rotation of body, etc. some people call this as ‘Vichinna suvaasam’. 
 Tridosha asthma (Mukkutra iraippu noi): 
 In this disease, all the three will aggregate together. In view of this the upward 
directional and downward directional, diffuse directional and central directional 
factors are deranged one by one. In addition, the severe body structures will also be 
reduced in strength and this results in severe Iraippu noi. The prodromal symptoms are 
dyspnoea, astonishment, shivering of the body and feeling sad. Later, wheezing may 
develop. The breath sounds will be similar to a big cows sound. The other features of 
the disease pain in the chest is tied tightly, giddiness occurs frequently, retention of 
urine and with distention of abdomen, incoherent talk, perplexion, decreased activity 
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of five senses, pain throughout the body, excessive sweating in the forehead. This is 
also called as Maghaa suvaasam.  
Upward asthma ( Melnokku iraippu noi): 
 If any of the disease mentioned above continues for many days without 
response to treatment, becomes upward directional the udhana vaayu loses its strength 
and be in such a situation, expiration may not be possible. The patient will develop 
dyspnoea and his eyeball will be prominent. There may be dryness of mouth. Patient 
may be unable to speak; he may appear astonished and will not lie down on the bed; 
he may look upward as if the mouth opened; he may also attempt to exhale. If proper 
treatment is given at this juncture he may survive. Otherwise, he may fall unconscious 
with darkening of face and may die with mouth open. 
 In addition to the five types of iraippu noi mentioned above, it has been 
mentioned in the modern medical text books that wheeze will also present in 
Thamaraga noi and also urinary interruption and strangury. 
Other factors affecting the disease: 
  Ôகா ெப¯t zºெபா² தzண மாற 
  க¯தி¯ம மிக வா|தி ள|த கா² 
 
  Ôப{தேம மி|தா லைள 
  ெபல{¢ நி 
      (®கிைவ{திய சி|தாமண)  
 
• Eating foods which will induce excessive kapha. 
• Exposure to chill air. 
• Living in the mountains. 
• Walking in the dew. 
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In addition, the kapha dosha gets deranged and in association with pitha dosha, 
produced inflammation of the throat, nose, palate and lungs, resulting in secretions of 
mucus and fever occur. 
The udhana vaayu which rises from the chest (anaagatham) will also become 
aggressive. 
Some authors opine that the disease develops due to vatha dosha. It is 
considered that their opinion may be true as there is block in the passage of vatha 
through respiratory organ.  
As already stated above, the ancient physicians have opined that the disease 
mainly develops due to kapha dosha. It is considered that this opinion is also true as 
the phlegm blocks the lumen of the respiratory tract and prevents the entry of air. 
நா: 
Ôகபமலா¢ காச வாச வாரா¢ 
 
Ôபாuகான வாத{தி ேச{¢ம நா 
ப¾ச{தா திமிேமº «ைளvச லா 
தuகான இ¯ம´ட} ச}ன ேதாட 
ேச|தவட ெவைல இ¯{ ேதா 
ஓuகான ர«டேன வாச காச 
உzடா ெவேநாt «²தி தாேன 
(ப .சி நா) 
 ஐய நா மி|தா´, வள ஐய ெதா|த{தா´, வா­வா 
£zட~பyட ப{த மிதியா´, ஐய ப{த ெதா|த{தா´ இைர~© ேநா 
உzடா. 
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Other factors in the genesis of the disease: 
 Sputum: If the sputum is found excessive in quantity, light weight and foamy, 
it is considered that the disease developed due to kapha dosha. 
 If the sputum is black in color, hard and with smell of flesh, it will denote 
kapha dosha. 
 If it is found white like pus and mixed with yellow color, it will denote pitha 
dosha. 
3.5. MODERN ASPECT OF THE DISEASE 
BRONCHIAL ASTHMA 
Definition: 
 Asthma is an ancient Greek word meaning “panting or shortdrawn breath”. It 
is the most troublesome of respiratory diseases. 
 Asthma is a common chronic inflammatory condition of the lung airways 
whose cause is incompletely understood. Symptoms are cough, wheeze, chest 
tightness and shortness of breath, often worse at night. 
It has 3 characteristics: 
• Airflow limitation which is usually reversible spontaneously or with 
treatment. 
• Airway hyper-responsiveness to a wide range of stimuli. 
• Inflammation of the bronchi with eosinophils, T lymphocytes and mast 
cells with associated plasma exudation, oedema, smooth muscles 
hypertrophy, mucus plugging and epithelial damage. 
In chronic asthma, inflammation may be accompanied by irreversible airway 
limitation. 
Prevalence: 
 In many countries the prevalence of asthma is increasing, particularly in the 
second decade of life where this disease affects 10-15% of the population. There is 
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also a geographical variation, with asthma being common more developed countries, 
some of the highest rate in New Zealand, but being much rarer in Far Eastern 
countries such as China and Malaysia, and in Africa and Central and Eastern Europe. 
 Between 1982 and 1994, the national prevalence of asthma in India increased 
66% overall. It increased upto 73% among children/young adults of age 18 years, 
affecting 15 million people (nearly five million under the age of 18).  
 Long-term follow-up in developing countries suggests that the disease become 
more frequent as individuals become more ‘westernized’.  Studies of occupational 
asthma suggest that a high % of the work force, perhaps up to 20%, may become 
asthmatic if exposed to potent sensitizers. 
Current estimates suggest that 300 million people world-wide suffer from 
asthma and an additional 100 million may be diagnosed with asthma by 2025.  
In childhood, asthma is more common in boys, but following puberty females 
are more frequently affected. The socio-economic impact of asthma is enormous, 
particularly when poor control leads to days lost from school or work, hospital 
admissions and, for some patients, a premature death. 
Factors that triggers asthma:   
 Asthma episodes can be triggered by various factors, known as allergens, 
infections, environmental pollutant and non specific stimuli such as exercise and 
emotional states.  
In adults 50-70% of people with asthma suffer from allergies. In children 
under 3 years of age, viral infections are the most common trigger. After 3 years of 
age, the allergies also begin to play an increasing role as a trigger.  After 20 years of 
age, occupational exposure to any toxic substances and allergens also can be important 
triggers. 
 
  
 
 
 
PG Gunapadam departmant  Page 19 
 
Classification: 
Asthma is broadly divisible into 2 groups. 
• Extrinsic asthma 
• Intrinsic asthma 
Extrinsic in which there is an external factor which can be detected or inferred and 
intrinsic (non-extrinsic). Extrinsic is much more common. 
 Extrinsic             Intrinsic 
IgE raised in at least 70%     IgE normal or low 
Usually atopic subjects     Non-atopic subjects 
Onset in early years      Onset in middle age 
Often intermittent       usually constant 
Family history of atopy     Family history of asthma 
Etiology and pathogenesis:  
 Variable narrowing of the peripheral airways (broncho-constriction) is due to 
one or all of the following: 
• Contraction of brochial smooth muscle 
• Oedema of the mucous membrane 
• Mucus within in the lumen 
Bronchoconstriction is a normal response to noxious stimuli such as cigarette 
smoke and sulphur dioxide-also alteration in the concentration of oxygen and carbon 
dioxide in the lumen. These responses are either direct or mediated reflexly by the 
vagus nerve. Normal bronchial tone can be demonstrated in bronchial mucus 
musculature by a decrease in airway resistance after administration of atropine and 
isoprenaline. All these physiological responses are very small in degree and are not 
felt by a normal individual. 
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The pathogenesis of bronchoconstricton in asthma is not yet fully understood. 
Although it is known that various agents such as histamine, bradykinin, slow reacting 
substance in anaphylaxis (SRS-A), prostaglandins, and hydroxytryptamine are 
librated, there are other as yet unidentified substances which are released in the 
bronchial wall probably from mast cells too- all of these agents with known and 
unknown cause  bronchoconstricton, and their reactive important is uncertain. Many 
factors appear to be responsible either directly or indirectly for release of these 
mediators amongst which are exercise, allergy, infection, but the mode of release is 
conjectural. Other factors, for instance psychological or pharmacological, may 
potentiate bronchoconstricton. 
Clinical features:  
 Patient experiencing asthma exhibit symptoms that are virtually identical to 
those suffering from airflow limitation caused by COPD. Wheezing attacks and 
episodic shortness of breath are almost universal. Symptoms are usually worse during 
a night. Cough is a frequent symptom that sometimes predominates and is often 
misdiagnosed as being due to bronchitis. Nocturnal can be presenting feature. 
 There is a tremendous variation in the frequency and duration of the attacks. 
Some patients have only one or two attacks a year that last for a two hours, whilst 
others have lasting for two weeks. Some patients having chronic symptoms. Attacks 
may be precipitated by occupational sensitizers, viral infections, atmospheric 
pollutions, cold air, drugs (oral/topical) and irritant dusts, vapour and fumes.  
Clinical grading of severity of asthma: 
1A Patient able to carry out housework or job with moderate difficulty, sleep 
occasionally disturbed. 
1B Patient only able to carry out housework or job with great difficulty, sleep 
frequently disturbed. 
2A Patient confined to chair or bed but able get up with moderate difficulty, sleep 
is disturbed with little relief from inlaler. 
2B Patient confined to chair or bed and only able to get up with great difficulty. 
Unable to sleep. Pulse rate over 120/minute. 
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3 Patient totally confined to chair or bed. No sleep. No relief from inhaler. Pulse 
rate over 120/minute. 
4 patient immobilized and completed exhausted. 
Status asthmaticus: 
It is prolonged asthma, unrelieved by treatment, which may threaten life. In 
status asthmaticus there is increasing obstruction of smaller airways by tenacious 
mucus plugs infiltrated with eosinophils. These plugs tend to be laminated due to 
excessive layering of mucus. Sometimes the mucus is aspirated peripherally and in 
fatal cases there is detachment of the superficial lining of the mucus membrane 
together with thickening of the basement membrane. 
It is medical emergency patient is hypoxic and cyanosed due to severe 
bronchospasm. It is characterized by tachycardia, tachypnoea, sweating, altered level 
of consciousness, and an inspiration-expiration ratio of 1:3 or 1:4. 
Tests and diagnosis: 
The diagnosis of asthma is usually straightforward and is based on the history 
and examination and established by simple tests of ventilator y capacity (i.e. FEV1 or 
PEF) before and after a bronchodilator. Investigations may help to confirm diagnosis, 
to document the degree of reversibility, and to exclude complicating factors. 
Blood tests: 
 The most important abnormality on haematological examination is the 
presence of eosinophilia, a feature of both allergic and intrinsic asthma. 
Lung function tests: 
 Central to the diagnosis of asthma is the demonstration physiologically if 
airflow limitation which is variable.  
Skin tests: 
 In young atopic asthmatics, routine skin testing is unnecessary if the diagnosis 
is clear and there is no history of allergic exposure.  
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Diagnosis:   
Clinical diagnosis 
• Episodic asthma: Paroxysms of wheeze, dyspnoea and cough, 
asymptomatic between attacks. 
• Acute severe asthma: Upright position, use accessory respiratory muscles, 
can’t complete sentences in one breath, tachypnea > 25/min, tachycardia > 
110/min, PEF < 50% of pred or best, pulsus paradoxus, chest 
hyperresonant, prolonged expiration, breath sounds decreased, inspiratory 
and expiratory rhonchi, cough.  
• Life-threatening features: PEF < 33% of pred or best, silent chest, 
cyanosis, bradycardia, hypotension, feeble respiratory effort, exhaustion, 
confusion, coma, PaO2 < 60, PCO2 normal or increased, acidosis (low pH 
or high [H+]). 
• Chronic asthma: Dyspnea on exertion, wheeze, chest tightness and cough 
on daily basis, usually at night and early morning; intercurrent acute severe 
asthma (exacerbations) and productive cough (mucoid sputum), recurrent 
respiratoryinfection, expiratory rhonchi throughout and accentuated on 
forced expiration. 
 Physiological diagnosis 
• Demonstration of variable airflow obstruction with reversibility by means of 
FEV1 and PEF measurement (spirometer and peak flow meter). 
1. FEV1 < 80% of pred – PEF < 80% of pred. 
2. Reversibility: A good bronchodilator response is a 12% and 200ml 
improvement in FEV1 20 min after inhalation of 200ug salbutamol (2 
puffs). 
3. Diurnal peak flow variation: Normal variation: Morning PEF 15% 
lowers than evening PEF. With asthmathis variation is > 15% (morning 
dipping). 
4. Provocation studies: 
 (a) Exercise: A 15% drop in FEV1 post exercise indicates exercise 
induced asthma. 
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(b) Metacholine challenge: A 20% reduction in FEV1 at Metacholine     
concentrations < 8mg/ml indicates bronchial hyperreactivity. This is 
expressed as a PC20 value of eg 0.5mg/ml (= a 20% reduction in FEV1 
at 0.5mg/ml Metacholine). 
Immunological diagnosis 
• Skin pricks wheal and flare response. 
• IgE  
• Peripheral blood and sputum eosinophilia 
• Chest X Ray may be normal between attacks, Rule out other causes of 
wheezing. 
Differential diagnosis: 
• Chronic bronchitis 
• Emphsema  
• Cystic fibrosis 
• Foreign body aspiration 
• Cardiac failure 
• Pulmonary embolism 
• Pulmonary eosinophililia 
 
3.6. LATERAL RESEARCH: 
 
Evaluation of hypolipidemic activity of various extracts from whole plant of 
Ionidium suffruticosum (ging.) (family: violaceae) in rat fed with high fat diet. 
d.satheesh kumar and a. kottai muthu 
The present study was designed to investigate the hypolipidemic effect of 
different extracts from whole plant of Ionidium suffruticosum (Ging.) The elevated 
levels of total cholesterol, triglycerides, phospholipids, LDL-C and VLDL-C were 
observed in rats fed with high fat diet (group II). After treatment of methanolic extract 
of Ionidium suffruticosum (200mg/kg/day) showed a significant (p<0.001) decrement 
in body weight, plasma and tissue total cholesterol, triglycerides, phospholipids, 
plasma LDL-C and VLDL-C along with an increase in plasma HDL-C when 
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compared to HFD rats (group II). The similar result was not found in other two extract 
treatment groups. The methanolic extract of Ionidium suffruticosum could 
protectagainst atherosclerosis and decrease the atherogenic index than that of other 
extract treatment groups. 
CNS activity of aerial parts of Hybanthus enneaspermus mull 
d.m.kar*, l.maharana, s.p.rout, department of pharmacology, school of pharmaceutical 
sciences, siksha ‘o’ anusandhan university, kalinga nagar. 
 Role of ethanolic and aqueous extract of aerial parts of Hybanthus 
enneaspermus in animal models of general behavioral profiles, maze test (plus, Y-
maze), barbiturate and alcohol-induced sleeping time, tail suspension test, despair test, 
head dip test, locomotor activity, motor coordination test was studied. 
In vitro free radical scavenging activity of various extracts of whole plant of 
Ionidium suffruticosum (Ging) 
Author: D.Satheeshkumar, A. Kottai Muthu*and R. Manavalan 
Journal: Journal of Pharmacy Research ISSN: 09746943 Year: 2011 Volume: 4 Issue: 
4 Pages: 976-977 Provider: DOAJ Publisher: Association of Pharmaceutical 
Innovators  
The in vitro free radical scavenging activity whole plant of Ionidium 
suffruticosum (Ging) obtained by sequential extraction with different polarities of 
solvents, was evaluated by three different in vitro methods: DPPH, Iron chelating 
activity and total phenol content assessment assay. The methanolic extract of Ionidium 
suffruticosum showed best DPPH radical scavenging activity;IC50 value 170 μg/ml 
more effective than that of standard ascorbic acid IC50 value 480 μg/ml. The iron 
chelating activity of methanolic extract of Ionidium suffruticosum was found better 
result than that of other two extracts. The high phenolic content was found in 
methanolic extract of Ionidium suffruticosum than that of other extracts. The high 
antioxidant capacity observed for methanolic extract of Ionidium suffruticosum 
suggested that this plant could be used as an additive in the food industry providing 
good protection against oxidative damage. 
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In-vivo antioxidant and lipid peroxidation effect of whole plant of ionidium 
suffruticosum (ging.) in rats fed with high fat diet 
D.satheeshkumar, a. Kottai muthu*and r. Manavalan 
Department of pharmacy, Annamalai University, Annamalai Nagar-608 002, India , 
Email: arthik03@yahoo.com 
Received: 26 January 2012, Revised and Accepted:16 April 2012 
The objective of the present investigation was to evaluate the in vivo antioxidant and 
lipid peroxidation effect of various extracts from whole plant of Ionidium 
suffruticosum (Ging.) in rat fed with high fat diet. Various extracts (Petroleum ether, 
Ethyl acetate and Methanol) of Ionidium suffruticosum (200 mg/kg body weight) was 
administered orally to rats fed with high-fat diet (HFD) daily for 9 weeks and the 
tissue (liver, heart and aorta) samples were collected at the end of experimental period. 
High fat diet rats showed significantly (P<0.001) reduced the levels of tissues 
enzymatic antioxidant and non enzymatic antioxidant (Glutathione). After 
administration of methanolic extract of Ionidium suffruticosum in high fat diet rats 
were showed significantly (P<0.001) increased the levels of antioxidant enzymes such 
as Superoxide dismutase (SOD), Catalase (CAT), Glutathione peroxidase (GPx), 
Glutathione reductase (GR) and incresed the level of non enzymatic antioxidant 
Glutathione (GSH) when compared with HFD rats (Group II). Similar result was not 
observed in other two extract treatment groups. Based on the results, we concluded 
that the methanolic extract of Ionidium suffruticosum is a significant source of natural 
antioxidant, which might be helpful in preventing the progress of various oxidative 
stresses. 
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4. MATERIALS AND METHODS 
Materials: 
Orithazhthamarai chooranam was taken as a single herbal drug for 
Suvasakaasam (Bronchial asthma) from the siddha literature. The preparation was 
collected from “Gunapaddam, first part Mooligai Vaguppu written by K.S.Murugesa 
Mudaliyar”. 
Collection of the drug: 
Orithazhthamarai plant was collected from Erode, Tamilnadu during the 
month of June 2012, and from Chennai and surrounding area during the month of 
November 2012. 
Identification and Authentification of the drug: 
The test drug Orithazhthamarai was identified and authenticated by 
Gunapadam Experts, P.G Gunapadam branch, GSMC, Arumbakkam, Chennai-106. & 
Director Plant Anatomical Centre. Sample of the herb kept in PG Gunapadam 
department for future reference. 
4.1. PREPARATION OF THE DRUG: 
 Orithazhthamarai plants were collected, and then dried in shadow, and the 
dried plant is grinded and sieved to make a fine powder. 
Purification of the chooranam : 
      The chooranam   is purified by pittavial method.  Pittavial is the best method of 
purification of chooranam. The  chooranam  is  mixed  with  of  milk .A vessel half 
filled with  equal  amount  of  milk and  water  is  kept  in a  stove  and  the  vessel  is  
covered  with  cloth.  The prepared chooranam is kept in the cloth over the vessel. 
Then it is covered with lid and heated.  By this process the chooranam is purified  
 
Preservation 
    The   purified  chooranam  was  stored  in a  clean,  air  tight  glass  container. 
because the life time of   the  chooranam  is  only for  3  months and  it  was used  
within  that  period. 
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Fig.1 Orithazhthamrai (Ionidium suffruticosum) 
 
 
Fig.2 Dried orithazthamarai 
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Fig.3 Orithazhthamarai chooranam 
 
 
 
Administration of the Drug: 
 Form of the medicine  :  Chooranam 
 Route of Administration :  Enteral 
 Dose    :   1gm 
 Anubanam (Vehicle)  :   Honey 
 Time of Administration :   Two times a day, after food 
 Duration   :   1-3 months 
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4.2. STANDARDIZATION OF DRUG  
The standardization of the drug is to establish the consistent biological activity, 
consistent chemical profile standardization is the first step. Standardized herbal 
products of desirable quality which containing well-defined chemical constituents are 
required for clinical trials and to provide consistent effective therapeutic index.  
Pharmacological properties of siddha herbal or herbomineral formulation 
depend on active phytochemical constituents present in it. Development of authentic 
analytical methods which can reliably profile the phytochemical composition, 
including quantitative analyses of bioactive compounds and other constituents, 
without consistent quality of a phytochemical mixture, a consistent pharmacological 
effect is not expected. 
4.2.1. PHARMACOGNOSTIC STUDY 
 
Materials and methods for anatomical studies: 
Collection of specimens:  
The plant Orithazhthamarai for the proposed study was collected from Erode, 
Tamilnadu Dt. Care was taken to select healthy plants and normal organs. The 
required samples of different organs were cut and removed from the plant and fixed in 
FAA (Farmalin-5ml+ Acetic acid-5ml + 70% Ethyl alcohol-90ml).After 24 hrs of 
fixing, the specimens were dehydrated with graded series of tertiary –Butyl alcohol as 
per the schedule given by Sass, 1940. Infiltration of the specimens was carried by 
gradual addition of paraffin wax (melting point 58-60 C) until TBA solution attained 
super saturation. The specimens were cast into paraffin blocks. 
Sectioning: 
The paraffin embedded specimens were sectioned with the help of Rotary 
Microtome. The thickness of the sections was 10-12 μm. Dewaxing of the sections 
was by customary procedure (Johansen, 1940). The sections were stained with 
Toluidine blue as per the method published by O’Brien et al. (1964). Since Toluidine 
blue is a polychromatic stain. The staining results were remarkably good; and some 
cytochemical reactions were also obtained. The dye rendered pink colour to the 
cellulose walls, blue to the lignified cells, dark green to suberin, violet to the 
 
 
 
PG Gunapadam departmant  Page 30 
 
mucilage, blue to the protein bodies etc. wherever necessary sections were also 
stained with safranin and Fast-green and IKI(for Starch) 
For studying the stomatal morphology, venation pattern and trichome 
distribution, paradermal sections (sections taken parallel to the surface of leaf) as 
well as clearing of leaf with 5% sodium hydroxide or epidermal peeling by partial 
maceration employing Jeffrey’s maceration fluid (Sass, 1940) were prepared. 
Glycerine mounted temporary preparations were made for macerated/cleared 
materials. Powdered materials of different parts were cleared with Naoh and mounted 
in glycerine medium after staining. Different cell component were studied and 
measured. 
Photomicrographs: 
Microscopic descriptions of tissues are supplemented with micrographs 
wherever necessary. Photographs of different magnifications were taken with Nikon 
labphoto 2 microscopic Unit. For normal observations bright field was used. For the 
study of crystals, starch grains and lignified cells, polarized light was employed. 
Since these structures have birefringent property, under polarized light they appear 
bright against dark background. Magnifications of the figures are indicated by the 
scale-bars. Descriptive terms of the anatomical features are as given in the standard 
Anatomy books (Esau, 1964). 
Microscopic features: 
Leaf: 
 The leaf consists of prominent midrib fairly thick lamina. The midrib is 
prominently conical on the adaxial side and wider abaxial part (fig1.1). The midrib is 
400µm thick. The adaxial cone is 150µm wide and the abaxial part is 250µm wide, the 
epidermal layers of midrib consist of small, thick walled cells. The palisade zone of 
the lamina is horizontally trans current across the adaxial part of the midrib. The 
abaxial part consists of wide, circular thin walled compact parenchyma cells. These is 
a single, small collateral vascular strand which consists of rows of thick walled xylem 
elements and small clusters of phloem elements. 
Lamina: 
 The lamina is about 160µm thick. It is dorsiventral with much dilated elliptical 
adaxial epidermal cells. The abaxial epidermal layer is stomatiferous. The palisade 
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tissue consists of two layers of narrow cylindrical less compact columnar cells. The 
spongy parenchyma includes four layers of short elliptical cells arranged in horizontal 
layers simulating the palisade tissue (fig.6). 
Stem: 
 The stem is circular and is 1.8mm thick. It consists of intact epidermal layer of 
Squamish thick walled cells. At certain regions of the stem, there is seen a narrow 
periderm of 3 or 4 layers of tabular cells. The cortex is wide and intact. Comprising of 
about 7 layers of circular wide parenchyma cells with narrow inter cellular spaces. 
The inner boundary of the cortical zone is marked by a thin, discontinuous of 
selesenchyma elements which are thick and liquefied. The phloem region narrow and 
continuous and the phloem elements are in compact radical rows. The xylem cylinder 
hollow and thick. It encloses with pith. The xylem includes long radial multiple of 
narrow, thick walled vessels and thick walled liquefied fibres. The vessels angular in 
sectional outlone(fig.8) and are 20µm in diameter. The pith wide and parenchymatous. 
The pith cells are circular and less compact. 
Root: 
 Fairy old root measuring 1.4mm thick was studied. It consists of thick 
periderm and well developed vascular cylinder (fig3.1,2). The periderm in thickness 
all around the root. It is 7 or 8 layered, the cells homogenous, tabular in shape 
suberised (fig4.1). 
 Inner to the periderm does a distinct zone of cortex comprise 5 or 6 layers of 
loosely arranged spherical parenchyma cells. 
 The vascular cylinder consists of a circular, solid central core of secondary 
xylem ensheathed by wide cylinder of secondary phloem. Secondary xylem consists 
of mostly solitary circular or angular vessels. The cells are narrow in the centre and 
the diameter of the vessels increases gradually towards the periphery (fig 4.2). The 
vessels are up to 40µm in diameter. The xylem fibres have wide lumen, thick liquefied 
secondary walls. Secondary phloem includes regular radial files sieve-elements. The 
elements narrow thick walled cells (fig 4.1). 
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Fig.4. T.S of leaf through midrib    Fig.5. T.S of midrib-enlarged  
      
Fig.6. T.S of Lamina                             Fig.7. T.S of stem-Entire view 
      
Fig.8. T.S of stem & sector enlarged  Fig.9. T.S of thin root 
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Fig.10. T.S of thick root 
 
Fig.11. T.S of root and sector enlarged 
 
Fig.12. T.S of root and sector enlarged 
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4.2.2. PHYSICO-CHEMICAL ANALYSIS 
 
Scanning Electron Microscope (SEM): 
 
Resolution : 1.2 nm gold particle separation on a carbon substrate 
Magnification: From a min of 12x to greater than 1, 00,000 X 
The Scanning Electron Microscope (SEM) is a microscope that was electrons 
rather than light to form an image. There are more advantages to using the SEM 
instead of a light microscope. 
The SEM has a great depth of field, which allows a large amount of the sample 
to be in focus at one time. 
The SEM also produces images of high resolution, which means that closely 
spaced features can be examined at a high magnification. Preparation of the samples is 
easy since most SEM one require the sample to be conductive. 
The combined effect of higher magnification, larger depth of focus, greater 
resolution, and easy of sample observation marks the SEM one of the most heavily 
used instruments in research areas today. So I selected this method for doing my 
medicine. 
 
Fourier Transform Infrared Spectroscopy (FTIR): 
 In FTIR analysis, a spectrum showing molecular vibrations is obtained, in 
order to identify or characterize organic materials such as polymers, lubricants, 
adhesives and cleaning agents. A limited number of inorganic compounds can also be 
evaluated using FTIR. For semiconductors, FTIR is used to make quantitative 
measurements of hydrogen bonds in silicon nitride films and to measure the inertial 
oxygen content in bulk silicon. It’s ideal uses are,  
• Identifying organic contaminants (e.g. particles, residues) 
• Characterization or identification of organic materials (e.g. solids, powders, 
films, or liquids) 
• Quantification of O and H in Si, and H in SiN wafers (Si-H vs. N-H) 
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4.2.3. QUALITATIVE PHYTO CHEMICAL ANALYSIS: 
Medicinal plants are of greater importance for the health of human beings and 
communities because of the presence of phytochemicals. They are the most amazing 
and effective tools for fighting disease and are essential for good health. 
 The medicinal values of these plants depend on the phytochemicals which are 
some chemical constituents that produce a definite physiological action on the human 
body. 
Test for Phenol: 
Substance in water is added with 5 % alcoholic ferric chloride. Dark blue or 
green colour shows presence of phenol. 
Test for Tannin: 
Substance is shaken with water and added with lead acetate solution. White 
precipitate shows the presence of tannin. 
Test for Flavonoids (Shinoda test): 
Substance is dissolved in alcohol, added with magnesium bits and concentrated 
hydrochloric acid. On heating over a water bath, the appearance of majenta colour 
shows the presence of flavonoids.  
Triterpenoids (Noller’s Test): 
To fewmg of extract, add tin and thionyl chloride and heat in water bath. 
Purple colour indicates the presence of tritepenoids. 
 
Test for Proteins (Biuret test) 
To the sample solution in a test tube, add sodium hydroxide solution and then 
add a few drops of very dilute (1 %) copper II sulphate solution and mix gently.  
Appearance of purple colour indicates the presence of protein.  
Test for Glycosides  
Substance is treated with anthrone and concentrated sulphuric acid. On heating 
over a water bath, the appearance of green colour shows the presence of glycoside. 
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Test for Reducing sugar  (Fehling’s Test) 
To the sample solution, Fehling’s reagent is added. The appearance of brick 
red precipitate or colouration indicates the presence of reducing sugar. 
Test for Anthraquinones 
Few milligram of crude powder is shaken with 10 ml of benzene and  filtered. 
To this filtrate, 0.5 ml of 10 % ammonia solution is added and the mixture is shaken 
well and the presence of the violet colour in the layer phase indicates the presence of 
the anthraquinone.  
Test for Quinones 
Few mg of extract, add few drops of concentrated sulphuric acid. Appearance 
of red colour shows the presence of quinone. 
Test for Alkaloids (Dragendorff’s Test)  
Few mg of extract in separate test tube was warmed with 2% Sulphuric acid 
for 2 minutes. And it was filtered in separate test tube and few drops of Dragendorff’s 
reagent were added.  The presence of orange red precipitates indicates the presence of 
alkaloids. 
Test for Saponins 
Few mg of extract distilled water is added and shaken well. The formation of 
foam indicates the presence of saponin. 
Test for Cardiac glycoside (Keller-Killani Test) 
Add 2 ml of glacial acetic acid containing a drop of ferric chloride solution and 
and 0.5 ml of concentrated sulphuric acid to the chloroform extract of the plant. The 
blue color in the acetic acetic acid layer shows presence of cardiac glycosides. 
 
Thin layer chromatography: 
 
Solvent system: 
Toluene : Ethyl acetate (4:1.5). 
TLC plate: 
  Aluminium plate precoated with silica gel 60F254 of 0.2 mm thickness (Merck). 
Developing chamber: 
 Camag’s twin trough chamber. 
Visualizing reagent: 
 Vanillin-sulphuric acid reagent. 
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Extract Preparation:  
4 g of the chooranam was soaked overnight in chloroform. Boiled on a water 
bath for 10 mins, filtered and concentrated to 10 ml.  
Procedure: 
 The extract was applied on the TLC using capillary and developed in the 
solvent system.  The developed TLC plate was air dried and photograph was taken in 
white light. Then dipped in vanillin-sulphuric acid reagent, heated in an oven at 105°C 
until the development of coloured spots and photograph taken. 
 
4.2.4. CHEMCIAL ANALYSIS: 
 
Preparation of Extract: 
Add 5 gm of the sample to 50ml of distilled water. Boil the solution for 20 minutes, 
cool and then filter. Use the Extract for the following tests. 
Table.1 
S.No Experiment Observation Inference 
1. Test for reducing Sugar : 
To 5ml of Benedicts qualitative 
reagent, add 10 drops of extract, then 
boil for two minutes 
Absence of Green / 
Yellow / Red PPT 
Absence of 
Reducing 
Sugar 
2. Test for Starch : 
To 5 ml of extract add 2ml of acetic 
acid and then add few drops of N/50 
Iodine Solution. 
Absence Blue Colour Absence of 
Starch 
3. Test for Proteins : 
To 2 ml of extract, add 2ml of 5% 
Sodium Hydroxide mix and add 2 
drops of Copper Sulphate Solution. 
Absence Violet or 
Purple Colour 
Absence of 
Proteins 
4. Test for amino Acid : 
Place 2 drops of extract on a filter 
paper and allow to dry well. Then 
spray 1% ninhydrin over the same and 
allow to dry. 
Absence Violet 
Colour 
Absence of 
Amino 
Acid 
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5. Test for Albumin : 
To 2 ml of extract, add 2ml of 
Esboch’s reagent. 
Absence Yellow PPT Absence of 
Albumin 
6. Test for Phosphate : 
To 2ml of extract, add 2ml of 
ammonium Molybdate solution and 
2ml of concentrated Nitric Acid. 
Absence Yellow PPT Absence of 
Phosphate 
7. Test for Sulphate : 
To 2 ml of extract add 2ml of 4% 
ammonium oxalate solution. 
Absence White PPT Absence of 
Sulphate 
8. Test for Chloride :  
Add 2ml of extract to dilute nitric acid 
till the effervescence ceases. Then add 
2 ml of Silver Nitrate Solution. 
Presence of Cloudy 
White PPT 
Presence of 
Chloride 
9. Test for Iron : 
To 2ml of extract, add 2ml of 
ammonium thio cynate solution and 
add 2ml of concentrated Nitric Acid. 
Presence of Red  
Color 
Presence of 
Iron 
10. Test for Calcium : 
To 2 ml of extract, add 2 ml of 4% 
ammonium Oxalate Solution. 
Absence of White 
PPT 
Absence of 
Calcium 
11. Test for Sodium : 
Make a paste with 2 pinches of the 
sample with Hcl and Introduce it into 
the blue flame.  
Absence of Yellow 
Flame 
Absence of 
Sodium 
12. Test for Potassium : 
Add a pinch of the sample to 2 ml of 
Sodium Nitrate Solution. Then add 
2ml of Cobal Nitrate in 20% acetic 
acid. 
Presence of Yellow 
PPT 
Presence of 
Potassium 
13. Test for Zinc : 
To 2ml of extract, add few drops of 
Sodium Hydroxide. 
 
Absence of White 
PPT 
Absence  
of Zinc 
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14. Test for Magnesium : 
To 2ml of extract, add few drops of 
Sodium Hydroxide Solution 
Absence of White 
PPT 
Absence of 
Magnesium
15. Test for Alkaloids : 
a. To 2ml of extract, add 2ml of 
Potassium Iodide Solution 
 
b. To 2ml of extract add 2ml of 
Picric Acid. 
 
c. To 2 ml of extract add 2ml of 
Phosphotunqstic Acid.  
 
Absence of Red 
Colour 
 
Absence of Yellow 
Colour 
 
Absence of White 
PPT 
 
Absence of 
Alkaloids 
 
Absence of 
Alkaloids 
 
Absence of 
Alkaloids 
16. Test for Tannic Acid : 
To 2ml of extract add 2 ml of Ferric 
Chloride Solution 
Absence of Black 
PPT 
Absence of 
Tannic 
Acid 
 
4.2.5. TOXICOLOGICAL STUDY: 
Toxicology studies are required to establish the toxicological profiles of new 
drug candidates prior to administration to humans, and to extend the known profiles of 
existing drugs (e.g., new indications, new formulations, new routes of administration, 
etc.) 
Acute toxicity study 
 The acute oral toxicity study was carried out as per the OECD guidelines-425 
in mice. One-tenth (1/10th) of the lethal dose was considered as therapeutic dose for 
further pharmacological study.  
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4.2.6. PHARMACOLOGICAL STUDIES 
EVALUATION OF ANTIHISTAMINIC AND BRONCHODILATOR 
ACTIVITY OF ORITHAZH THAMARAI ILAI CHOORANAM  
Aim: 
Materials and methods: 
 Histamine solution was freshly prepared in normal saline (NaCl, 8.5 g/l), 
Carboxy methyl cellulose (2%) (Loba chemie Pvt. Ltd). All other chemicals used were 
of analytical grade. 
Stock solution: 
The powdered Orithazhthamarai Chooranam was mixed uniformly in 
Carboxy methyl cellulose in saline solution to achieve 1mg/ml as main stock solution 
and used in this study.  
Animals: 
 Guinea pigs of either sex 350- 450 were procured from animal house, 
Department of Pharmacology, Vels University and throughout the study. Six animals 
were taken in each group and maintained under controlled environment (temperature 
25±20C and 12 h dark and light cycle) with standard diet and water ad libitum during 
experiment. All the animals used in this study were approved by CPCSEA 
(XIII/VELS/PCOL/34/2000/CPCSEA/IAEC/08.08.2012) 
In-vitro antihistaminic activity: 
 Guinea pig was sacrificed and a segment from ileum (2 cm) was dissected 
from the terminal ileum and mounted in an organ bath containing Tyrode solution (10 
ml) between two stainless steel hooks under 0.5 to 1g initial tension. The lower hook 
was fixed at the bottom of the organ bath and upper one was connected to an isotonic 
transducer. The Tyrode solution composition (pH 7.4) was (concentration in gm/lit.) 
NaCl 8.0, KCl 0.2, CaCl2 0.2, MgCl2 0.1, NaHCO3 1.0, NaH2PO4 0.05, and Glucose 
1.0gm/liter.  
 It was continuously aerated and maintained at 37 ± 0.5ºC The equilibrium 
period was 60 min and the bath solution was refreshed every 15 min. After 
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equilibrium period, a dose response curve for histamine in variant molar 
concentrations, by maintaining 45 min time cycle was used.  
   
        
   Fig.13 
Evaluation Of Anti Asthmatic Activity:  
 Experimental bronchial asthma was induced in guinea pigs by exposing them 
to histamine. Overnight fasted guinea pigs of either sex (350-450) were selected and 
randomly divided in to five groups each consisting of six animals. Group 1-3 was 
treated as Test group and received of Orithazhthamarai Chooranam at the dose levels 
of (100-400mg/kg). Group 4 was considered as standard and administered with 
Promethazine (300mg/kg, p.o). All the doses were given orally. Prior to drug 
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treatment each guinea pigs were exposed to an atomized fine mist of 2% w/v 
histamine dihydrochloride aerosol (dissolved in normal saline) using a nebulizer in the 
histamine chamber. Guinea pigs exposed to histamine aerosol showed progressive 
signs of difficulty in breathing leading to convulsions, asphyxia and death. The time 
until signs of convulsion appeared is called pre-convulsion time (PCT) and was 
determined from the time of exposure to onset of convulsions.  
As soon as pre convulsion time was noted, animals were removed from the 
chamber and placed in fresh air to recover. The percentage protection offered by 
treatment was calculated by using the following formula: Percentage protection = (1 - 
T1/T2) × 100. Where; T1 = the mean of PCT of control group animals. T2 = the mean 
of PCT of test group animals. 
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4.5. CLINICAL ASSESSMENT 
Aim: 
          Bronchial asthma is a common disease and frequently encountered disease of 
respiratory apparatus. It has very complex mechanism and multiple inducing factors. 
A strategy for discovering biologically active compounds with high probability in 
siddha herbal  medicine.This study will focus on a new siddha therapy on Bronchial 
asthma.The study will also investigate the efficacy of the siddha drugs and treatments 
on Bronchial asthma, and provide an effective therapy for this disease..  
Objectives:  
 To evaluate the Broncho dilator and anti-histaminic activity of 
Orithazhthamarai chooranam. 
 To explore the efficacy of Orithazhthamarai chooranam in op patients 
with bronchial asthma. 
Design of the Study:  
 The Open clinical trial phase-2B 
 Study period was 2-3 months 
Study Centre:  
Govt.Siddha medical college hospital and Aringar anna government hospital of 
Indian Medicine and Homeopathy, Arumbakkam, Chennai – 106.  
Study Participants:  
Both men and women and members of all races and ethnic groups were 
eligible for this trial. Treatment was being administered on an inpatient/outpatient 
basis. The patients were selected from the In-patient and Out-patient department of 
Govt Siddha medical college hospital and Arignar Anna Government Hospital of 
Indian Medicine and Homeopathy, Chennai – 106.   
Number of Subjects:  
Number of participants will be 40-50.  
Registration Process:  
To register a patient, the following documents should be completed by the 
investigator.  
 Copy of required laboratory tests  
 Signed patient consent form  
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 Other appropriate forms (e.g., Trial profoma).  
Clinical trials are an important part of medical research. They help scientists 
find better ways to prevent, detect, and treat diseases and medical conditions.  These 
kinds of studies are needed to develop new treatments for serious diseases. Clinical 
trials are to learn whether a new treatment works and is safe for people. 
This Clinical trial is an ethical and scientific quality standard for designing, 
conducting and recording trials that involve the participation of human subjects. 
Compliance with this standard provides assurance to public that the rights, safety and 
well being of trial subjects are protected, consistent with the principles enshrined in 
the Declaration of Helsinki and ensures that clinical trial data are credible 
Selection of patients 
The Clinical trial is usually focus on asthma control as measured by pulmonary 
function test (FEV1, FVC, PEFR, FVR), symptom scores and medication requirement. 
After taking the short history of patient, all the selected cases were carefully examined 
and records were maintained. To arrive at the diagnosis along with the history taking 
and the following investigations were done. The patients were selected for clinical 
trials as per the following criterias, which are listed below 
 Recurrent wheezing 
 Coughing 
 Trouble in breathing 
 Chest tightness 
 Symptoms that occurs or worsen at night 
 Symptoms that are triggered by cold air,exercise or exposure to dust,smoke 
and pollens     
 Family history also taken. 
Consent form 
Patients were included in this clinical study only after getting the concern form 
accordance of ‘Helsinki’. Consent form provides essential information for prospective 
research subjects. Voluntary written assent of a subject’s willing to participate in this 
study and it is documented. To explain the benefits and risk of study participation 
about the trial including an explanation of its status as research, its objectives, 
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potential benefits, risks and inconveniences, alternative treatment that may be 
available and of the subject’s rights provided to the subject.   
The patients were selected for clinical trials as per the following criterias, which are 
listed below 
Inclusion criteria: 
 Co operative patient 
 Cough with expectoration 
 Expiratory wheeze 
 Tightness of the chest 
 Positive allergic history 
 History of previous attack 
 Exclusion criteria: 
 Infectious disease patient 
 Pulmonary tuberculosis 
 Malignancy 
 Renal diseases 
 Cardio vascular diseases 
Withdrawal criteria: 
 Exacerbations of symptoms 
 Unacceptable adverse events 
 Patient decided to withdraw from the study 
 Irregular visit 
 Irregular Medications  
 Alcohol intake 
Investigations criteria: 
Blood: TC, DC, ESR, Hb, blood sugar PP. 
Stool: Routine examination 
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Urine: Routine examination 
      Chest: X-ray 
      Sputum for AFB 
      ECG to exclude cardiac disease 
Peak flow meter reading 
      Spirometry reading 
PEAK FLOW METER          
 
      Fig.14 
Peak flow meter: 
A peak flow meter is a small device, that patient blow into. It measures the 
fastest rate of air (airflow) that they can blow out of the lungs. It records airflow in 
litres per minute (l/min). There are different brands of peak flow meter. 
Measuring method: 
Step 1: Before each use, make sure the sliding marker or arrow on the Peak Flow 
Meter is at the bottom of the numbered scale (zero or the lowest number on the scale).  
Step 2: Stand up straight. Take a deep breath (as deep as we can). Put the mouthpiece 
of the peak flow meter into the mouth. Close lips tightly around the mouthpiece. Be 
sure to keep the tongue away from the mouthpiece. In one breath, blow out as hard 
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and as quickly as possible. Blow a "fast hard blast" rather than "slowly blowing" until 
emptied out nearly all of the air from the lungs.  
Step 3: The force of the air coming out of the lungs causes the marker to move along 
the numbered scale. Note the number on a piece of paper.  
Step 4: Repeat the entire routine three times.   
Step 5: Record the highest of the three ratings. Do not calculate an average. This is 
very important. Can't breathe out too much when using the peak flow meter but can 
breathe out too little. Record the highest reading.  
Spirometry: 
The spirometry test is performed using a device called a spirometer, which 
comes in several different varieties. Most spirometers display the graphs, called 
spirograms. 
Procedure 
The basic forced volume vital capacity (FVC) test varies slightly depending on 
the equipment used. Generally, the patient is asked to take the deepest breath they can, 
and then exhale into the sensor as hard as possible, for as long as possible, preferably 
at least 6 seconds. It is sometimes directly followed by a rapid inhalation (inspiration), 
in particular when assessing possible upper airway obstruction. Sometimes, the test 
will be preceded by a period of quiet breathing in and out from the sensor (tidal 
volume), or the rapid breath in (forced inspiratory part) will come before the forced 
exhalation. During the test, soft nose clips may be used to prevent air escaping 
through the nose. Filter mouthpieces may be used to prevent the spread of 
microorganisms. 
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Drug and dosage: 
Drug   :  Orithazhthamarai chooranam 
Route   :  Oral 
Dose   : 1 gm two times a day (After food) 
Vehicle  : Honey 
Dietery advice:  
 Omega-3 and omega-6 fatty acids,  
 foods high in flavonoids and beta carotene,  
 Vitamin B6 (Vitamin B6 deficiency is common in asthmatics),  
 Vitamin B12 high amounts of vitamin B12 supplements (1,500 mcg per day) 
have been found to reduce the tendency for asthmatics to react to sulfites, 
Selenium, Vitamin E, Vitamin C, and Magnesium (magnesium can prevent 
spasms of the bronchial passages). 
Medical advice: 
 Patients are advised to avoid known allergen which is identified either by 
experience or by skin sensitivity test. 
 Take light meals at night and sleep early 
 Try to avoid dust, pollens, cigarette smoke and smoky surroundings. 
 Avoid cold water bath. Avoid cold, deep fried food. 
 Avoid keeping pets such as dogs, cats. 
 Avoid alcohol, lime and bananas. 
 Advice to do breathing exercise 
 Avoid pollution 
 Avoid over crowding 
Criteria for assessment of response to therapy: 
1. Marked Relief :  75%-90% relief in the presenting signs and symptoms 
marked normality pathological investigation. 
2. Moderate Relief : 60%– 75% relief signs and symptoms, moderate 
normality of pathological investigation. 
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3. Mild Relief : 50%-60% relief of signs and symptoms no marked 
changes in pathological investigations. 
4. Poor  :        Below 50% relief of signs and symptoms 
Observation: 
 The duration of the treatment ranged between 45-90 days. 
 At the time of treatment, no adverse effects were observed. 
 The drug was well accepted by all the patients. 
Ethical Review:  
The protocol and any amendments have been submitted to the Govt. Siddha 
Medical College, Chennai-106. Institutional Ethical Committee (IEC) for formal 
approval to conduct the study. 
Statistical analysis:  
   The data were subjected to paired student‘t’ test to determine the significance 
of changes followed by   comparisons to analyze the significance of difference within 
the before and after treatment. P values of <0.05 were taken as significant. 
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CLINICAL STUDY ON ORITHAZHTHAMARAI CHOORANAM IN OP. DEPT ON MANAGEMENT OF BRONCHIAL ASTHMA 
 
 
0SI 
NO 
Op. 
No 
Name/ Age/ 
Sex Complaints 
Duration 
of Days 
B
T 
&
 
A
T 
INVESTIGATION  
 
Results 
BLOOD    
Blo
od 
CL 
Urine Peak Flow 
Meter 
Reading 
L/s 
TC 
cells/c
umm 
DC (%) ESR(mm) Hb 
gm 
Sgr 
mg/
dl 
Ur 
mg
/dl 
  
Sgr 
  
Alb 
   
Dep      
P 
     
L 
   
E 
½ 
hr 
 1 
hr 
1.  8129  Kanchana 
40/Female 
Cough,expectoration, 
wheezing,dyspnoea, 
chest pain 
26.7.12 
To 
2.9.12 
B
T 
10200 62 36 4 14 28 10 110 17 169 NIL NIL PCS 200 
 Good 
 A
T
9900 60 40 5 8 10 12.
5
108 21 161 NIL NIL NIL 350 
2.  9283 Rajammal 
60/Female 
Cough,expectoration, 
wheezing,dyspnoea, 
head ache 
29.7.12 
To 
12.11.12 
B
T 
9400 66 34 6 8 22 12 129 20 160 NIL NIL NIL 150 
 
Good 
 
A
T 
9500 59 39 3 6 12 12.
8 
89 19 155 NIL NIL NIL 250 
3. 413  Meenakshi 
55/Female 
Cough,expectoration, 
wheezing,sneezing, 
headache 
1.8.12 
To 
20.9.12 
B
T 
9700 60 39 4 15 33 14.
8 
90 20 143 NIL NIL FPC 200 
 
Good 
 
A
T 
8800 57 36 6 12 18 14 90 17 158 NIL NIL NIL 350 
4.  1198 Kadhar 
38/Male 
Cough,expectoration, 
wheezing,dyspnoea, 
head ache,sneezing 
3.8.12 
To 
4.10.12 
B
T
9900 64 45 4 7 20 9 112 22 154 NIL NIL FPC 200 Good 
 
A
T 
9500 53 42 5 2 7 10 110 19 140 NIL NIL NIL 350 
 
5.  2489 Vijayalakshmi 
40/Female 
Cough,expectoration, 
wheezing,dyspnoea, 
headache,sneezing 
12.8.12 
To 
11.9.12 
B
T 
9900 57 35 5 28 55 12 91 25 168 NIL NIL NIL 150 
 
  
 
     Poor      A
T 
9000 55 34 4 25 40 12.
3 
91 21 158 NIL NIL NIL 200 
SI Op. Name/ Age/ Complaints Duration B INVESTIGATION  
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BLOOD    
Blo
od 
CL 
Urine Peak Flow 
Meter 
Reading 
L/s 
TC 
cells/c
umm 
DC (%) ESR(mm) Hb 
gm 
Sgr 
mg/
dl 
Ur 
mg
/dl 
  
Sgr 
  
Alb 
   
Dep      
P 
     
L 
   
E 
½ 
hr 
 1 
hr 
6. 3419 Malliga 
61/Female 
Cough,expectoration,w
heezing,dyspnoea,head 
ache 
16.8.12 
To 
17.9.12 
B
T 
10500 64 31 5 12 26 10 102 18 165 NIL NIL PCS 200 
 Goo
 A
T 
9900 57 40 3 6 8 12 98 20 160 NIL NIL NIL 350 
7. 4510 Pandian 
45/Male 
Cough,expectoration,w
heezing,dyspnoea,head 
ache,sneezing 
18.8.12 
To 
15.9.12 
B
T 
10400 64 34 5 9 20 12 139 21 170 NIL NIL FPC 180 
 
Goo
 
A
T 
9500 56 39 3 6 12 13 89 19 155 NIL NIL NIL  
340 
8.  1358  Kuppusamy 
48/Male 
Cough,expectoration,w
heezing,dyspnoea,head 
ache,sneezing 
22.8.12 
To 
1.10.12 
B
T
9100 60 38 2 5 12 14 80 20 133 NIL NIL FPC 250 Poor
 
A
T 
8400 56 38 6 9 15 14 90 18 168 NIL NIL NIL 300 
9. 2182 Priya 
23/Female 
Cough,expectoration,w
heezing,dyspnoea,head 
ache,sneezing 
24.8.12 
To 
29.9.12 
B
T 
9800 54 42 4 3 6 9.4 87 23 164 NIL NIL FPC 300 
 
Goo
 
A
T 
9500 53 42 5 2 5 10 89 19 153 NIL NIL NIL 350 
 
10. 4123 Ranjini 
21/Female 
Cough,expectoration,s
neezing,dyspnoea,whe
ezing,head ache 
25.8.12 
To 
10.10.12 
B
T 
9100 58 38 3 28 53 11.
2 
91 21 165 NIL NIL NIL 180 
 
  
 
     GooA
T 
9000 55 39 6 23 40 12 91 23 158 NIL NIL NIL 250 
SI 
NO 
Op. 
No Name/ Age/ Sex Complaints 
Duration 
of Days 
BT 
& 
INVESTIGATION  
 BLOOD    Urine Peak flow 
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STUDY ON ORITHAZHTHAMARAI CHOORANAM  IN OP DEPT ON MANAGEMENT OF BRONCHIAL ASTHMA 
 
 
AT TC 
cells/c
umm 
DC (%) ESR(mm) Hb 
gm 
Sgr 
mg/
dl 
Ur 
mg
/dl 
Blo
od 
CL 
  
Sgr 
  
Alb 
   
Dep 
meter 
reading L/s 
Results 
     
P 
     
L 
   
E 
½ 
hr 
 1 
hr 
11. 712 Vanithavani 
28/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing,head ache 
1.9.12 
To 
15.10.1
2 
BT 9700 53 37 4 4 9 12.1 85 18 141 NIL NIL PCS 240 
 Good 
 AT 9400 57 40 3 3 6 13 83 16 138 NIL NIL NIL 380 
12. 742 Dhanalakshmi 
49/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing,head ache 
2.9.12 
To 
11.10.1
2 
BT 8600 56 40 4 15 23 12 85 21 153 NIL NIL FPC 260 
 
Moderate 
 
AT 8200 59 39 3 8 12 13.8 76 19 135 NIL NIL NIL 300 
13. 967 Manjula 
42/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing,head ache 
4.9.12 
To 
5.10.12 
BT 9200 58 33 6 10 15 14 90 20 177 NIL NIL FPC 160 
 
Moderate 
 
AT 8400 56 38 6 12 18 13 90 18 168 NIL NIL NIL 240 
14. 1429 Shanthiraj 
48/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing,head ache 
6.9.12 
To 
14.01.1
2 
BT 9800 57 42 3 3 6 9.2 89 23 164 NIL NIL PCS 120 
 
Good 
 
AT 9300 54 42 4 3 6 9.6 87 19 153 NIL NIL NIL 250 
15. 2849 Rejinabanu 
 39/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing,head ache 
9.9.12 
To 
13.10.1
2 
BT 9900 56 39 5 28 53 11 91 21 160 NIL NIL NIL 200  
Moderate  
 
                   
AT 9400 53 39 8 15 20 12.3 88 18 152 NIL NIL NIL 250 
SI Op. Name/ Age/ Complaints Duration BT INVESTIGATION  
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STUDY ON ORITHAZHTHAMARAI CHOORANAM IN OP DEPT ON MANAGEMENT OF BRONCHIAL 
ASTHMA 
 
 
 
 
BLOOD    
Blo
od 
CL 
Urine Peak Flow 
Meter 
Reading 
L/S 
TC 
cells/c
umm 
DC (%) ESR(mm) Hb 
gm 
Sgr 
mg/
dl 
Ur 
mg
/dl 
  
Sgr 
  
Alb 
   
Dep      
P 
     
L 
   
E 
½ 
hr 
 1 
hr 
16. 3418 Ramalingam 
41/Male 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing, 
8.9.12 
To 
10.10.12 
BT 10400 56 39 6 10 28 11 85 18 143 NIL NIL PCS 200 
 Goo
 AT 9900 57 40 3 6 12 11 85 20 152 NIL NIL NIL 350 
17. 9166 Bavani 
34/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing,head ache 
11.9.12 
To 
14.11.1
2 
BT 9800 58 40 2 15 25 13.
5 
78 21 159 NIL NIL FPC 180 
 
Goo
 
AT 8500 56 39 5 8 14 13 80 18 145 NIL NIL NIL 270 
18. 942 Pandiyammal 
59/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing, 
13.9.11 
To 
14.10.1
2 
 8200 58 38 6 13 15 12 98 20 173 NIL NIL FPC 150 
 
Goo
 
 8400 56 38 6 7 10 13 92 18 164 NIL NIL NIL 250 
19. 1987 Parameshwwari 
44/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing, 
17.9.12 
To 
1.11.12 
BT 9300 52 48 4 3 6 11.
8 
89 23 164 NIL NIL FPC 130 
 
Moder
 
AT 9100 50 42 4 3 6 12 85 19 153 NIL NIL NIL 220 
20. 2345 Maariyammal 
58/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing,head ache 
20.9.12 
To 
28.10.1
2
BT 9400 56 39 5 28 55 11.
2 
91 21 160 NIL NIL NIL 120 
 
 
Moder
 
           
AT 9000 69 36 3 18 22 12 89 18 158 NIL NIL NIL 200 
SI Op. Name/ Age/ Complaints Duratio BT INVESTIGATION  
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STUDY ON ORITHAZHTHAMARAI CHOORANAM IN OP DEPT ON MANAGEMENT OF BRONCHIAL ASTHMA 
 
 
 
BLOOD    
Blo
od 
CL 
Urine Peak Flow 
Meter 
Reading 
L/S 
TC 
cells/
cum
m
DC (%) ESR(mm) Hb 
gm 
Sgr 
mg/
dl 
Ur 
m
g/
dl
  
Sgr 
  
Alb 
   
Dep      
P 
     
L 
   
E 
½ 
hr 
 1 
hr 
21. 5311 Lalitha 
35/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing,head ache 
24.9.12 
To 
2.11.12 
BT 9600 59 32 10 6 22 11 120 18 175 NIL NIL PCS 200  
 Good 
 AT 9400 57 40 3 4 9 13 110 20 157 NIL NIL NIL 250 
22. 6181 Jarina  
31/Female 
Cough,expectoration,sn
eezing,dyspnoea,wheez
ing 
28.9.12 
To 
4.11.12 
BT 9800 52 39 9 6 12 12 110 21 163 NIL NIL FPC 150 
 
Good 
 
AT 9500 57 39 3 14 24 12 110 19 158 NIL NIL NIL 250 
 
 
23. 7280 Pazhani 
40/Male 
Cough,,sneezing, 
dyspnoea,wheezing, 
headache 
30.9.12 
To 
28.10.1
2
BT 9400 58 38 4 12 10 12.
8 
102 20 173 NIL NIL FPC 100 
 
Good 
 
AT 8900 54 45 4 8 11 13 98 18 169 NIL NIL NIL 220 
 24. 9010 Pavvalakodi 
48/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing,head ache 
2.10.12 
To 
22.11.1
2 
BT 9600 57 39 4 15 26 9 87 23 169 NIL NIL FPC 100 
 
Good 
 
AT 9300 54 44 2 3 8 10 87 19 155 NIL NIL NIL 200 
25. 729 Suganya 
28/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing, 
6.10.12 
To 
20.11.1
2
BT 9500 55 39 6 12 25 11.
2 
93 21 210 NIL NIL FPS 120 
 
 
   Good  
 
                  
AT 9000 58 39 3 8 13 12 81 23 159 NIL NIL NIL 250 
SL
N
Op. 
No 
Name/ Age/ 
Sex Complaints 
Duratio
n of 
B
T 
INVESTIGATION  
 BLOOD    Urine Peak 
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 STUDY ON ORITHAZHTHAMARAI CHOORANAM IN OP DEPT ON MANAGEMENT OF BRONCHIAL ASTHMA 
 
 
O Days & 
A
T 
TC 
cells/
cum
m 
DC (%) ESR(mm) Hb 
gm 
Sgr 
mg/
dl 
Ur 
m
g/
dl 
Blo
od 
CL 
  
Sgr 
  
Alb 
   
Dep 
Flow 
Meter 
Reading 
L/S 
Results 
     
P 
     
L 
   
E 
½ 
hr 
 1 
hr 
26. 831 Parveen 
10/Female 
Cough,expectoration,sn
eezing,dyspnoea, 
wheezing,head ache 
13.10.1
2 
To 
1.12.12 
B
T 
9000 45 48 7 8 20 10 85 18 149 NIL NIL FPC 250 
 Good 
 A
T 
9300 57 40 3 4 9 11 88 20 152 NIL NIL NIL 340 
27. 1299 Bala 
45/Male 
Cough,expectoration, 
sneezing,dyspnoea, 
head ache,rhinitis 
15.9.12 
To 
2.11.12 
B
T 
8800 65 31 4 12 28 14 119 21 179 NIL NIL FPC 200 
 
Good 
 
A
T 
8500 59 39 3 14 26 14 85 19 155 NIL NIL NIL 280 
28. 1757 Mohan 
36/Male 
Cough,expectoration,sn
eezing,dyspnoea,wheez
ing,head ache 
28.9.12 
To 
7.12.12 
B
T 
8400 56 38 6 10 15 14 90 20 173 NIL NIL FPC 100 
 
   poor 
 
A
T 
8300 56 41 3 8 12 15.
2 
87 18 168 NIL NIL NIL 160 
29. 2345 Suganthi 
32/Female 
Cough,expectoration,sn
eezing,dyspnoea,wheez
ing,head ache 
30.9.12 
To 
7.12.12 
B
T 
9700 54 42 4 8 16 9.4 87 23 164 NIL NIL FPC 150 
 
Good 
 
A
T 
8800 54 44 2 3 6 12.
6 
82 19 153 NIL NIL NIL 250 
30. 2844 Malathi 
29/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing,head ache 
2.10.12 
To 
7.12.12 
B
T 
9600 58 36 3 28 53 11.
2 
91 21 160 NIL NIL NIL 150 
 
 
   poor 
                  A
T 
9000 56 39 2 26 49 11 95 23 163 NIL NIL NIL 180 
SI 
N
O 
Op. 
No 
Name/ Age/ 
Sex Complaints 
Duratio
n of 
Days 
B
T 
& 
INVESTIGATION  
 
Results 
BLOOD    
Blo
Urine Peak 
Flow TC DC (%) ESR(mm
) 
Hb S U        
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           STUDY ON ORITHAZHTHAMARAI CHOORANAM IN OP DEPT ON MANAGEMENT OF BRONCHIAL ASTHMA 
 
A
T 
cells/
cum
m 
     
P 
     
L 
   
E 
½ 
hr 
 1 
hr 
gm gr 
m
g/
dl 
r 
m
g/
dl 
od 
CL 
Sgr Alb Dep Meter 
Readi
ng 
L/S 
31. 5237  Madassamy 
39/Male 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing,head ache 
5.10.1
2 
To 
7.11.1
2 
B
T 
9800 45 48 7 8 20 10 85 18 143 NIL NIL PCS 250 
 Good 
 A
T 
9400 58 40 3 4 9 11 90 20 152 NIL NIL NIL 350 
32. 7455 Sharmila 
34/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
head ache,rhinitis 
8.10.1
2 
To 
17.11.
12 
B
T 
8300 60 31 4 12 28 15.2 12
3 
21 173 NIL NIL FPC 200 
 
300 
Good 
 
A
T 
8500 59 39 3 14 24 15 85 19 154 NIL NIL NIL 
33. 9034 Alamelu 
60/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing,head ache 
10.10.
12 
To 
7.10.1
2 
B
T 
8900 56 37 6 10 15 14 90 20 173 NIL NIL FPC 100 
 
160 
Mild 
 
A
T 
8300 56 41 3 8 12 14 87 18 169 NIL NIL NIL 
34. 213 Selvaraj 
25/Male 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing,head ache 
12.10.
12 
To 
25.11.
12 
B
T 
9600 54 42 4 8 16 10 87 23 164 NIL NIL FPC 150 
 
220 
Good 
 
A
T 
8800 56 46 2 3 6 12 82 19 155 NIL NIL NIL 
35. 934 Abdhul 
58/Male 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing,head ache 
15.10.
12 
To 
17.11.
12 
B
T 
9300 58 39 3 28 53 11.2 91 21 160 NIL NIL NIL 250 
 
350 
Good  
 
              A
T 
9000 56 39 2 19 32 12 88 23 150 NIL NIL NIL 
SL 
N
Op. 
No 
Name/ Age/ 
Sex Complaints 
Duratio
n of 
B
T 
INVESTIGATION  
 BLOOD    Urine  Peak 
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       STUDY ON ORITHAZHTHAMARAI CHOORANAM IN OP DEPT ON MANAGEMENT OF BRONCHIAL ASTHMA 
 
 
 
O Days & 
A
T 
TC 
cells/
cum
m 
DC (%) ESR(mm) Hb 
gm 
Sgr 
mg
/dl 
Ur 
m
g/
dl 
Blo
od 
CL 
  Sgr   
Alb 
   
Dep 
FlowMet
er 
Reading 
L/S 
Results 
     
P 
     
L 
   
E
½ 
hr 
 1 
hr 
36. 2400  Kanmani 
29/Female 
Cough,expectoration,
sneezing,dyspnoea, 
wheezing,head ache 
20.10.1
2 To 
31.11.1
2 
B
T 
8800 55 34 6 21 42 12 99 18 141 NIL NIL PC
S 
200  
 Good 
 A
T 
8400 57 40 3 14 19 13 83 20 152 NIL NIL NIL  340 
37. 4238 Raja 
35/Male 
Cough,expectoration,
sneezing,dyspnoea, 
wheezing 
23.10.1
2 
To 
28.11.12 
B
T 
9500 59 40 3 15 25 12 85 21 159 NIL NIL FP
C 
180 
 
Good 
 
A
T 
9300 58 39 2 8 12 13 90 19 155 NIL NIL NIL 250 
38. 5108 Kanaga 
32/Female 
Cough,expectoration,
sneezing,dyspnoea, 
wheezing,head ache 
25.10.1
2 To 
28.11.1
2 
B
T 
8900 56 38 6 10 14 13 98 20 174 NIL NIL FP
C 
150 
 
Good 
 
A
T 
8500 54 42 5 9 12 13 82 18 167 NIL NIL NIL 260 
39. 6125 Sivakumar 
37/Male 
Cough,expectoration,
sneezing,dyspnoea, 
wheezing 
29.10.1
1 To 
31.11.1
2 
B
T 
1000
0 
64 31 5 2 5 15 87 23 164 NIL NIL FP
C 
240 
 
Good 
 
A
T 
9800 54 42 4 3 6 15 83 19 153 NIL NIL NIL 380 
40. 7892 Bhathmaja 
46/Female 
Cough,expectoration,
sneezing,dyspnoea, 
wheezing,head ache 
31.11.1
2 To 
28.12.1
2 
B
T 
8700 55 39 6 10 26 9 110 29 170 NIL NIL NIL 280 
 
 
Moderat
e  
 
                
A
T 
8400 58 39 3 5 14 12 98 23 154 NIL NIL NIL 320 
 
SL 
N
Ip. 
No 
Name/ Age/ 
Sex Complaints 
Duratio
n of 
B
T 
INVESTIGATION  
 BLOOD    Urine  Peak 
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CLINICAL STUDY ON ORITHAZHTHAMARAI CHOORANAM IN IN PATIENT WARD ON THE MANAGEMENT OF BRONCHIAL 
ASTHMA 
 
 
 
O Days & 
A
T 
TC 
cells/
cum
m 
DC (%) ESR(mm) Hb 
g
m 
Sgr 
mg
/dl 
Ur 
m
g/
dl 
Blo
od 
CL 
  
Sgr 
  
Alb 
   
Dep 
FlowMet
er 
Reading 
L/S 
Results 
     
P 
     
L 
   
E 
½ 
hr 
 1 
hr 
1. 1438  Pazhani 
40/Male 
Cough,expectoration,
sneezing,dyspnoea, 
wheezing,head ache 
15.9.12 
To 
21.10.1
2 
B
T 
8900 55 39 6 20 44 11 85 18 143 NIL NIL PC
S 
220  
 Good 
 A
T 
8400 57 40 3 14 19 12 89 20 155 NIL NIL NIL  320 
2. 1480  Ganesan 
27/Male 
Cough,expectoration,
sneezing,dyspnoea, 
wheezing 
17.9.12 
To 
29.10.1
2 
B
T 
8600 59 40 3 15 25 11 85 21 159 NIL NIL FP
C 
180 
 
Good 
 
A
T 
8300 58 36 2 8 13 12 80 19 159 NIL NIL NIL 260 
3. 58  Abubakar 
50/Male 
Cough,expectoration,
sneezing,dyspnoea, 
wheezing,head ache 
22.9.12 
To 
5.10.12 
B
T 
8600 56 38 6 10 14 13 90 20 174 NIL NIL FP
C 
150 
 
Moderat
e 
 A
T 
8100 52 42 4 8 15 13.
8 
88 18 169 NIL NIL NIL 220 
4. 71  Thoudasetiyar 
65/Male 
Cough,expectoration,
sneezing,dyspnoea, 
wheezing 
24.9.12 
To 
12.10.1
2 
B
T 
1000
0 
65 31 5 2 5 14 90 23 164 NIL NIL FP
C 
220 
 
Good 
 
A
T 
9800 54 44 4 3 6 15 92 19 158 NIL NIL NIL 350 
5. 1483 Anjalai Cough,expectoration,
sneezing,dyspnoea, 
wheezing,head ache 
12.9.12 
To 
22.10.1
2 
B
T 
8600 55 39 6 10 28 9 110 29 170 NIL NIL NIL 250 
 
 
Moderat
e  
 
                
A
T 
8100 58 38 3 5 14 10 115 23 158 NIL NIL NIL 320 
 
SL Ip. Name/ Age/ omplaints Duratio B INVESTIGATION  
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CLINICAL STUDY ON ORITHAZHTHAMARAI CHOORANAM IN IN PATIENT WARD ON THE MANAGEMENT OF BRONCHIAL ASTHMA 
N
O 
No Sex n of 
Days 
T 
& 
A
T 
BLOOD    
Blo
od 
CL 
Urine  Peak 
FlowMete
r Reading 
L/S 
 
Results TC 
cells/
cum
m
DC (%) ESR(mm
) 
Hb 
gm 
Sgr 
mg
/dl 
Ur 
m
g/
dl
  
Sgr 
  
Alb 
   
Dep 
     
P 
     
L 
   
E 
½ 
hr 
 1 
hr 
6. 130 Krishnaveni 
60/Female 
Cough,expectoration,
sneezing,dyspnoea, 
;wheezing,head ache 
1.910.1
2 To 
7.11.12 
B
T 
8700 55 39 6 2
0 
44 11 85 18 143 NI
L 
NI
L  
PCS 200  
 Good 
 A
T 
8400 57 40 3 1
4 
19 13 83 20 152 NI
L 
NI
L 
NIL  320 
7. 135 Sarojimi 
41/Female 
Cough,expectoration,
sneezing,dyspnoea, 
wheezing 
1.10.12 
To 
22.10.1
2 
B
T 
8500 59 40 3 1
5 
25 12 85 20 159 NI
L 
NI
L  
FPC 180 
 
Good 
 
A
T 
8800 58 39 2 8 3 12 85 19 155 NI
L 
NI
L 
NIL 260 
8. 191 Vasantha 
45/Female 
Cough,expectoration,
sneezing,dyspnoea, 
wheezing,head ache 
8.10.12 
To 
31.10.1
2 
B
T 
8400 56 38 6 1
0 
14 12 90 20 183 NI
L 
NI
L 
FPC 150 
 
Mild 
 
A
T 
8100 54 42 4 8 12 13 85 18 168 NI
L 
NI
L 
NIL 220 
9. 325 Knagarani 
40/Female 
Cough,expectoration,
sneezing,dyspnoea, 
wheezing 
26.10.1
2 To 
2.11.12 
B
T 
1000
0 
66 31 5 2 5 12 87 23 164 NI
L 
NI
L  
FPC 220 
 
Good 
 
A
T 
9800 56 42 4 3 6 13 88 20 154 NI
L 
NI
L 
NIL 350 
10.  462 Savithri 
40/Female 
Cough,expectoration,
sneezing,dyspnoea, 
wheezing,head ache 
21.11.1
2 To 
5.12.12 
B
T 
8900 55 39 6 1
0 
28 9 110 29 170 NI
L 
NI
L 
NIL 280 
 
 
Moderat
e  
 
                
A
T 
8200 58 39 3 5 14 12 100 23 159 NI
L 
NI
L 
NIL 350 
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5. RESULTS & DISCUSSION 
 
Several studies have been conducted in this trial drug Orithazhthamarai 
chooranam. The study includes literary collections, physico and Phyto chemical 
analysis, pharmacological study, toxicological study and clinical study.  
Orithazhthamarai chooranam was taken for the treatment of Bronchial asthma, in 
reference with Gunapaddam, First Part-Mooligai Vaguppu (Porutpanbu Nool). 
Literary collections about the drug from various siddha text books were done. 
The literary review shows the efficacy of the drug in the treatment of Bronchial 
asthma. It gives confidence about its broncho dilator activity. 
Phyto chemical analysis: 
Table.6 
Steroids   + ve 
Triterpenes + ve 
Glycosides  + ve 
Saponin   + ve 
Phenol  + ve 
Flavonoids + ve 
Tannin + ve 
Anthraquinones + ve 
Coumarin - ve 
Cardiac glycosides - ve 
 
 From these results steroids were identified. Plants steroids are important to 
cure the chronic inflammatory diseases like BA. 
 Terpenoids were identified and are important to cure the chronic diseases and 
nervine disorders. It has anti-inflammatory activity. 
 Saponins have the unique ability to stimulate the cell-mediated immune 
system. 
 Phenols containing plants are having Anti-oxidant and Expectorant properties.  
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 High Molecular Weight Plant Tannins as Biological Antioxidants 
(Ann.E.Hagerman.et.al) 
 
Chemical analysis: 
The bio-chemical analysis of Orithazhthamarai chooranam contains the 
following chemical constituents,  
Magnesium, Iron, Chloride and Potassium. 
 Presence of iron in the drug has increased Hb concentration in the blood. It 
enhances the arterial oxygen level. It maintains the normal arterial PAO2 (12 
KPa).The drug enhancecs oxygen supply and promotes the normal ventilation 
of the lungs and reduces the dyspnoea. 
 The Mg ions are responsible for broncho dilator and anti cholinergic action 
which helps in acute asthma. 
Physio chemical analysis: 
Table.7. Report of orithazh thamarai chooranam  
 
Parameter Mean Value 
Loss on Drying at 105°C 7.172 % 
Total Ash  10.195 % 
Acid insoluble Ash   1.199 % 
Water Soluble Extractive 18.5 % 
Alcohol Soluble Extractive 6.95 % 
Particle size Completely passes 
through sieve no.44 
pH 6.5 
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Thin layer chromatography: (TLC) 
 
 
Fig.15. After spray with visualizing agent 
 
 
Sl.No After Dipping in Vanillin-Sulphuric acid 
 
Rf value Colour of the spot 
 
1 0.11 Grey 
2 0.31 Purple 
3 0.36 Purple 
4 0.65 Purple 
5 0.69 Purple 
6 0.81 Purple 
7 0.98 Violet 
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Sem results:  
 
 
Fig.16. SEM picture showing Nano particle size of the sample 
.  
Orithazhthamarai chooranam have good nano particle size that indicates 
absorption is very good and pharmaco therapeutic value is good. 
 
FTIR absorptions:  
 
  
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 600 400.0
0.0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100.0
cm-1
%T 
3420.0
2922.6
2360.3
2343.6
1645.6
1429.4
1319.8
1258.5
1052.1
780.1
668.2
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Table.8 
Frequency, cm-1 Bonds  Functional groups 
3420.0 N-H Stretch Amines  
2922.6 C-H Stretch Alkanes  
2360.3 C=O Stretch Carbonyl 
2343.6 P-H stretch Phosphines 
1645.6 R2C=N-R stretch Imines 
1429.4 O-H bend carboxylic acids 
1319.8 C-O stretch carboxylic acids 
1258.5 C-C(O)-C stretch 
(acetates) 
Esters 
1052.1 C-O stretch anhydrides 
780.1 C-H bend (meta) aromatics 
668.2 C-Cl stretch alkyl halides 
 
Toxicological study: 
Acute toxicity study: 
 The acute oral toxicity study was carried out as per the OECD guidelines-425 
in mice. One-tenth (1/10th) of the lethal dose was considered as therapeutic dose for 
further pharmacological study.  
Pharmacological studies: 
Histamine induced bronchoconstriction is the traditional immunological model 
of antigen induced airway obstruction. Histamine when inhaled causes hypoxia and 
leads to convulsion in the guinea pigs and causes very strong smooth muscle 
contraction, profound hypotension and capillary dilation in the cardiovascular system. 
A prominent effect caused by histamine is severe bronchoconstriction in the guinea 
pigs that causes asphyxia and death. Histamine was released after degranulation of 
mast cell by an antigen exposure by antigenic stimulation causing smooth muscle 
contraction, increased vascular permeability and mucus formation. Histamine is one of 
the important mediator of allergy, inflammation and bronchoconstriction. Targeting 
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histamine, either prevention of its release from mast cell or use of histaminergic 
receptor antagonist becomes part of antihistaminic therapy in allergic diseases.  
 In-vivo study of Orithazhthamarai Chooranam have been also shown the 
significant increase in pre-convulsion time due to pre-treatment with 
Orithazhthamarai Chooranam at the dose of 100, 200 and 400mg/kg of body weight 
of guinea pigs, when the guinea pigs were exposed to histamine. The results of 
Orithazhthamarai Chooranam suggested that it is effective in reducing the symptoms 
of bronchial asthma and also improve the lung function parameters of asthmatic 
subjects. The percentage protection of Orithazhthamarai Chooranam -100, 200 and 
400mg/kg, is 9.02, 13.00 and 27.44% respectively. 
In the present study, guinea pigs were used because of the extreme sensitivity 
of their airways to the primary mediators of bronchoconstriction, including histamine 
and leukotrienes and their ability to be sensitized to foreign proteins. Although there 
are various model of asthma, guinea pig airways react to histamine, acetylcholine, 
leukotrienes and other bronchoconstrictors in a manner similar to that seen in humans. 
Another similarity between the guinea pig model and asthmatic patients is that 
enhanced bronchoconstriction occurs in both species following sensitization, in 
response to β-adrenergic antagonists. Thus, the guinea pig model resembles the human 
allergic pathology in several aspects, especially in terms of mediator release. 
Histamine antagonists can be conveniently recognized and assayed by their ability to 
protect guinea pigs against lethal effects of histamine-induced bronchospasm.  
 
 
 
 
 
 
 
 
 PG Gunapadam department  Page 71 
 
Table-9: Effect of Orithazhthamarai Chooranam on isolated Guinea pig ileum 
preparation  
Values are expressed in mean ± SEM, **p< 0.01;*p<0.05 compared with histamine 
induced contraction (23mm as 100%); n=3. 
Table-10: Bronchodilator effect of Orithazhthamarai Chooranam on Histamine 
induced Bronchoconstriction. 
Treatment Pre-Treatment 
Exposition in 
seconds 
Post-Treatment 
Exposition in seconds 
% Protection 
 
Orithazh Thamarai 
Chooranam 100mg/kg. 
p.o. 
98.24 ±4.83 108.12±4.35 9.02 
Orithazh Thamarai 
Chooranam  
200mg/kg. p.o. 
100.22±5.04 115.20±4.42 13.00 
Orithazh Thamarai 
Chooranam 400mg/kg. 
p.o. 
92.38±4.21 127.32±5.17** 27.44 
Promethazine  
(300mg/kg, p.o) 
107.15±4.58 166.19±4.65** 35.52 
N=6; Values are expressed as mean ± SEM; *Significant between pre and post 
treatment time (Student’s –‘t’) **P<0.01. 
 
 
S. No Dose of Histamine 
(μg/ml) 
Percent of maximum response 
Histamine alone 
Histamine+Orithazh 
Thamarai Ilai Chooranam  
(% of Inhibition) 
1 10 1.7±0.12 0.7±0.06 (58.82%)** 
2 20 1.9±0.18 1.1±0.09 (15.78%)* 
3 40 2.3±0.22 1.6±0.12 (30.43%)* 
PG
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Statistical analysis: 
Data were expressed as Mean ± SEM. Differences between groups were 
analyzed by one way analysis of variance (ANOVA) followed by Dunnet “t” test. 
Differences were considered significant when P< 0.05 and P< 0.01. 
Clinical study: 
50 patients of both sexes were selected. Among the 50 patients, 40 patients 
were treated as out- patients in the Post graduate department of Gunapadam, 
Govt.Siddha medical college hospital and Govt. Arignar Anna hospital, Arumbakkam, 
Chennai- 106.  10 patients were treated as in - patients. The results revealed that the 
drug possess 68% good relief, 16% moderate relief, 8% mild relief, 8% cases there 
was no improvement. 
Improvement in clinical features: 
Table.11 
 
 
 
 
 
 
 
 
 
 
 
Signs and symptoms 
no. of patients 
BT AT Imp. Improvement (%) 
Dyspnoea 50 6 44 88 
Cough with Expectoration 50 5 45 90 
Tightness of chest 31 7 24 77.4 
Rhinitis 18 3 15 83.3 
Sneezing 32 4 28 87.5 
Head ache 23 5 18 78.2 
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Statistical analysis: 
“p” value and statistical significance:  
Table.12 
Group Mean SD SEM NO 
BT 184.60 49.54 7.01 50 
AT 282.40 62.26 8.80 50 
 
From the table we calculated the descriptive statistic like Mean, S.D & S.E.M 
of Mean for the peak flow meter score before and after treatment. 
The two-tailed P value is less than 0.0001, by conventional criteria, this difference is 
considered to be extremely statistically significant.  
 
Confidence interval: 
The mean of Group One minus Group Two equals -97.80 
95% confidence interval of this difference: From -108.76 to -86.84  
Intermediate values used in calculations: 
t = 17.9343 
df = 49 
standard error of difference = 5.453  
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6. CONCLUSION 
 
The test drug Orithazhthamarai chooranam is selected from the text 
Gunapaddam, First Part-Mooligai Vaguppu written by K.S.Murugesa Mudaliyar” for 
the evaluation of safety, efficacy and the theraupeutical potential of the drug in the BA 
patients. 
Several recent controlled clinical studies have found that Orithazhthamarai 
chooranam improved lung function and reduced symptoms when used as 
monotherapy, or as a complement to conventional standard therapy for the treatment 
of asthma.  
The results from our earlier preliminary clinical study on Orithazhthamarai 
chooranam suggested that there was appreciable decrease in severity of symptoms of 
asthma and also simultaneous improvement and lung function parameters. The result 
of the effect of the Orithazhthamarai chooranam on four basic symptoms of BA 
(dyspnoea, wheezing, chest tightness, cough) revealed that score of all symptoms was 
reduced significantly. Our results support the effectiveness of Orithazhthamarai 
chooranam in ameliorating the symptoms of BA. On phytochemical analysis iron was 
confirmed and thus presence of iron in the drug has increased Hb concentration in the 
blood. It enhances the arterial oxygen level. It maintains the normal arterial PAO2 (12 
KPa).The drug enhancecs oxygen supply and promotes the normal ventilation of the 
lungs and reduces the dyspnoea. The Mg ions are responsible for broncho dilator and 
anti cholinergic action which helps in acute asthma. 
OTC did not produce any oral acute or sub acute toxicity in both female and 
male rats. Overall results suggest that Orithazhthamarai chooranam is relatively safe 
in rats. These results showed that the use of Orithazhthamarai chooranam is safe  
The acute oral toxicity study was carried out as per the OECD guidelines-425 
in mice. One-tenth (1/10th) of the lethal dose was considered as therapeutic dose for 
further pharmacological study.  
However the detailed clinical and experimental studies revealed the 
bronchodilator and antihistaminic activity and were elaborated.  
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The results of present study suggested that OTC significantly protected the 
Guinea pigs against histamine-induced bronchospasm. OTC use traditionally in the 
management of asthma is justified. OTC significantly prolonged the latent period of 
convulsions at the dose level of 400mg/kg following the exposure of histamine 
aerosol. Thus, our findings suggest that OTC possess significant antihistaminic 
activity.  
After the above evaluation the drug Orithazhthamarai chooranam is subjected to 
open clinical trial. The open clinical trial results reveal that 70% of patients were 
having 75% of improvement and 16% have 60% of improvement in the clinical 
futures and biochemical reports. 
From the above pre-clinical and clinical observation, Orithazhthamarai 
chooranam is endowed with the new hope in the treatment part of Bronchial asthma 
which is cost effective and has easiest preparation method. Hence it can be concluded 
that this drug is effective in BA. 
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7. SUMMARY 
I selected Orithazhthamarai chooranam in this study to elaborate the broncho 
dilator and anti-histaminic activity. Thereby collected the assorted information about 
the drug from existing literatures coming to an assertion about the drug and its 
efficacy on Bronchial asthma. 
The Phytochemical analysis of the drug evaluates that it contains iron, 
magnesium, phenolic compounds, glycosides, flavonoids and steroids which 
contributes much in relieving the symptoms of BA. 
The preclinical study showed that the drug has got safety and significant 
Broncho dilator and Anti-histaminic activity. 
The patients were relieved well from the signs and symptoms gradually and no 
adverse effects were reported. 
The clinical result reveals that 70% of patients were having 75% of 
improvement in the clinical features and biochemical reports. 
A remarkable action of Broncho dilation and Anti-histamine and high 
therapeutical value against the disease of Bronchial asthma has been revealed from 
this study of Orithazhthamarai chooranam . This must be implicated in the future 
studies to explorate the accurate target activity such as anti-tuberculosis and to explore 
the active compounds for the standardization. 
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1. INTRODUCTION 
 
Siddha system of medicine is an integrated part of Indian system, which is 
very efficient and unique system when compared with other traditional systems in 
existence. Siddha medicine being one of the world’s most complex and intricate forms 
of medicine is on the verge of being lost due to many reasons like life style changes. 
Many chronic diseases considered incurable in western medicine, can be treated 
successfully with siddha medicine. 
The medicines are enriched with prayers and power which not only cures the 
disease but also provides peace of mind and spiritual elevation to the soul. This divine 
system of medicine is having a treasure of numerous medicines. The medicines which 
are available today are very few, comparatively as many of them are still hidden either 
in the hands of traditional families. However, the medicines range from simple 
preparations like juice of an herb to the higher medicines like parpam and 
chendooram (calcination process) which can be preserved life-long. The methods of 
preparation and purification of raw drugs are considered very important during 
processing of drug. 
Siddha medicines are generally divided into three classes (i) Miracle 
medicines, (ii) Sophisticated medicines and (iii) Common medicines. Miracle   
medicines are becoming rare and should be learnt directly from the masters who, 
having undergone all forms of initiation and hazards of apprenticeship, have reached 
perfection in all respects. Sophisticated medicines may be scientifically prepared and 
used by the well trained physicians without much risk. Common medicines are most 
simple and cheap ones which were in wide use till the beginning of the 20th century 
and are still in use in remote rural areas of our country. Many diseases from common 
ailments to severe degenerative diseases are treated by these drugs. 
The incidence and prevalence of kidney stones is increasing globally. These 
increases are seen across sex, race, and age. Changes in life style and food habits may 
be a key driving force. In addition, global warming may influence these trends. 
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 Kidney stones affect up to 5% of the population, with a lifetime risk of 
passing a kidney stone of about 8-10%. Increased incidence of kidney stones in the 
industrialised world is associated with improved standards of living and is strongly 
associated with race or ethnicity and region of residence. A seasonal variation is also 
seen, with high urinary calcium oxalate saturation in men during summer and in 
women during early winter. Stones form twice as often in men as women. The peak 
age in men is 30 years; women have a bimodal age distribution, with peaks at 35 and 
55 years. Once a kidney stone forms, the probability that a second stone will form 
within five to seven years is approximately 50%. 
In the United States, overall stone prevalence has doubled since the 1964–1972 
time period, and appears to have stabilized since the early 1980s.  Other countries with 
documented increases in prevalence include Germany, Spain, and Italy. Regional 
reports from Milan, Italy, also document an increased prevalence. Only Scotland had a 
slight decrease in prevalence from 3.83% in 1977 to 3.5% in 1987 (V Romero, H 
Akpinar et.al). 
Urinary stones have adjoined humans since the dawn of history. The first 
known stones were discovered in Egyptian mummies. In 1901, the English 
Archaeologist E. Smith found a bladder stone from a 4500-5000 year old mummy in 
El Amrah, Egypt. Treatments for stones were mentioned in ancient Egyptian medical 
writings from 1500 B.C. In the 4th century B.C., Hippocrates specifically mentioned 
stones in his Hipprocratic Oath, which is historically taken by newly trained 
physicians. 
In the oath, this is the line that refers to stones: “I will not use the knife, not 
even on sufferers from stone, but will withdraw in favor of such men as are engaged in 
this work.” Most historians feel that this statement was a warning that physicians 
should refrain from participating in surgery, which was considered dangerous. 
 In siddha system there are lot of drugs which have lithontriptic activity which 
is more effective. Thus as per siddha literature, Neeradaipu thelineer is indicated for 
urolithiasis and no research work have been done for lithontriptic activity so far. 
Hence, I have taken up clinical and preclinical studies on Neeradaipu thelineer for 
scientific exploration. 
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2. AIM AND OBJECTIVES 
Aim 
 Renal stone formation or urolithiasis is a complex process that is a 
consequence of an imbalance between promoters and inhibitors in the kidneys. The 
recurrence of urolithiasis represents a serious problem as patients who have formed 
one stone are more likely to form another. 
 Not all standard pharmaceutical drugs used for the  prevention of  urolithiasis 
are effective in all patients, and many have adverse effects that compromise their long 
term use, and hence there is a continuous thirst in search of new drugs for this disease. 
Hence, the main aim of this trial is to validate the safety and to elaborate the 
lithontriptic activity of “Neeradaippu thelineer”. 
Objectives 
• To collect the relevant literature of the ingredients of the drug that 
supports the study. 
• Collection, identification, authentication, and preparation of the trial 
drug.  
• Standardization of the trial drug through quantitative and qualitative 
methods. 
• Determination of LD50 and ED50. 
• Determination of therapeutic index. 
• Toxicological studies. 
• To evaluate the efficacy of the trial drug through pharmacological 
studies. 
•  To evaluate the safety and efficacy of the trial drug clinically. 
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3. REVIEW OF LITERATURE 
 
The literature support for my trial drug was collected from the Siddha text 
books, classical literatures of Siddha, Materia medica, Compendium of Medicinal 
Flora, Wealth of India. 
3.1. BOTANICAL ASPECT: 
Achyranthes aspera(Naayuruvi): 
Bentham and Hooker classification: 
Kingdom : Plantae 
Division : Angiosperms 
Order  : Caryophyllales 
Family  : Amaranthaceae 
Genus  : Achyranthes 
Species : Aspera 
Vernacular names: 
Tamil  : Naayuruvi, Sirukadaladi 
English : Rough chaff tree, Prickly chaff flower 
Sanskrit : Aghata, Apamerga 
Hindi  : Chirchira, Latijira 
Malayalam : Kadaladi 
Telugu  : Antisha, Uttaraene 
Indonesia : Jarong 
Habitat : Small herb found all over India. 
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Part used:  
Herb, leaves, seeds and root. 
Constituents: 
 It contains triterpenoid saponins which posses oleanolic acid as the aglycone. 
Ecdysterone, as an insect moulting hormone and long chain alcohols are also found. 
 Fruit contains a large percentage of alkaline ash containing potash. 
Actions: 
 Astringent 
 Diuretic 
 Alterative 
 Antiperiodic 
 Purgative 
Medicinal uses: 
 Decoction is a good diuretic efficacious in renal dropsies, general anasarca and 
early stages of diarrhoea and dysentery. 
 Juice is also useful in stomach ache and bowel complaints, piles, boils, skin 
eruptions etc, in large doses it produces abortion or labour pains. 
 Fresh leaves ground into a paste with jiggery or mixed with black pepper and 
garlic and made into pills are used as antiperiodic especially in quartan fevers. Leaves 
rubbed into a paste with water are applied with much bebefit to bites of poisonous 
insects, wasps, bees etc. fresh juice of the leaves thickened into an extract by exposure 
to the sun mixed with a little opium is an efficacious applicationto primary syphilitic 
sores. 
 An infusion of the root is given as a mild astringent in bowel complaints. A 
pinch of the root powder with a pinch of pepper powder and honey is a nice remedy 
for cough.  
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 The flowering spikes or the seeds, ground and made into a paste with water, 
are used as an external application for bites of poisonous snakes and reptiles. Spike 
with seeds used as an expectorant. 
 Seed rubbed with rice water is given bleeding piles. Payasam or Kheer made 
of seeds in milk is a good remedy for diseased brain. 
 Root taken on Sunday conjoined with pushya nakshitra after bathing and kept 
hanging in a corner is used in stimulating labour pains and expecting delivery. It is 
tied into the hair or into the waist of the woman in pains. 
 Ashes of the root rubbed with honey and administered is a cure for cough. 
Ashes with water and jiggery cures dropsies such as ascites, anasarca etc.  
 Apamarga Taila – Take of sesamum oil 4 seers, alkaline water prepared from 
the ashes of Achyranthes aspera 16 seers, ashes of the plant 1 seer and boil with them 
together in the usual way. This oil is poured into the meatus in cases of moise in the 
ears and in deafness. Instilled into the nostrils it cures nose-bleeding. The drug also 
used in snake-bites. 
3.2. MATERIA MEDICA (GUNAPADAM ASPECT): 
Achyranthes aspera(Naayuruvi): 
Synonyms :    Abamarki, kaanjari, sanam, sigisiram, kathari, saramanjari,       
sirukadaladi,                        suvaanam, naaikuruvi, sagarigam, 
segareegam, kittavi, vittirukki, segari, naayaranji, maamuni. 
It is grown all over india. It is also called as padarurukki. 
Part used : Herb 
Taste : Kaippu, thuvarppu, kaarppu 
Thanmai : Veppam 
Pirivu : Kaarppu 
Actions: 
 Astringent 
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 Diuretic 
 Alterative 
 Antiperiodic 
General characters: 
மலிகாரu ைக~©ள அபமாtகி ய}ேவரா வசிய «zடா 
இைல¬ல உதிரம|த ேபதிகப வயºத|தி யறu ேமக 
மைலேய² ப©¾­ «ள¾சி மா² வனச ¬ல 
பலமாதt ள¸tைக நtவuகv சி|£ர பz மாேறா 
      (ேதைரய ணவாகட) 
The root gives glows to the skin. Leaves cure rectal bleeding, diarrhea, kapha 
diseases, sweating and leucorrhea. Whole plant helps in eliminating the puerperal 
discharges. 
Other uses: 
 The root decoction is a diuretic. The leaves juice cures stomach pain and 
itching.  
Tribulus terrestris(nerunjil): 
Botanical aspect: 
Kingdom : Plantae 
Division : Angiosperms 
Order  : Zygophyllales 
Family  : Zygophyllaceae 
Genus  : Tribulus 
Species : Terrestris 
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Vernacular names: 
Tamil  : Cherunerinche, neinji, nerinjal 
English : Small caltrops 
Sanskrit : Ikshukandha 
Hindi  : Chota-gokhru 
Punjabi : Kurkundai 
Bengali : Gokhuri 
Telugu  :  Palleru-mullu 
Malayalam : Nerungil, nerinnil 
Plant description: 
 Thid trailing plant is common sandy soil throughout india and Ceylon, 
plentiful in the United provinces and in Madras. The carpels or cocci of the fruit 
resemble a cloven hoof of the cow. This variety is known as mitha(sweet) gokhru as 
distinguished from kuduva or moto gokhru. 
Chemical constituents: 
 Extract of the powdered fruit was found to contain an alkaloid, a resin, fat and 
mineral matter, essential oil, fixed oil and nitrates. The fruit is said to contain a 
substance having an aromatic smell and it gives off a fragrant odour when it is burnt. 
Actions: 
 Plant and dried spiny fruit are esteemed as cooling, demulcent, diuretic, tonic 
and aphrodisiac. The diuretic properties of the plant, no doubt, are due to the large 
quantities of the nitrates present as well as the essential oil which occurs in the seeds. 
 Stem are considered astringent. Its action on the mucous membrane of the 
urinary tract closely resembles that of Buchu and Uvaursi flowers. 
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Medicinal uses: 
 Plant and dried spiny fruits are used in decoction or infusion in cases of 
spermatorrhoea, phosphaturia, diseases of the genitor-urinary system such as dysuria, 
gonorrhoea, gleet, chronic cystitis, calculous affections, urinary disorders, 
incontinence of urine, gout and impotence. 
 It is also used in Northern India in cough, diseases of the heart and suppression 
of urine. Gokshuradi churnam was given a good trial in cases of Bright’s disease with 
dropsy. 
Materia medica: 
Tribulus terrestris(Nerunjil): 
Synonyms : Thirigandam, thirithandam, neerunjiputhum, asuvasatiram,        
suvathattam, kogandam, kaamarasi, suvaathugandam, kittiram, 
kondam, sutham. 
Part used : Whole plant 
Suvai : Astringent, sweet 
Thanmai : Seetham 
Pirivu : Inippu 
The flowers are yellow in color. They are 2 types 
1) Siru nerunjil 
2) Peru nerunjil(Yaanai nerunjil) 
Yaanai nerunjil also called yaanai vanangi. 
Actions: 
 Refrigerant    Tonic 
 Diuretic    Aphrodisiac 
 Demulcent    Astringent 
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Other uses: 
 The seeds are good diuretic. 
 The plant taken with goat’s milk and honey cures impotence. 
 Decoction of seeds of tribulus terrestris and coriander cures renal calculi and 
burning micturition. 
 Take tribulus terrestris, carbonate of iron, cinnamomum cassia, cardamoms 
and sugar. Mix and make a powder, it cures jaundice. 
Musa paradisiaca(vaazhai): 
Botanical aspect: 
Classification: 
Kingdom : Plantae 
Division : Magnoliophyta 
Class  : Liliopsida 
Order  : Zingiberales 
Family  : Musaceae 
Genus  : Musa 
Species : Paradisiaca 
Synonyms: 
 Musa sapientum 
Vernacular names: 
Tamil  : Kadali, vizhaip-pazham 
English : Plantain or banana 
Sanskrit : Vana Laxmi, kadali, rambha 
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French  : Bananier, plantanier 
German : Gemenier pisang 
Arab & pers : Mong, mouz 
Hindi  : Kela 
Telugu  : Kadalamu 
Malayalam : Vasha 
 This plant is cultivated universally in many varieties throughout India for its 
nutritious and delicious fruit. 
Part used: 
Fruit, leaves and stems. 
Constituents: 
 Plant contains about 37 pc of dry matter. Growing parts of the plant contain 
much tannic gallic acids.  
A sound ripe fruit contains sugar being crystallisable. Over ripe fruit contains 
crystallisable and uncrystallisable sugar. Besides sugar it contains starch, albuminoids, 
non-nitrogenous extractives and ash containing phosphoric anhydride, lime, alkalies, 
iron, chlorine etc. There are large quantities of vitamin C and vitamin A present.  
Flower-stem juice contains potash, soda, lime, magnesia, alumina, chlorine, 
sulphuric anhydride, silica. Juice of the tender roots contains much of tannin. 
Medicinal uses: 
 Older and greener leaves make an excellent eye shade in eye diseases. 
 Root in powder is used in anaemia and cachexia. Juice of the tender root is 
used with mucilage for checking haemorrhages from the genital and air passages, 
bronchocele and strumous affections. 
 Juice of the stem is used in otalgia and hemoptysis. 
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 Root juice in which burnt borax and nitre are dissolved is given in retention of 
urine, mixed with ghee and sugar it is given in gonorrhoea. 
 Cooked flowers are used in diabetes. Flowers soup is given in convalescence 
after diarrhoea.  
 The plant is useful in bite of boa-constrictor. 
Materia medica: 
Vaazhai (Musa paradisiaca: 
Synonyms : Ambanam, arambai, osai, kadhali, kavar, sekili, thiranapathi 
Part used : Leaf, flower, tender fruit, fruit, bark, wood, stem, juice 
Suvai  : Astringent 
Thanmai : Veppam 
Pirivu  : Kaarppu 
Actions: 
 Astringent    Refrigerant 
 Styptic     Demulcent 
 Diuretic    Laxative 
 Antipitha    Nutritive 
General characters: 
 The root produces heat. The stem helps to eliminate the hair, skin and toxins in 
the intestine. Flower cures leucorrhea. Tender cures piles. It produces gas in whole 
body. 
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Aerva lanata (Sirukanpeelai) 
Botanical aspect of plant: 
Scientific classification:  
Kingdom :  Plantae 
Division :  Angiospermes 
Class  :  Magnoliopsida 
Subclass :  Caryophyllidae 
Order  :  Caryophyllales 
Family  :  Amaranthaceae 
Genus  :  Aerva 
Species :  Lanata  
Synonyms: 
Achyranthes lanata L. 
Illecebrum lanatum (L.) Murr 
Aerva arachnoidae Gand. 
Aerva incana Suess. 
Aerva sansibarica Suess. 
Illecebrum lanatum  
Vernacular names: 
English  : Common wayside weed  
Tamil  :  Sirupeelai 
Sanskrit    : Astmabayda 
Hindi       :  Gorkhabundi, Kapurijadi 
Spanish     : Sanguinara de Cuba 
Bengal             : Chaya 
Malayalam : Cherula 
Telugu  : Pindikumda 
 
Plant description: 
Erect or prostrate with a long tap root, branched from near the base; branches 
many, terete, pubescent or woolly-tomentose, striate leaves alternate, 2-2.5 by 1-1.6 
cm.On the main stem 6-10 by 5-6 mm. On the branches elliptic or obovate, or sub 
orbicular, obtuse or acute, entire, pubescent above more or less white with cottony 
hairs beneath; Petioles 3-6 mm. long, often obscure. Flower greenish white , very 
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small ,sessile, often bisexual in small dense subsessile axillary heads or spikes 6-13 
mm. long often closely crowded and forming globose clusters; bracteoles 1.25 mm. 
long, membranous, broadly obate, concave ,apiculate, silky-hairy on the back. Utricle 
broadly ovoid, acute; stigmas 2. Seed 0.85 mm. dia,., smooth and polished, black. [4] 
 
Distribution and habitat: 
  A. lanata prefers damp sites and found in forests and slopes of mountain, 
found on waste and disturbed ground, deserted cultivation and coastal scrub and at 
altitudes from sea level to 900 meters (3,000 ft). 
It is found throughout India and also Srilanka,Malaysia,Indonesia, Phillippines,Saudi 
Arabia,Somalia,Kenya,Uganda,Liberia,Madagascar,South Africa, Australia etc,[1]                            
 
Materia medica (Gunapadam aspect)                                                                                                   
Other names: Sirukanpeelai, Karbedhi, Pashanabedhi, Kanpeelai 
Parts used : Whole plant 
Suvai  : Kaipu (bitter) 
Thanmai : Veppam 
Pirivu  : Kaarpu 
Actions: 
Diuretic 
Lithontriptic 
Emmenagogue 
Alexipharmic 
 
Glycyrrhiza glabra (Athimathuram): 
Botanical aspect: 
Kingdom : Plantae 
Division : Angiosperms 
Order  : Fabales 
Family  : Fabaceae 
Genus  : Glycyrrhiza 
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Species : Glabra 
Vernacular names: 
Tamil  : Athimathuram 
English : Sweetwood, liquorice 
Hindi  : Mithilakdi 
Telugu  : Yashti madhukam 
Arab  : Aslussiesa 
French  : Bois doux 
Constituents: 
 Root contains Glycyrrhizin, a yellow amorphous powder, asparagin, sugar, 
starch, acid, gum, mucilage, phosphoric, sulphuric and malic acids, calcium and 
magnesium salts. 
 Bark contains a small quantity of tannin. 
Actions: 
 Tonic     Expectorant 
 Coolant    Diuretic 
 Demulcent    Emmenagogue 
Medicinal uses: 
 Root is used in scorpion sting. Extract and decoction of the root is useful as a 
demulcent in inflammatory affection or irritable conditions of the bronchial tube, 
bowels and catarrh of the genito-urinary passages. 
 It cures cough, asthma, dysuria and sore throat etc. 
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Borax: 
Botanical aspect: 
Tamil  : Vengaram 
Sans  : Tan-kana 
Arab  : Burak-es-saghah 
Hindi  : Sohaga 
Telugu  : Elegaram 
Malayalam : Vellakaram 
 Borax occurs in the large form of transparent monoclinic prisms, often dulled 
on the surface. It is sparingly soluble in cold water, but is more soluble in hot water. 
Modern aspect 
Chemical Name:      Sodium borate 
                                  Hydratedsodiumborate Na2B4O7 -10H2O  
Source: 
 It occurs as a natural deposit. Crude borax is found in masses by evaporation 
of water, on shores of dried up lakes in India and Tibet. It is also obtained from the 
mud of lakes surrounded by hills of Nepal. In this crude state it is known as sohagoor, 
when purified by dissolving it in water, straining through cloth, evaporating to dryness 
and crystallizing, it is called borax. 
Chemical properties: 
These are several borates of Sodium, Sodium tetra borate is used commonly in 
all purposes. 
Specific gravity       - 1.7 
Purification: 
Borax is purified by being steeped for a night in kanji and dried in the sun. 
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Action: 
Diuretic     Emmenogouge 
Antacid     Local sedative 
Astringent    Anti septic 
Uses of borax: 
External 
Borax have the power of destroying micro-organisms and are thus disinfectant 
and antiseptic,  and it is much more active in preventing than in inhibiting 
decomposition. The action is extremely local.  
Internal 
Borax checks the action of saliva on starch, but, if anything, they increase the 
action of the gastric juice and the pancreatic secretion. Large amounts, however, 
slightly retard digestion, and still larger are gastro-intestinal irritants. -Materia 
Medica Pharmacy, and Pharmacology and Therapeutics", by W. Hale White. 
• They are largely used to keep wounds, ulcers, and sores sweet. The action 
is so local that they cannot be used to dress cavities. 
• Borax has been given in epilepsy, and its use is gaining ground. It is often 
prescribed with advantage in combination with bromides, but it is 
decidedly inferior to them, although in exceptional cases it may succeed 
when they have failed. As it is an antiseptic it has been given internally in 
typhoid fever and phthisis, but with doubtful benefit. . 
• In rare cases its use has caused either psoriasis, a papular eruption 
especially marked near the elbows, an erythematous rash, or eczema. 
Nausea, loss of appetite, vomiting, and diarrhoea may be produced. 
• Borax is used internally in dose varying from 10-30 grains, in acidity of 
stomach, amennorrhoea, dysmenorrheal, menorrhagia, puerperal 
convulsions and to promote uterine pain during labour. 
               -Dr.Nadkarni’s materia medica 176 
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Other uses: 
 Borax has excellent fluxing properties and is used in several smelting, 
soldering and welding operations.  
 Borax is employed to give glaze to certain kinds of paper and playing cards. It 
is used in curing hides and skins, in finishing leather, in paints and varnishes and in 
the textile industry, as a solvent bleach, detergent and fire proofing material. 
Gunapadam Aspect 
Synonyms:   
porikaaram, urukkinam, urkkumithiran, danganam, thoomaththaiyadakki >  
“fhup nghupf;fhup fLk;Ngjfkzp 
 NeupAUf;fpdk; Neu;e;j kzpfhuk; 
 thupa J}kj;ij alf;fpa rpw;gup 
 fhupare;jhdp fupj;jFNlhupNa”      
(rl;il Kdpepfz;L 1200) 
Sources: 
It is largely available in kalifornia, india and thibet. 
 
Characters: 
 It present in the form of white transparent crystals. It is soluble in water 
and insoluble in alcohol. 
Suvai  :  Sweet with astringent. 
Veeriyam : Veppam 
 
Actions: 
Internal: 
Refigerant      
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Diuretic       
Lithontriptic   
External: 
Alterative 
Astringent          
Antiseptic 
General character: 
 “nrhwpGilnaz; Fd;keik Nrhup aurk; 
 gwpfpufzp fy;Y}dk; gd;Ndha; - newpiaj; 
 jlq;fzq;f gq;fpUkp ru;g;gtplQ; re;ep 
 aplq;fzq;f yf;fpw;Ngh nkz;”;. 
       -gjhu;j;j Fzrpe;jhkzp 
It cures all types of ulcers, bleeding piles, renal calculi, kapha diseases and dysuria;. 
“ntq;fhuQ; Nrj;Jkj;ij NtWgz;Z NkfLF  
    jq;Frpy ePu;Kwpaj; jhd;thq;Fk;”. 
 fgj;ijAk;> ePu;g;gpzpiaAk; thq;Fk;. 
 
Purifications: 
 Borax is dipped in buffalo urine and kept for few hours.  
 Fried and grinded with lemon juice;. 
 Roasted in a pan till the moisture is lost. 
 Grinded with lemon juice and then dry well. 
Medicinal uses: 
 Roasted borax grinds with ghee. It cures mouth ulcers. 
 Vengara mathu: roased borax with honey cures apthous ulcer and angular 
stomatitis. 
 Borax is mixed with water. A cotton cloth is dipped and its applied externally 
for wounds. 
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 Borax with pig ghee cures painful piles. 
 Borax with tender coconut cures anuria. 
 It is mixed with water and used for cleaning the eyes in eye diseases. 
        
3.3. SIDDHA ASPECT OF THE DISEASE: 
Kalladaippu (Urolithiasis) 
Other name: Achmari 
Nature of the disease: 
 Intermittent cessation of urine, pain at the tip of penis, burning micturition, 
back ache and small pebble spouses found in urine. 
Aetiology: 
 Drinking stagnant water 
 Food which increases vadha and kapha 
 Pics disease 
 Genital diseases 
Types: 
 Vali kalladaippu 
 Azhal kalladaippu 
 Iya kalladaippu 
 Mukkutra kalladaippu 
Vali kalladaippu: 
 Pricking pain of lower abdomen 
 Pain and inflammation of penis 
 Dysuria 
 Dyspnoea 
 Abdominal distension 
 Mucosal livings found in urine 
Azhal kalladaippu: 
 Irritation resembling the touch of melted iron over the bladder 
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 Pyrexia 
 Haematuria 
 Pricking pain of bladder 
 Small red stone found in urine 
Iya kalladaippu: 
 Umbilical arches and pain 
 Pain over the lumbar 
 Stabbing of the penis 
 Perspiration 
 Small whites found in the urine 
Mukkutra kalladaippu: 
 Lower bladder pain 
 Intermittent urinataion 
 Dysuria 
 Handful of sand like stones found in urine per day 
 Urine along with seminal fluid 
General symptoms: 
 Frequent urination 
 Dysuria 
 Pain over the penis and anus 
 Irritation of the lower abdomen and bladder 
 Haematuria  
3.4. MODERN ASPECT OF THE DISEASE: 
Urinary system: 
 Excretion is the process by which the unwanted substances and metabolic 
wastes are eliminated from the body to keep the body in healthy condition. The renal 
system is the one having maximum capacity of excretory function. It contains several 
parts including the kidneys, ureters, bladder and urethra. 
Kidneys play the principal role in homeostasis and maintenance of internal 
environment, water balance, electrolyte balance and acid-base balance. It regulates the 
blood pressure, hormones and blood calcium level. 
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Renal calculi: 
 Kidney stones are the most common and painful disorders of the urinary tract. 
It is a solid concentration or crystal aggregation formed in the kidneys from dietary 
minerals in the urine. In most cases, the presence of renal stone is associated with an 
increased blood level and urinary excretion of its principal component. 
Aetiology: 
 Infection  
 High concentration urinary salts 
 Vitamin A deficiency 
 Para-thyroid tumor 
 Nephrocalcinosis 
 Prolonged immobility 
 Dehydration 
 Urinary retention 
 High purine and calcium intake 
 Congenital disorders 
 Genetic disorders 
 Obstructive disorders 
 Papillary necrosis 
Sites of renal stones: 
 Within the renal pelvis 
 Pelvic ureteric junction 
 Ureters 
 Crossing of vas deferens in  males 
 Crossing of broad ligament in females 
 Junction of ureter with the bladder 
 Urethra 
Pathogenesis: 
 A stone in the urinary tract consists of Crystals, bound by mucoprotein called 
matrix. These substances are normally present in the urine in solution and there are 
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normal physiological substances that keep crystals in solution (and prevent formation 
of stone). Stone formation may occur due to three factors. 
1. Increased crystalloid concentration in the urine, which may be 
i) Relative: due to reduced urine volume 
ii) Absolute: where there is actually excessive excretion of the crystal. 
2. Urinary reaction: 
Urinary reaction acts by altering the solubility of the crystals. 
Uric acid stones form  under pH 5.5 
Calcium phosphate form above pH 6.6 
Triple phosphate form above pH 7.1 
Cystine crystals form  above pH 7.8 
Oxalate stone formation is not pH dependent. 
3. Absence of stone-inhibitors: 
It is certain now that inhibitors of crystallisation are important factors 
maintaining the solubility of different crystals in urine e.g., citrates. 
Process of stone formation: 
1. Phase of nucleation:  
Precipitations of crystals occur in a state of super-saturation – either 
spontaneous precipitation, or precipitation of crystals triggered off by a nucleus of 
mucoprotein-like substance. Epitaxy is the process in which one kind of crystal 
undergoes oriented over-growth on the surface of a different but existing crystal. 
2. Phase of growth and aggregation: 
The embryo nuclei enlarge in size depending on the high level of crystal 
saturation. 
3. Phase of trapping: 
The large crystal-aggregate is now entrapped in some part of the renal 
anatomy. Various types described are i) papilla, ii) lumen, iii) interstitium, iv) renal 
lymphatics, v) surrounding the blood vessels, vi) epithelium of the renal tubule and 
any of these may be localisation sites of stone. 
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4. Phase of stone formation:  
The large crystal-aggregates trapped in any of the above sites now grow 
forming a clinical and radiological stone. 
Types of stones and their genesis: 
Calcium stones: 
 These comprise over 75% of stones in most countries and are commonly 
oxalate, less commonly phosphate. Calcium plays an important role throughout the 
body. Its absorption from the gut is responsible for the blood calcium level. It is 
affected by parathormone, intestinal property, vitamin D and oxalibactor formigenes. 
Crystalluria: In stone formers, urine contains crystals more frequently and larger size. 
Most frequent crystal is calcium-oxalate monohydrate. 
Hypercalciuria: This is the basic cause of the calcium-stone formation, and is defined 
as excretion of more than 300mg/day of calcium in 24hrs, on a normal diet. 
 Calcium oxalate precipitation is prevented by mucoproteins, urea, magnesium, 
pyrophosphates etc.  
Phosphate stones: 
 Phosphates are an integral part of blood-bone-urolithiasis circuit. 
Phosphatic stone types: 
i) Calcium phosphates 
ii) Magnesium phosphate 
iii) Triple phosphate- struvite 
90% of plasma proteins are filtered in glomerulus, of which only 20% are excreted in 
urine.  
Magnesium ammonium phosphate stones are formed largely following infections by 
urea-splitting bacteria, which convert urea to ammonia. 
Struvite stones are often defined by their large size and stag horn edges.  
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Uric acid stones: 
 About 5-7% of urinary stones are uric acid stones. Uric acid and mono sodium 
urate act also as nuclear for calcium oxalate stones. Uric acid dissolves in the blood, 
passing through the kidneys into the urine where it is eliminated. But when the body 
produces excess amount of it, or kidneys are unable to eliminate it, uric acid 
accumulates and form crystals. 
Causes: 
 Gout 
 Secondary hyperuricaemia 
 Hypeeraacid urine 
 Ileostomy 
 Dietary purine 
Uric acid stone types: 
i) Uric acid 
ii) Uric acid dehydrate 
iii) Ammonium acid urate 
iv) Sodium acid urate monohydrate 
Cystine stones: 
 About only 3% of renal stones contain cystine. Cystine stones are uncommon 
but represent a significant percentage of childhood calculi and occur exclusively with 
hereditary cystinuria. Although the stones entirely composed of cystine, they may be 
enveloped by a layer of calcium phosphate. 
Xanthine stones: 
 These stones are very rare. 
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Indigo stones: 
 They are also rare stones. 
Features of urinary calculi: 
Types  Special features 
Calcium oxalate 
 
Phosphate (calcium, ammonium, 
magnesium phosphate) 
 
Uric acids and urates 
 
 
Cystine stones 
 
Xanthine stones 
 
Indigo stones 
- Extremely hard, frequently spiny       
(mulberry calculus) and dark colored. 
- Larger, smoother and more friable, 
chalky, alkaline urine, generally 
secondary to infection. 
- Pale yellow color with an obviously 
crystalline surface, moderately hard, 
acid urine 
- Reddish in color, stag horn, radio 
opaque. 
- Smooth and soft, brownish yellow in 
color 
- Blue in color 
Clinical features: 
 Pain 
 Coliky pain 
 Fixed pain 
 Dull ache 
 Nausea and vomiting 
 Haematuria 
 Dysuria 
 Increased frequency of micturition 
 Strangury and interruption of urine stream 
 Diaphoresis 
 Calculus anuria 
 Urinary tract infection 
 Bladder distension 
 Fever and tachycardia 
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Complications: 
 Obstructive complications 
 Hydrocalycosis 
 Hydronephrosis 
 Hydroureteronnephrosis 
 Retention of urine 
 Calculous anuria 
 Infective complications – calculous pyonephrosis 
 Irritative complications 
 Haemorrhage 
 Ulceration 
 Squamous metaplasia 
 Squamous cell carcinoma 
 Calculous ureterocele 
 Uraemia 
Laboratory assessment: 
Blood investigation: 
 Complete blood count 
 Blood urea 
 Serum creatinine 
 Serum calcium, phosphate and uric acid 
 Serum electrophoresis 
 Serum electrolytes 
Urinalysis: 
 Urinary pH 
 Deposits  
 Pus cells 
 Crystals 
Radiographic assessment: 
 KUB – X-ray of kidneys, ureters and bladder 
 IVP – Intravenous pyelogram 
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 Ultra sonogram 
 CT scan 
 MRI scan 
 Endoscopy  
Diet for renal stones: 
 The patient suffering from renal stones should avoid following: 
For calcium oxalate stones: 
 Table salt 
 Food rich in oxalate 
 Egg 
 Fish 
 Meet products 
 Pork 
 Beer 
For calcium phosphate stones: 
 Whole cereals 
 Animal tissue and organs 
 Legumes 
 Banana 
 Nuts and seeds 
For uric acid stones: 
 Food rich in purine 
 Eggs 
 Fish 
 Alcohol 
 Cashew nuts 
For cystine stones: 
 Fish 
 Proteins 
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4. MATERIALS AND METHODS: 
Materials: 
Neeradaippu thelineer has been selected from the siddha literature, “Agathitar 
vaithiya pillaithamizh written by Dr. Hakeem. P.M. Abdulla saybu. 
Ingredients: 
Group I: 
 Ahyranthes aspera (dried whole plant)  - 168ml 
 Musa paradisiacal (dried leaf)   - 168ml 
 Tribulus terrestris (dried whole plant)  - 168ml 
 Tribulus terrestris (yaanai nerunjil) (dried whole plant) - 168ml 
 Aerva lanata (dried whole plant)   - 168ml 
Group II: 
 Borax (purified)     - 2.1gm 
 Glycyrrhiza glabra      - 0.5gm 
Purification of drugs: 
Borax:  
The salt is powdered and then parched in a mud vessel to get rid of water 
content and then the purified salt is collected. 
4.1. Preparation of neeradaippu thelineer: 
 The drugs under group I are burnt separately into ashes then dissolved in 
water, kept still for day and night and then clear is obtained, to which the powder 
made by grinding the drugs under group II are added and administered, twice or thrice 
a day. 
Dose    : 160ml, twice a day after food 
Route of administration :  Enteral route. 
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 Fig.1. Sirupeelai (Aerva lanata)  Fig.2. Naayuruvi (Achyranthes aspera) 
  
   Fig.3,4. Nerunjil (Tribulus terrestris) 
   
Fig.5. Vaazhai (Musa paradisiaca)   Fig.6Athimathuram(Glycyrrhiza glabra)
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Fig.7. Vengaram (Borax)   Fig.8.Ash preparatiion  
   
 
 
Fig.9. Ash     Fig.10. Neeradaippu thelineer 
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4.2. STANDARDIZATION OF THE DRUG: 
4.2.1. Physiochemical analysis of neeradaippu thelineer: 
Table.1.Report of neeradaippu thelineer  
   
S.No Parameter Mean Value 
1.  Total Solids  0.92 % 
2.  pH  12.1 
3.  Specific gravity   0.992 
 
4.2.2. Biochemical analysis of neeradaippu thelineer: 
Add 5 gm of the sample to 50ml of distilled water. Boil the solution for 20 
minutes, cool and then filter. Use the Extract for the following tests. 
Table.2 
S.No Experiment Observation Inference 
1. Test for reducing Sugar : 
To 5ml of Benedicts qualitative reagent, 
add 10 drops of extract, then boil for two 
minutes 
Absence of Green / 
Yellow / Red 
precipitate  
Absence of 
Reducing Sugar 
2. Test for Starch : 
To 5 ml of extract add 2ml of acetic acid 
and then add few drops of N/50 Iodine 
Solution. 
Absence Blue Colour Absence of Starch 
3. Test for Proteins : 
To 2 ml of extract, add 2ml of 5% Sodium 
Hydroxide mix and add 2 drops of Copper 
Sulphate Solution. 
Absence Violet or 
Purple Colour 
Absence of Proteins 
4. Test for amino Acid : 
Place 2 drops of extract on a filter paper 
and allow to dry well. Then spray 1% 
ninhydrin over the same and allow to dry. 
Absence Violet Colour Absence of Amino 
Acid 
5. Test for Albumin : 
To 2 ml of extract, add 2ml of Esboch’s 
reagent. 
Absence Yellow 
precipitate 
Absence of 
Albumin 
6. Test for Phosphate : 
To 2ml of extract, add 2ml of ammonium 
Molybdate solution and 2ml of 
concentrated Nitric Acid. 
Absence Yellow 
precipitate 
Absence of 
Phosphate 
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7. Test for Sulphate : 
To 2 ml of extract add 2ml of 4% 
ammonium oxalate solution. 
Presence of White 
precipitate 
Presence of 
Sulphate 
8. Test for Chloride :  
Add 2ml of extract to dilute nitric acid till 
the effervescence ceases. Then add 2 ml 
of Silver Nitrate Solution. 
Presence of Cloudy 
White precipitate 
Presence of 
Chloride 
9. Test for Iron : 
To 2ml of extract, add 2ml of ammonium 
thio cynate solution and add 2ml of 
concentrated Nitric Acid. 
Presence of Red          
Color 
Presence of Iron 
10. Test for Calcium : 
To 2 ml of extract, add 2 ml of 4% 
ammonium Oxalate Solution. 
Absence of White 
precipitate 
Absence of Calcium 
11. Test for Sodium : 
Make a paste with 2 pinches of the sample 
with Hcl and Introduce it into the blue 
flame.  
Absence of Yellow 
Flame 
Absence of Sodium 
12. Test for Potassium : 
Add a pinch of the sample to 2 ml of 
Sodium Nitrate Solution. Then add 2ml of 
Cobal Nitrate in 20% acetic acid. 
Presence of Yellow 
precipitate 
Presence of 
Potassium 
13. Test for Zinc : 
To 2ml of extract, add few drops of 
Sodium Hydroxide. 
Absence of White 
precipitate 
Absence of Zinc 
14. Test for Magnesium : 
To 2ml of extract, add few drops of 
Sodium Hydroxide Solution 
Absence of White 
precipitate 
Absence of 
Magnesium 
15. Test for Alkaloids : 
d. To 2ml of extract, add 2ml of 
Potassium Iodide Solution 
 
e. To 2ml of extract add 2ml of 
Picric Acid. 
 
f. To 2 ml of extract add 2ml of 
Phosphotunqstic Acid. 
 
Absence of Red Colour 
 
 
Absence of Yellow 
Colour 
 
Absence of White ppt 
 
Absence of 
Alkaloids 
 
Absence of 
Alkaloids 
 
Absence of 
Alkaloids 
16. Test for Tannic Acid : 
To 2ml of extract add 2 ml of Ferric 
Chloride Solution 
Absence of Black ppt Absence of Tannic 
Acid 
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4.2.3. PHYSICO-CHEMICAL ANALYSIS OF TEST DRUG: 
SEM: 
The Scanning Electron Microscope (SEM) is a microscope which uses 
electrons rather than light to form an image. There are many advantages in using the 
SEM instead of a light microscope. 
The advantage of SEM is that, it has a large depth of field, which allows a 
large amount of the sample to be in focus at one time and also produces high 
resolution images, which means that closely spaced features can be examined at a high 
magnification. Preparation of the samples is relatively easy since most SEM require 
the sample to be conductive. 
The combination of higher magnification, larger depth of focus, greater 
resolution, and easy sample observation marks the SEM to be one of the most heavily 
used instruments in research areas today. 
FTIR (Fourier Transform Infrared Spectroscopy):  
• Identification of all types of organic and many types of inorganic compounds 
• Determination of functional groups in organic materials 
• Determination of the molecular composition of surfaces 
• Identification of chromatographic effluents 
• Quantitative determination of compounds in mixtures 
• Nondestructive method 
• Determination of molecular conformation (structural isomers) and 
stereochemistry (geometricalisomers) 
• Determination of molecular orientation (polymers and solutions) 
The interpretation of infrared spectra involves the correlation of absorption 
bands in the spectrum of an unknown compound with the known absorption 
frequencies for types of bonds. Significant for the identification of the source of an 
absorption band are intensity (weak, medium or strong), shape (broad or sharp), and 
position (cm-1) in the spectrum 
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4.2.4. TOXICOLOGICAL STUDIES: 
Acute and sub acute toxicity study on neeradaipu thelineer 
Animals: 
 Mice of either sex weighing 25-30g and rats weighing 210-240g were obtained 
from the animal house of Vels University. The animals were used with the approval of 
the Institute animal ethics committee and obtained from Vels University, Chennai. 
They were fed with a balanced standard pellet diet and maintained under standard 
laboratory conditions, providing 24-280C temperature, standard light cycle (12 h light, 
12 h dark) and water ad libitum. Animals were kept in cages with raised floors of wide 
mesh to prevent coprophagy. Animal welfare guidelines were observed during the 
maintenance period and experimentation. The rats were randomly assigned to control 
and different treatment groups, six animals per group. The animals were acclimatized 
for one week under laboratory conditions.  
Acute toxicity study: 
 Acute oral toxicity test for the Neeradaipu thelineer was carried out as per 
OECD Guidelines 425. As with other sequential test designs, care was taken to ensure 
that animals are available in the appropriate size and age range for the entire study. 
The Neeradaipu thelineer is administered in a single dose by gavage using a stomach 
tube or a suitable intubation cannula. The fasted body weight of each animal is 
determined and the dose is calculated according to the body weight. After the 
substance has been administered, food was withheld for a further 2 hours in mice. The 
animals were observed continuously for the first 4 h and then each hour for the next 
24 h and at 6 hourly intervals for the following 48 h after administering of the test 
drug, to observe any death or changes in general behaviour and other physiological 
activities. Single animals are dosed in sequence usually at 48 h intervals. However, the 
time interval between dosing is determined by the onset, duration, and severity of 
toxic signs. Treatment of an animal at the next dose was delayed until one is confident 
of survival of the previously dosed animal.  
Observation of toxicity signs: General behavior, respiratory pattern, cardiovascular 
signs, motor activities, reflexes, change in skin and fur, mortality and the body weight 
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changes were monitored daily. The time of onset, intensity, and duration of these 
signs, if any, was recorded.  
Sub-acute toxicity  
 In a 28-days sub acute toxicity study, twenty four either sex rats were divided 
into four groups of 6 rats each. Group I that served as normal was administered with 
distilled water (p.o.) while groups II, III and IV were administered daily with the 
Neeradaipu thelineer (p.o.) for 28 days at a dose of 0.5, 1.0 and 2.0ml/kg respectively. 
The animals were then observed daily for gross behavioural changes and any other 
signs of subacute toxicity. The weight of each rat was recorded on day 0 and weekly 
throughout the course of the study, food and water consumption per rat was 
calculated. At the end of the 28 days they were fasted overnight, each animal was 
anaesthetized with diethylether, following which they were then dissected and blood 
samples were obtained by cardiac puncture into heparinised tubes. The blood sample 
collected from each rat was centrifuged with 3000 X g at 4oC for 10 min to separate 
the serum and used for the biochemical assays.  
Hematological and blood biochemical analyses: 
 At the end of the study, all animals were kept fasted for 16-18 h and then 
anesthetized with anesthetic ether on the 28th day. Blood samples for hematological 
and blood chemical analyses were taken from retro orbital vein. Heparinized blood 
samples were taken for determining complete blood count (white blood cell count, 
differential white blood cell count, platelet count, red blood cell count, hematocrit, and 
hemoglobin) by semiautomated hematology analyzer. The serum from non-
heparinized blood was carefully collected for blood chemistry and enzyme analysis 
(glucose, creatinine, total protein, albumin, total and direct bilirubins, serum 
glutamate-oxaloacetate transaminase, serum glutamate pyruvate transaminase, and 
alkaline phosphatase were automatically determined using autoanalyzer. 
Necropsy: 
 All rats were sacrificed after the blood collection. The positions, shapes, sizes 
and colors of internal organs were evaluated. The Spleen, Testes, Pancrea, Lung, 
Liver, Brain, Heart, Stomach, Intestine, Bone, Ovary, and Kidney tissues were excised 
from all rats to visually detect gross lesions, and weighed to determine relative organs’ 
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weights and preserved in 10% neutral formalin for histopathological assessment. The 
tissues were embedded in paraffin, and then sectioned, stained with haematoxylin and 
eosin and were examined microscopically. 
Statistical analysis 
Values were represented as mean ± SEM. Data were analysed using one-way 
analysis of variance (ANOVA) and group means were compared using the Dunnet 
Multiple Comparison Test using Instat-V3 software. P values < 0.05 were considered 
significant. 
4.2.5. PHARMACOLOGICAL STUDIES: 
 
ANTIUROLITHIATIC ACTIVITY OF NEERADAIPU THELINEER IN 
ETHYLENE GLYCOL INDUCED LITHIATIC RATS 
 
Fig.11 Anatomy of kidney 
         
 Urinary lithiasis is one of the most common diseases of mankind where in 
there is aggregation of crystalline components like oxalate, calcium, phosphate, uric 
acid etc., in the kidneys and urinary tract. This is likely to be associated with 
crystalluria. The treatment of urolithiasis involves the dissolution of existing stones in 
the urinary tract and prevention of recurrence of further stone formation. Though 
many medical and sophisticated surgical therapies have been tried, they are associated 
with renal damage. In India, many traditional medicines have been used in the 
treatment of urinary stones from ancient times, and they need scientific evaluation to 
understand their mode of action.  
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Fig.12. Mechanism of stone formation 
 
 Urinary super saturation with respect to the stone forming constituents is 
considered to be one of the prime factors in determining the pathogenesis of stone 
formation. Urinary excretion of marker enzymes has found a very high diagnostic 
value in understanding the biochemical mechanisms underlying stone formation. 
Calcium phosphate lithiasis would be favored by an alkaline urine because it would 
contain less pyrophosphate and newly released phosphate as a result of its 
pyrophosphatase activity. This reduction may be due to the fact that dialyzable 
components in urine like oxalate and sulphate ions are found to inhibit the enzyme 
activity.  
 Stone formation in the kidney is one of the oldest and most wide spread 
diseases known to man. Reference to stone formation is made in the early Sanskrit 
documents in India between 3000 and2000 BC. Calcium containing stones, especially 
calcium oxalate monohydrate, calcium oxalate dehydrate and basic calcium phosphate 
are the most commonly occurring ones to and extent of 75-90% followed by 
magnesium ammonium phosphate to an extent of 10- 15%, Uric acid 3-10% and 
cystine 0.5-1. 
 
    Fig.13 
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 Kidney stones form as a result of physicochemical or genetic derangements 
leading to supersaturation of the urine with stone-forming salts or, less commonly, 
from recurrent urinary tract infection with urease producing bacteria. Stasis in the 
upper urinary tract due to local anatomic anomalies may also promote or enhance 
stone formation in susceptible individuals. In contrast, bladder stones form almost 
exclusively as a result of urinary stasis and/or recurrent infection due to bladder outlet 
obstruction or neurogenic bladder. 
 
 The patient populations at risk for different locations of stones are disparate, 
with kidney stones occurring most often in otherwise healthy individuals and bladder 
stones occurring in those with neurologic and/or anatomic abnormalities.  The 
treatment of urolithiasis involves the dissolution of existing stones in the urinary tract 
and prevention of recurrence of further stone formation.  
     Fig.15 
 
Though many medical and sophisticated surgical therapies have been tried, 
they are associated with renal damage. In India, many traditional medicines have been 
used in the treatment of urinary stones from ancient times, and they need scientific 
evaluation to understand their mode of action.  Hence in the present study, an effort 
has been made to evaluate the antiurolithiatic activity of Neeradaipu thelineer using 
ethylene glycol induced lithiatis in rats. 
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MATERIALS AND METHODS: 
Preparation of drug stock solution: 
 The siddha drug Neeradaipu thelineer was freshly prepared everyday for oral 
administration by gastric intubation method. The final filtered solution was adjusted to 
the concentration 60mg/ml of active principle as a stock solution this was directly 
administered directly to the animals at different dose level to ascertain the 
antiurolithiatic activity as well as the toxicity study. 
Animal selection: 
 For acute toxicity studies, Wistar albino mice of either sex weighing between 
28 and 30 g were selected. For the antiurolithiatic study, male Wistar weighing 
between 180-220 g were used. The animals were acclimatized to standard laboratory 
conditions (temperature: 25±2°C) and maintained on 12-h light: 12-h dark cycle.  
They were provided with regular rat chow and drinking water ad libitum. (Approval 
number: XIII/VELS/PCOL/20/2000/CPCSEA/IAEC/08.08.2012). 
Acute toxicity studies: 
 The acute oral toxicity study was carried out as per the OECD guidelines 425. 
One-tenth of the median lethal dose was taken as an effective dose. The animals were 
kept fasting overnight providing only water, after which the Neeradaipu Thelineer was 
administered orally at the dose level of 2 ml/kg body weight by gastric intubation and 
observed for 14 days. If mortality was observed in two out of three animals, then the 
dose administered was assigned as toxic dose. If mortality was observed in one 
animal, then the same dose would be repeated again to confirm the toxic dose. 
According to the results of the acute toxicity test, the doses were chosen for 
experiments. 
Ethylene glycol induced urolithiasis model: 
 Ethylene glycol induced urolithiatic model in rat was used to assess the effect 
of Neeradaipu thelineer. The study is designed to find out the effect of Neeradaipu 
thelineer on therapeutic usage against ethylene glycol induced urolithiasis. All rats 
were housed in metabolic cages for entire duration of the experiment. Animals were 
divided into five groups containing six animals in each.  Group I served as control and 
received regular rat food and drinking water ad libitum.  Ethylene glycol (0.75%) in 
drinking water was fed to Groups II-V for induction of renal calculi till 28th day.  
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Group II received Ethylene glycol alone and served as urolithiatic control. Group III 
received Neeradaipu thelineer (1ml/kg body weight) and Group IV received 
Neeradaipu thelineer (2ml/kg body weight) from 15th day till 28thday, Group V 
received standard antiurolithiatic drug, cystone (750mg/kg body weight) from 15th day 
till 28th day.   
 
Group and Treatment1: 
Group 1: Treated with Normal saline 
Group 2: Treated with Control (ethylene glycol) + vehicle 
Group 3: Treated with Neeradaipu thelineer (1ml/kg) + ethylene glycol 
Group 4: Treated with Neeradaipu thelineer (2ml/kg) + ethylene glycol 
Group 5: Treated with Standard (ethylene glycol + Cystone) 
All doses were given once daily by oral route. 
Assessment of antiurolithiatic activity: 
Collection and analysis of urine: 
 All animals were kept in individual metabolic cages and urine samples of 24h 
were collected on 28th day.  Animals were allowed free access to drinking water 
during the urine collection period.  A drop of concentrated hydrochloric acid was 
added to the urine before being stored at 4°C.  Urine was analyzed for calcium, 
phosphate and oxalate content. 
Serum Analysis: 
 After the experimental period, blood was collected from the retro-orbital vein 
under anesthetic conditions and animals were sacrificed by cervical decapitation.  
Serum was separated by centrifugation at 10,000x g for 10 min and analyzed for 
creatinine, uric acid and urea nitrogen. 
Kidney homogenate analysis: 
 The abdomen was cut open to remove both kidneys form each animal.  
Isolated kidneys were cleaned off extraneous tissue and preserved in 10% neutral 
formalin.  The kidneys were dried at 80°C in a hot air oven.  A sample of 100mg of 
the dried kidney were boiled in 10ml of 1N hydrochloric acid for 30min and 
homogenized. The homogenate was centrifuged at 2000x g for 10min and the 
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supernatant was separated. The calcium, phosphate and oxalate content in kidney 
homogenate were determined. 
DIURETIC ACTIVITY: 
Standarsization Of Furosemide:  
 Seven groups of six male wistar albino rats were employed four doses of 10, 
15, 20, 25mg/kg b.w of furosemide were administered intraperitoneally to each group 
of rats separately.  The control animals received normal saline alone. The animals 
were placed in separate cages and the urine output over 24hr period was collected. 
This procedure was repeated.   
Evaluation of diuretic activity: 
 Five groups of six male Wistar albino rats were used. First group received 
normal saline.  Second group received Neeradaipu thelineer 1ml/kg.  The third group 
received Neeradaipu thelineer 2ml/kg. The fourth group was administered furosemide 
20mg/kg.  Immediately after administration of the drug, the rats were placed in 
metabolic cages, specially designed to separate urine and fecal matter and was 
observed at room temperature. The animals were denied for food and water during the 
experiment. The urine volume (ml/day) was measured and then assayed for Na+ and 
K+ and Cl- concentrations in mMol/l, Cl was measured using routine method. 
Statistical analysis: 
 Results expressed as mean ± S.E.M.  Differences among data were determined 
using one-way ANOVA followed by Dunnet ‘t’test.  
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CLINICAL ASSESSMENT: 
Aim: 
 Urolithiasis makes revolution in day today life. Recurrent stone formation is a 
common part of the medical care of patients with stone disease. Renal calculi affects 
12% of the world population. The disease is frequently increasing in the past few 
decades due to lifestyle and dietary habits. Many remedies have been employed in the 
treatment of renal calculi, but systematic and scientific evaluation has been done only 
few. 
  Hence in this clinical study a new attempt has been made to evaluate the 
antilithiatic activity of Neeradaippu thelineer. 
Objectives:  
• To evaluate the efficacy of. Neeradaippu thelineer clinically. 
• To evaluate the safety of Neeradaippu thelineer. 
Design of the Study:  
. Phase-II(B) open clinical trial method was followed for this clinical study.  
Study Centre:  
Govt.Siddha medical college hospital and Aringar anna government hospital of 
Indian Medicine and Homeopathy, Arumbakkam, Chennai – 106.  
Selection of patients: 
 50 patients were selected for clinical trial. The selection was based on the 
inclusion and exclusion criteria. Both men and women and members of all races and 
ethnic groups are participated in this trial. Patients of different age group and different 
socio economic status were selected, 40 patients were selected as outpatients and 10 
patients were selected as inpatients and admitted in our hospital. 
Inclusion criteria:  
• Age group 20-75 
• Stone less than 1cm 
• Pain in the lion/back 
• Increase in pain with movements 
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• Burning micturation 
• Dysuria 
Exclusion criteria: 
• Acute renal colic 
• Strangury 
• Anuria 
• With Diabetes 
• Pregnant or locating women 
• With hepatic or renal or cardiac disease 
Withdrawal cretria: 
• Irregular medications 
• Sudden increase in pain 
• Alcohol abuse 
• Biphasic treatment method 
• Irregular follow up 
• In case of emergencies due to complications. 
Investigation cretria: 
 All the 50 patients were investigated for the following parameters before and 
after treatment. 
 1. Blood - TC, DC, ESR, Hb, Sugar (Random) 
 2. Serum – Urea, Creatinine, cholesterol 
 3. Routine urine analysis  
 4. Ultrasound abdomen 
Criteria for assessment of response to therapy: 
1) Marked response  : 80-90% completes relief in signs and symptoms, complete 
expulsion of    calculi, complete normalcy of pathological 
investigations. 
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2) Moderate response : 70-80%  relief in the presenting signs and symptoms, marked 
change in size, shape ,position of the calculi, marked normalcy 
of pathological conditions. 
3) Mild response      : 50-60% relief of signs and symptoms, moderate normalcy of 
pathological investigations. 
4) Poor response :below 50%  relief of signs and symptoms with no marked 
change in pathological investigations. 
Drug and dosage: 
Drug    :  Neeradaippu thelineer 
Route    :  Enteral 
Dose    :  168ml (After food) 
Medical advice 
• Drink plenty of water  
• Limit salt intake to 6g/day 
•  Reduce intake of animal protein (meat and dairy) 
• Maintain adequate dietary calcium intake (at least the recommended daily 
allowance) from food sources.  
•  Increase intake of fruit and vegetables (at least 5 portions per day)  
• Avoid grapes juice  
• Take well balanced diet 
• Ensure adequate fibre intake.  
• Restriction of oxalate rich foods, such as chocolate, nuts, soya beans and 
spinach, plus maintenance of an adequate intake of dietary calcium 
• Avoidance of beverages 
• Avoiding large doses of vitamin C 
• Avoid drinking contaminated and stagnant water 
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Statistical analysis 
 The statistical analysis of the clinical observation was analyzed with the help 
of a bio statistician, where the following test was used to find the significance of the 
results. 
Unpaired t test is a statistical test used to determine the probability of obtaining 
the 
Observed results by chance under a specific hypothesis. The results of the statistical 
analysis were discussed later. 
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5. RESULTS AND DISCUSSION: 
 The trial drug Neeradaippu thelineer was observed for various studies. The 
study includes literature survey, standardization of the drug through physio-chemical 
analysis, biochemical assay, toxicological studies, pharmacological studies and 
clinical study. These studies were carried out in the trial drug Neeradaippu thelineer. 
 Literary collections about the drug from various text books give hope about its    
Lithontriptic activity. Neeradaippu thelineer is a herbo mineral preparation, which 
contains sirukanpeelai, naayuruvi,sirunerunjil, perunerunjil, vaazhaisarugu, 
athimathuram, vengaram as its constituents. The combined effect of these plants gives 
a effective remedy for treating urolithiasis. As they have diuretic activity which helps 
to dissolve the stone. 
 Venkaram chemically called as sodium bi borate, and it is mainly used as a 
diuretic, antioxidant and has mild antiseptic activity. It may inhibit lipid peroxidation 
and enhances antilithiatic activity.  
Physio-chemical analysis: 
         Table. Report of neeradaippu thelineer  
 
S.No Parameter Mean Value 
4.  Total Solids  0.92 % 
5.  pH  12.1 
6.  Specific gravity   0.992 
 
Biochemical analysis of neeradaippu thelineer: 
 Bio chemical analysis of the trial drug shows the presence of Chloride, 
Sulphate, Iron, Magnesium, potassium. 
 Potassium is an important nutrient, the lack of potassium in the human diet, it 
makes the urine too alkaline, too much of alkaline urine results in the formation of 
kidney stones. Biochemical analysis done in neeradaippu thelineer shows the 
presence of potassium, so the trial drug is good remedy for renal stones. 
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 Magnesium is a macronutrient. The lack of magnesium leads to an increase 
alkalinity of the urine which favour the formation of stones of calcium phosphate, a 
diet rich in magnesium prevents the formation of new stones hence administration of 
the trial drug may be considered as a good remedy for renal calculi since neeradaippu 
thelineer contains magnesium. 
SEM results:  
Fig.16. SEM picture shows Nano particle size of the sample 
 
.  
Neeradaippu thelineer have good nano particle size that indicates absorption is 
very good and pharmaco therapeutic value is good. 
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FTIR absorptions: 
 
  Fig.17. showing FTIR results 
 
Frequency, cm-1 Bonds Functional 
groups 
3447.0 N-H stretch (1 
per N-H bond) 
Amines 
2362.5 P-H stretch Phosphines 
1637.0 N-H bend Amides 
687.6 C-Cl stretch Acid chlorides 
 
 
 
 
 
 
 
 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 600 400.0
0.0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100.0
cm-1
%T 
3420.0
2922.6
2360.3
2343.6
1645.6
1429.4
1319.8
1258.5
1052.1
780.1
668.2
 PG Gunapadam department  Page 137 
 
Acute toxicity study: 
Table 3: Dose finding experiment and its behavioral Signs of Toxicity 
No 
Dose 
ml/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1 10 + - - + - + - - - - - - - - - - - - -  - 
2 20 + - - + - + + - - - - - + - - - - - - - 
1. Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch Response 
7. Decreased Motor Activity 8. Tremors 9. Convulsions 10. Muscle Spasm 11. Catatonia 12. 
Muscle relaxant 13. Hypnosis 14. Analgesia 15.Lacrimation 16. Exophthalmos 17. Diarrhoea 
18. Writhing 19. Respiration 20. Mortality 
Table 4: Diuretic activity of Neeradaipu thelineer in rats 
 
Group Treatment 
and Dose 
Volume of 
Urine 
(ml/4hrs) 
Sodium 
(mMol/l) 
Potassium 
(mMol/l) 
Chloride 
(mMol/l) 
 
I Normal 
(Saline) 
0.80±0.12** 72.10±3.42** 66.21±3.8* 86.50±4.9** 
II Positive control 
(0.75% EG) 
0.66±0.14 90.02±7.2 82.2±6.4 118.2±7.8 
III Neeradaipu 
Thelineer 
1ml/kg 
1.31±0.18a 102.6±6.4b 74.2±5.11 112.24±5.6 
IV Neeradaipu 
Thelineer 
2ml/kg 
4.15±0.20** 128.42±8.0** 105.4±6.50 100.12±6.2 
V Furesemide 
20mg/kg 
6.42±1.32*** 138.64±5.7*** 82.58±6.15 98.52±7.4 
 
All values are expressed as mean ±S.E.M for six rats in each group. 
Comparisons made between ***p<0.001; **p<0.01;*p<0.05 Vs control; ap<0.001; 
bp<0.01; cp<0.05 Vs Standard. 
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Table 5: Estimation of Urinary Electrolytes of Normal and Urolithiatic Rats. 
S. 
No 
Group & Drug Treatment Estimation of Urinary Electrolytes 
Oxalate(mg/dl) Calcium(mg/dl) Phosphate(mg/dl) 
1 Normal (Saline) 0.38±0.06 2.52±0.16 3.28±0.06 
2 Positive control (0.75% EG) 2.36±0.09©,x 8.68±0.34©,x 10.32±0.14©,x 
3 Neeradaipu Thelineer 1ml/kg 1.27±0.21c,*** 4.77±0.19a,*** 7.18±0.08a,*** 
4 Neeradaipu Thelineer 2ml/kg 0.92±0.14*** 4.00±0.15*** 5.30±0.10a,*** 
5 Standard (Cystone 750 mg/kg) 0.64±0.08©,*** 3.25±0.24©,*** 4.12±0.12©,*** 
All values are expressed as mean ±S.E.M for six rats in each group. 
Comparisons made between 
ap<0.001,bp<0.01,cp,<0.05; T1,T2VsStandard. 
***p<0.001,**p<0.01,*p<0.05 ; T1,T2Vs Calculi induced. 
©p<0.001,αp<0.01,@p<0.05; Calculi induced Vs normal control. 
xp<0.001,yp<0.01,zp,<0.05; Calculi induced Vs Standard., One-way ANOVA followed by Tukey test. 
Table 6: Estimation of Kidney Homogenate Electrolytes of Normal And 
Urolithiatic Rats. 
S.No Group &Drug Treatment Estimation of Kidney Homogenate Parameters 
Oxalate(mg/dl) Calcium(mg/dl) Phosphate(mg/dl) 
1 Normal (Saline) 0.165±0.06 3.428±0.34 
 
2.12±0.08 
 
2 Positive control (0.75% EG) 1.025±0.08©,x 
 
7.02±0.26©,x 4.55±0.18©,x 
 
3 Neeradaipu Thelineer 1ml/kg 0.98±0.10a 
 
6.15±0.20a
 
2.83±0.14*** 
 
4 Neeradaipu Thelineer 2ml/kg 0.625±0.11* 5.23±0.13*** 2.36±0.09c,*** 
5 Standard (Cystone 750 mg/kg) 0.346±0.08©,*** 
 
4.40±0.18©,*** 3.00±0.12α,*** 
 
All values are expressed as mean ±S.E.M for six rats in each group.Comparisons made between 
ap<0.001,bp<0.01,cp,<0.05; T1,T2Vs Standard. 
***p<0.001,**p<0.01,*p<0.05 ; T1,T2Vs Calculi induced. 
©p<0.001,αp<0.01,@p<0.05; Calculi induced Vsnormal control. 
xp<0.001,yp<0.01,zp,<0.05; Calculi induced VsStandard., One-way ANOVA followed by Tukey test. 
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Table 7: Estimation of Serum Parameters of Normal and Urolithiatic Rats. 
S. 
No. 
Group & Drug 
Treatment 
Estimation of Serum Parameters 
BUN (mg/dl) 
Creatinine 
(mg/dl) 
Uric acid 
(mg/dl) 
1 Normal (Saline) 21.02±0.24 0.646±0.05 3.26±0.08 
2 Positive control (0.75% 
EG) 
32.15±0.36©,x 1.120±0.08α,z 6.52±0.09©,x 
3 Neeradaipu Thelineer 
1ml/kg 
27.00±0.64a,*** 0.928±0.11 5.21±0.06
a,*** 
4 Neeradaipu Thelineer 
2ml/kg 
24.48±0.42*** 0.855±0.10 5.10±0.08
a,*** 
5 Standard (Cystone 750 
mg/kg) 
22.76±0.38*** 0.720±0.08@,*** 4.03±0.07α,***
All values are expressed as mean ±S.E.M for six rats in each group. 
Comparisons made between 
ap<0.001,bp<0.01,cp,<0.05; T1,T2Vs Standard. 
***p<0.001,**p<0.01,*p<0.05 ; T1,T2Vs Calculi induced. 
©p<0.001,αp<0.01,@p<0.05; Calculi induced Vs normal control. 
xp<0.001,yp<0.01,zp,<0.05; Calculi induced Vs Standard., One-way ANOVA followed 
by Tukey test. 
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study, ethylene glycol-induced hyperoxaluria model was used to assess the antilithiatic 
activity in albino rats.  
 Chronic administration of 0.75% (v/v) ethylene glycol aqueous solution to 
male albino rats resulted in hyperoxaluria. Oxalate (2.36±0.09), calcium (8.68±0.34) 
and phosphate (10.32±0.14) excretion were increased in the calculi-induced (control) 
animals. The level of serum calcium and phosphorus levels in the urolithiatic rats 
treated with ethylene glycol is decreased and an increase in the level of oxalate. The 
decrease of serum calcium concentration indicates an increase of urinary calcium and 
calcium oxalate stone formation. The creatinine clearance of lithiatic control rats were 
altered (1.120±0.08), but it was improved significantly (P<0.001) in standard 
(0.720±0.08) and Neeradaipu thelineer (0.855±0.10) treated groups (P<0.001) when 
compared to normal rats. After treated with Neeradaipu thelineer, serum creatinine 
levels were restored to normal limits. 
  
Histopathology: 
 Histopathological studies of kidneys clearly revealed that the tissue samples 
from the control group shows tubules with single epithelial lining along the margin 
and were of normal size. In lithiatic control, all the tubules showed the presence of 
crystals, there was marked dilation of the tubules and total degeneration of epithelial 
lining with infiltration of inflammatory cells in to the interstitial space. But kidney 
architecture in standard and Neeradaipu thelineer treated groups showed characters 
similar to the normal control group. The biochemical mechanism involved in this 
process is associated with a raise in the urinary concentration of oxalate. Stone 
formation in ethylene glycol-fed animals is caused by hyperoxaluria, which causes 
increased renal retention and excretion of oxalate.  
 The glomerular filtration rate is an important parameter for ensuring renal 
function and it gets decreased in urolithiasis due to the obstruction to the outflow of 
the urine by stones in urinary system, which leads to a rise in nitrogenous waste 
products like urea, creatinine, and uric acid in blood. The urinary system is a group of 
organs in the body concerned with filtering out excess fluid and other toxic substances 
from the bloodstream. The substances are filtered out from the body in the form of 
urine. Urine is a liquid produced by the kidneys, collected in the bladder and excreted 
through the urethra and is used to extract excess minerals or vitamins as well as blood 
corpuscles from the body.  
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 One aspect of its function is to get rid of the body’s waste products that 
accumulate as a result of cellular metabolism. Because of this, the urinary system is 
sometimes referred to as the excretory system. The primary functions of kidneys are to 
maintain a stable internal environment for optimal cell and tissue metabolism. They 
separate urea, mineral salts, toxins and other waste products from the blood. 
Urolithiasis refers to calcifications that form in the urinary system, primarily in the 
kidney or ureter, and may also form in or migrate into the lower urinary system like 
bladder or urethra. Kidney stones are formed within the kidney, within the ureter or in 
the bladder. Stone formation is also caused by hyperoxaluria, which leads to increased 
renal retention and excretion of oxalate. Magnesium one of the inhibitors of stone 
formation, reduces the super saturation of calcium oxalate by reducing the saturation 
of calcium oxalate and the growth of calcium oxalate crystals. 
 
Sub acute toxicity study 
Table 8. Body wt (g) of albino rats exposed to Neeradaipu thelineer for 28days. 
Dose 
(ml/kg/day) 
Days 
1 7 14 21 28 
Control 121.15±4.00 120.54±5.51 124.20±4.52 128.11±4.24 132.04±5.00 
0.5 127.00±3.14 129.22±4.10 132.12±5.61 135.42±5.10 137.51±4.02 
1 124.24±4.24 128.18±5.18 131.00±4.10 134.11±4.18 136.32±5.10 
2 122.22±5.12 125.23±4.14 128.14±5.90 131.00±5.12 134.20±5.22 
Values are mean of 6 animals ± S.E.M. (Dunnett's test). nsP>0.05. Vs. control group 
In acute toxicity findings, there are no toxic effect was observed upto 2ml/kg 
of Neeradaipu thelineer treated via oral route over a period of 28 days. So, it can be 
concluded that the Neeradaipu thelineer can be prescribed for therapeutic use in human 
with the dosage recommendations of upto 2ml/kg. Body weight p.o. 
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Table 9. Food (g/day) intake of albino rats exposed to Neeradaipu thelineer for 
28days. 
 
Dose 
(ml/kg/day) 
Days (gms/rats) 
1 7 14 21 28 
Control 44.00±2.59 44.15±2.18 46.42±2.10 45.00±2.25 46.25±3.25 
0.5 42.21±2.47 45.30±2.42 46.40±2.16 49.15±2.18 47.18±3.05 
1 40.13±2.10 42.00±2.50 44.22±2.40 45.54±3.00 45.08±3.00 
2 42.16±2.12 45.28±2.32 46.10±2.55 45.15±2.05 45.04±3.10 
 
 
 
Table 10. Water (ml/day) intake of albino rats exposed to Neeradaipu thelineer 
for 28days. 
Dose 
(ml/kg/day) 
Days(ml/rat) 
1 7 14 21 28 
Control 52.05±2.77 50.00±3.22 52.22±3.12 52.30±3.24 50.42±3.22 
0.5 50.10±2.42 45.12±3.05 48.20±3.02 44.11±3.00 42.18±2.28 
1 48.47±2.58 44.18±3.28 45.18±3.32 45.14±2.82 44.15±3.22 
2 50.15±3.40 52.46±3.15 50.20±3.18 44.24±3.14 45.20±3.46 
Values are mean of 6 animals ± S.E.M. (Dunnett's test). nsP>0.05. Vs. control group 
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Table 11. Hematological parameters after 28days treatment with Neeradaipu 
thelineer. 
Parameter Control 0.5ml/kg 1ml/kg 2ml/kg 
RBC (mm3) 7.52±0.72 7.84±0.56 7.78±0.55 7.63±0.50 
HB (%) 15.10±0.38 15.21±0.43 15.50±0.40 15.00±0.44 
Leukocyte(x106/mL) 10.2±0.92 10.5±0.84 10.02±0.75 10.6±0.54 
Platelets/ul 454±27.00 456±30.00 486±28.14 488±26.00 
MCV (gl) 52.14±5.00 54.55±4.88 55.00±4.72 55.18±4.80 
Neutrophil 5.16±2.01 5.20±1.24 5.18±2.94 5.21±3.45 
Lymphocyte 91.00±2.92 90.10±2.50 91.20±2.12 92.02±2.11 
Monocyte 2.40±0.22 2.20±0.30 2.28±0.24 2.30±0.22 
Eosinophil 1.0±0.00  1.0±0.11 1.0±0.11 1.00±0.11 
Basophil 0 0 0 0 
ESR(mm) 1±00 1±00 1±00 1±00 
PCV 44.25±2.52 45.20±2.21 45.04±2.12 45.22±2.42 
Values are mean of 6 animals ± S.E.M. (Dunnett's test). nsP>0.05. Vs. control group 
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Table 12. Effect of treatment with Neeradaipu thelineer biochemical parameters. 
Dose (mg/kg) Control 0.5ml/kg 1ml/kg 2ml/kg 
Total Bilirubin 
(mg/dL) 
0.210±0.05 0.214±0.04 0.212±0.05 0.212±0.06 
Bilirubin direct 
(mg/dL) 
0.1±0.04 0.1±0.05 0.1±0.04 0.1±0.05 
Bilirubin 
indirect(mg/dL) 
0.1±00 0.1±00 0.1±00 0.1±00 
ALP (U/L) 272.42±10.10 270.19±11.22 278.10±10.12 285.4±10.56 
SGOT (U/L) 166.52±4.18 162.73±5.12 165.22±5.05 164.18±5.72 
SGPT(U/L) 46.8±2.23 46.2±2.32 45.00±2.25 45.28±4.11 
Total Protein (g/dl) 10.00±1.34 10.10±1.22 9.28±1.07 9.88±1.23 
Albumin(g/dl) 3.41±0.35 3.27±0.31 3.32±0.34 3.42±0.30 
Globulin(g/dl) 5.12±0.28 5.10±0.22 5.28±0.26 5.46±0.22 
Values are mean of 6 animals ± S.E.M. (Dunnett's test). nsP>0.05. Vs. control group 
Table.13 RFT 
Dose (mg/kg) Control 0.5ml/kg 1ml/kg 2ml/kg 
Urea(mg/dL) 55.00±1.34 55.42±2.62 55.12±2.84 55.42±2.30 
Creatinine (mg/dL) 0.74±0.05 0.73±0.05 0.74±0.06 0.75±0.05 
Uric acid (mg/dL) 1.5±0.10 1.6±0.12 1.6±0.14 1.6±0.12 
Na m.mol 132.21±5.00 135.3±4.04 134.12±4.28 140.12±5.00 
K m.mol 22.10±2.45 20.58±2.82 21.02±2.65 22.01±2.18 
Cl m.mol 101.00±4.22 101.02±4.12 99.56±4.12 100.00±4.12 
Values are mean of 6 animals ± S.E.M. (Dunnett's test). nsP>0.05. Vs. control group  
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Table14. Lipid Profile 
Dose (mg/kg) Control 0.5ml/kg 1ml/kg 2ml/kg 
Total cholestrol(mg/dL) 42.11±2.44 41.45±2.62 42.10±2.25 42.00±3.02 
HDL(mg/dL) 13.40±1.34 13.52±1.54 13.00±1.40 13.14±2.23 
LDL(mg/dL) 42.02±2.48 43.15±2.62 42.88±2.92 43.00±3.00 
VLDL(mg/dl) 16.28±2.22 16.26±2.30 16.12±1.42 16.26±1.54 
Triglycerides (mg/dl) 85.24±2.20 85.24±2.28 85.74±3.00 85.42±2.70 
TC/HDL ratio (g/dl) 3.36±0.26 3.40±0.24 3.27±0.28 3.53±0.24 
Blood glucose(mg/dl) 122.52±5.78 124.26±4.29 124.10±4.22 124.18±3.85 
 
Table.15 Urine Analysis 
Parameters Control 0.5ml/kg 1ml/kg 2ml/kg 
Colour Yellow Yellow Yellow Yellow 
Transparency Clear Slightly turbid Slightly cloudy Slightly turbid 
Specific gravity 1.010 1.010 1.010 1.010 
PH >7.2 >7.2 >7.4 >7.2 
Protein Nil 1+ 2+ 2+ 
Glucose Nil Nil Nil Nil 
Bilirubin -ve -ve -ve -ve 
Ketones -ve -ve -ve -ve 
Blood Absent Absent Absent Absent 
Urobilinogen Normal Abnormal Abnormal Abnormal 
Pus cells 0-cells/HPF 1-cell/HPF 2-cells/HPF 1-cell/HPF 
RBCs Nil Nil 0-1cells/HPF Nil 
Epithelial cells Nil 1-cell/HPF Nil 1-cell/HPF 
Crystals Nil Nil Nil Nil 
Casts Nil Nil Nil Nil 
Others Bacteria seen Bacteria seen Bacteria seen Bacteria seen 
 
  
 PG Gunapadam department  Page 149 
 
Table 16. Effect of oral administration of Neeradaipu thelineer on organ weight 
Dose (mg/kg) Control 0.5ml/kg 1ml/kg 2ml/kg 
Liver (g) 5.28±0.15 5.30±0.17 5.42±0.18 5.10±0.15 
Heart (g) 0.61±0.05 0.61±0.05 0.60±0.04 0.61±0.04 
Lung (g) 1.50±0.06 1.51±0.08 1.45±0.06 1.50±0.05 
Spleen (g) 0.65±0.05 0.66±0.04 0.65±0.04 0.65±0.05 
Ovary (g) 1.79±0.14 1.76±0.13 1.75±0.16 1.77±0.15 
Testes (g) 1.48±0.10 1.47±0.12 1.46±0.11 1.47±0.12 
Brain (g) 1.56±0.12 1.55±0.13 1.55±0.13 1.54±0.12 
Kidney (g) 0.70±0.04 0.71±0.04 0.71±0.04 0.71±0.05 
Stomach (g) 1.37±0.12 1.38±0.10 1.37±0.10 1.38±0.12 
Values are mean of 6 animals ± S.E.M. (Dunnett's test). nsP>0.05. Vs. control group 
 
Animals were not shown any significant toxic clinical signs during the dosing 
period of 28 days. All animals from control and all the treated dose groups survived 
throughout the dosing period of 28 days. Results of body weight determination of 
animals of control and different dose groups exhibited comparable body weight gain 
throughout the dosing period of 28 days. During dosing period, the quantity of food 
consumed by animals from different dose groups was found to be comparable and 
normal with that of control animals. Ophthalmoscopic examination of animals in 
control and Neeradaipu thelineer treated groups did not reveal any major and 
remarkable abnormality. These tests conducted on the experimental animals at 
termination and recorded did not reveal any abnormalities.  
 Urine analysis data of control group and treated group of animals determined 
in week 4 did not reveal any abnormalities. Comparison of organ weights of treated 
animals with respective control animals on day 28 was found to be comparable. Gross 
pathological examination of animals in control as well as the treated groups did not 
reveal any abnormalities. The results of haematological investigations revealed no 
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Sub acute toxicological study slides: 
    BONE 
 Fig.23. low dose   Mid dose              High dose 
             
      BRAIN  
Fig.24. low dose  Mid dose   High dose 
                
HEART 
Fig.25 low dose   Mid dose   High dose 
              
LUNG 
Fig.26. low dose  Mid dose   High dose 
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LIVER 
 Fig.27. low dose  Mid dose   High dose 
                                     
        PANCREAS 
Fig.28. low dose  Mid dose   High dose 
               
SPLEEN 
Fig.29. low dose  Mid dose   High dose 
            
STOMACH 
Fig.30. low dose  Mid dose   High dose 
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      INTESTINE 
Fig.31. low dose   Mid dose   High dose 
              
      KIDNEY 
Fig.32. low dose  Mid dose   High dose 
               
OVARY 
Fig.33. low dose  Mid dose   High dose 
               
TESTIS 
Fig.34. low dose   Mid dose   High dose 
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Histopathology of kidney: 
 Fig.35 Control     Control 
  
Fig.36 NT I     NT I 
  
 Fig.37 NT II     NT II 
  
 Fig.38 Std     Std 
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Histopathology of kidney: 
Fig.39 Control    Control 
    
Fig.40 Normal    Normal 
    
Fig.41 NT I    NT I 
    
Fig.42 NT II    NT II 
    
 Fig.43 Standard    Standard 
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Statistical analysis: 
P value and statistical significance:  
  The two-tailed P value equals 0.0032 
  By conventional criteria, this difference is considered to be very statistically 
significant.  
Confidence interval: 
  The mean of BT minus AT equals 24.88 
  95% confidence interval of this difference: From 11.51 to 38.24  
Intermediate values used in calculations: 
  t = 4.4012 
  df = 7 
  standard error of difference = 5.652  
Review your data: 
  Group   BT     AT   
 Mean 26.75 1.88 
           SD 16.17 1.46 
SEM 5.72 0.52 
             N   8       8     
 
The clinical study was based on phase II open clinical trial method. It was 
conducted in post graduate Gunapadam department of OP and IP at Aringar Anna 
Government Hospital of Indian Medicine. 50 patients were selected based on 
inclusion and exclusion criteria. A thorough history, symptomatic evaluation and 
clinical examination were done for all patients before and after treatment periods. All 
the patients were investigated for routine urine and blood analysis such as blood urea, 
serum creatinine and USG abdomen. 
Among 50 patients 31 were male and 19 were female a predominance of men 
over women. The maximum prevalence of disease was found between the age groups 
of 30-50 out of 50 patients 37 patients belongs to this age group. Among 50 patients 
43 patients were non-vegetarians, 15 were smokers and 18 were alcoholics. Among 
the distribution of the site of the calculi 14 had unilateral renal calculi, 32 had bilateral 
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renal calculi, and 2 had ureteric calculi and 1with vesicle calculi. The prevalence of 
unilateral and bilateral, bilateral calculi was maximum. 
Improvement in signs and symptoms there is 100 % improvement in burning 
micturition and haematuria, 92.8% recovered from back/loin pain, nausea and 
vomitting, 91.4% improvement in increase in pain with movements, 80% improved 
from dysuria. 
The gradation results shows among 50 patients 41 patients had marked 
response, 4 patients had moderate, 3 patients with mild response and 2 patients with 
poor response. The statistical result of the clinical study shows that the results are very 
statistically significant. Thus my drug is used for the treatment of unbearable 
symptoms of urolithiasis. 
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7. CONCLUSION 
 Renal calculus is a solid concretion or crystal aggregation formed in the 
kidneys from dietary minerals in the urine.  Urinary super saturation in respect to 
constituents which form stone is generally considered to be one of the causative 
factors in calculogenisis. Nowadays lithotripsy or surgery is choice for kidney stones 
though its adverse effects are very high. To get around these ill effects, a drug which 
inhibits calculogenisis with high success rates and having lower side effects and safety 
profile is an A1 choice for renal calculi; ergo in the present study the drug 
“neeradaippu thelineer” is taken for trial. 
 Neeradaippu thelineer is a herbo mineral preparation. The preparation of the 
trial drug was standardized through physio-chemical and bio-chemical studies.  
In acute toxicity findings, there are no toxic effect was observed upto 2ml/kg 
of Neeradaipu thelineer treated via oral route over a period of 28 days. So, it can be 
concluded that the neeradaipu thelineer can be prescribed for therapeutic use in 
human with the dosage recommendations of upto 2ml/kg. Body weight p.o. 
 The acute and sub-acute toxicity studies had been assessed in the drug which 
revealed nil toxic or harmful side effects, for as much as the drug is considered safe 
for human use. Also histopathological studies reveals that there are no toxic symptoms 
in acute and sub-acute studies. 
 The anti urolithiatic activity of neeradaipu thelineer was very well established 
in EG induced animal model studies. The results showed the trial drug had good 
antilithiatic activity and also good diuretic activity. 
 The clinical study had been conducted in 50 patients showed that the drug 
neeradaipu thelineer is very efficasious in treating renal calculi. The overall 
compliance of the drug was good. There are no clinically significant adverse reactions 
reported during the course of the study. 
 From the above studies it is clear-cut that the drug neeradaipu thelineer which 
dissolves and expels the stones and considerable reduction in overall signs and 
symptoms is an excellent and efficasious elixir for all renal calculi.  
 Further studies are required to establish the mechanism of action as an 
antiurolithiatic agent. 
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8. SUMMARY 
 Appertaining to strong literature evidence in Siddha text “neeradaippu 
thelineer” a herbo mineral preparation was opted for the trial to establish its activity in 
treating renal calculi. Collection of relevant literature evidences from various siddha 
texts and modern texts for the ingredients used in the preparation of neeradaippu 
thelineer which claims support as a lithontriptic agent. 
  The trial drug was subjected to various studies through which the efficacy of 
the drug is proved.  
The preparation of the drug and the physical character of the trial drug were 
standardized. 
The chemical analysis reveals the presence of various essential elements like 
Potassium, Magnesium, Calcium, Sodium, Phosphorus and sulphur. 
 The acute and sub acute toxicological studies proved that the drug is non toxic.   
The pharmacological studies conducted in experimental animal models reveal 
that the drug has effective anti urolithiatic activity and very good diuretic activity as 
well. 
Clinical study had been conducted in 50 patients of whom 40 patients were 
treated in the outpatient department and 10 patients were treated in the inpatient post 
graduate department of Gunapadam.  The results of the clinical study showed it is 
excellent and efficacious in treating urolithiasis. No clinically significant adverse 
effects were noted or observed during the course of the study. 
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1.  8129  Kanchana 
40/Female 
Cough,expectoration, 
wheezing,dyspnoea, 
chest pain 
26.7.12 
To 
2.9.12 
B
T 
10200 62 36 4 14 28 10 110 17 169 NIL NIL PCS 200 
 Good 
 A
T 
9900 60 40 5 8 10 12.
5 
108 21 161 NIL NIL NIL 350 
2.  9283 Rajammal 
60/Female 
Cough,expectoration, 
wheezing,dyspnoea, 
head ache 
29.7.12 
To 
12.11.12 
B
T 
9400 66 34 6 8 22 12 129 20 160 NIL NIL NIL 150 
 
Good 
 
A
T 
9500 59 39 3 6 12 12.
8 
89 19 155 NIL NIL NIL 250 
3. 413  Meenakshi 
55/Female 
Cough,expectoration, 
wheezing,sneezing, 
headache 
1.8.12 
To 
20.9.12 
B
T 
9700 60 39 4 15 33 14.
8 
90 20 143 NIL NIL FPC 200 
 
Good 
 
A
T 
8800 57 36 6 12 18 14 90 17 158 NIL NIL NIL 350 
4.  1198 Kadhar 
38/Male 
Cough,expectoration, 
wheezing,dyspnoea, 
head ache,sneezing 
3.8.12 
To 
4.10.12 
B
T 
9900 64 45 4 7 20 9 112 22 154 NIL NIL FPC 200 
 
Good 
 
A
T 
9500 53 42 5 2 7 10 110 19 140 NIL NIL NIL 350 
 
5.  2489 Vijayalakshmi 
40/Female 
Cough,expectoration, 
wheezing,dyspnoea, 
headache,sneezing 
12.8.12 
To 
11.9.12 
B
T 
9900 57 35 5 28 55 12 91 25 168 NIL NIL NIL 150 
 
  
 
     Poor      A
T 
9000 55 34 4 25 40 12.
3 
91 21 158 NIL NIL NIL 200 
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6. 3419 Malliga 
61/Female 
Cough,expectoration,w
heezing,dyspnoea,head 
ache 
16.8.12 
To 
17.9.12 
B
T 
10500 64 31 5 12 26 10 102 18 165 NIL NIL PCS 200 
 Good 
 A
T 
9900 57 40 3 6 8 12 98 20 160 NIL NIL NIL 350 
7. 4510 Pandian 
45/Male 
Cough,expectoration,w
heezing,dyspnoea,head 
ache,sneezing 
18.8.12 
To 
15.9.12 
B
T 
10400 64 34 5 9 20 12 139 21 170 NIL NIL FPC 180 
 
Good 
 
A
T 
9500 56 39 3 6 12 13 89 19 155 NIL NIL NIL  
340 
8.  1358  Kuppusamy 
48/Male 
Cough,expectoration,w
heezing,dyspnoea,head 
ache,sneezing 
22.8.12 
To 
1.10.12 
B
T 
9100 60 38 2 5 12 14 80 20 133 NIL NIL FPC 250 
 
Poor 
 
A
T 
8400 56 38 6 9 15 14 90 18 168 NIL NIL NIL 300 
9. 2182 Priya 
23/Female 
Cough,expectoration,w
heezing,dyspnoea,head 
ache,sneezing 
24.8.12 
To 
29.9.12 
B
T 
9800 54 42 4 3 6 9.4 87 23 164 NIL NIL FPC 300 
 
Good 
 
A
T 
9500 53 42 5 2 5 10 89 19 153 NIL NIL NIL 350 
 
10. 4123 Ranjini 
21/Female 
Cough,expectoration,s
neezing,dyspnoea,whe
ezing,head ache 
25.8.12 
To 
10.10.12 
B
T
9100 58 38 3 28 53 11.
2
91 21 165 NIL NIL NIL 180   
 
     Good     A
T 
9000 55 39 6 23 40 12 91 23 158 NIL NIL NIL 250 
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11. 712 vanithavani 
28/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing,head ache 
1.9.12 
To 
15.10.1
2 
BT 9700 53 37 4 4 9 12.1 85 18 141 NIL NIL PCS 240 
 Good 
 AT 9400 57 40 3 3 6 13 83 16 138 NIL NIL NIL 380 
12. 742 Dhanalakshmi 
49/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing,head ache 
2.9.12 
To 
11.10.1
2 
BT 8600 56 40 4 15 23 12 85 21 153 NIL NIL FPC 260 
 
Moderate 
 
AT 8200 59 39 3 8 12 13.8 76 19 135 NIL NIL NIL 300 
13. 967 Manjula 
42/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing,head ache 
4.9.12 
To 
5.10.12 
BT 9200 58 33 6 10 15 14 90 20 177 NIL NIL FPC 160 
 
Moderate 
 
AT 8400 56 38 6 12 18 13 90 18 168 NIL NIL NIL 240 
14. 1429 Shanthiraj 
48/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing,head ache 
6.9.12 
To 
14.01.1
2 
BT 9800 57 42 3 3 6 9.2 89 23 164 NIL NIL PCS 120 
 
Good 
 
AT 9300 54 42 4 3 6 9.6 87 19 153 NIL NIL NIL 250 
15. 2849 Rejinabanu 
 39/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing,head ache 
9.9.12 
To 
13.10.1
2 
BT 9900 56 39 5 28 53 11 91 21 160 NIL NIL NIL 200  
Moderate  
 
                   
AT 9400 53 39 8 15 20 12.3 88 18 152 NIL NIL NIL 250 
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16. 3418 Ramalingam 
41/Male 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing, 
8.9.12 
To 
10.10.12 
BT 10400 56 39 6 10 28 11 85 18 143 NIL NIL PCS 200 
 Good 
 AT 9900 57 40 3 6 12 11 85 20 152 NIL NIL NIL 350 
17. 9166 Bavani 
34/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing,head ache 
11.9.12 
To 
14.11.1
2
BT 9800 58 40 2 15 25 13.
5 
78 21 159 NIL NIL FPC 180 
 
Good 
 
AT 8500 56 39 5 8 14 13 80 18 145 NIL NIL NIL 270 
18. 942 Pandiyammal 
59/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing, 
13.9.11 
To 
14.10.1
2
 8200 58 38 6 13 15 12 98 20 173 NIL NIL FPC 150 
 
Good 
 
 8400 56 38 6 7 10 13 92 18 164 NIL NIL NIL 250 
19. 1987 Parameshwwari 
44/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing, 
17.9.12 
To 
1.11.12 
BT 9300 52 48 4 3 6 11.
8 
89 23 164 NIL NIL FPC 130 
 
Moderate 
 
AT 9100 50 42 4 3 6 12 85 19 153 NIL NIL NIL 220 
20. 2345 Maariyammal 
58/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing,head ache 
20.9.12 
To 
28.10.1
2 
BT 9400 56 39 5 28 55 11.
2 
91 21 160 NIL NIL NIL 120 
 
 
Moderate  
 
                   
AT 9000 69 36 3 18 22 12 89 18 158 NIL NIL NIL 200 
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21. 5311 Lalitha 
35/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing,head ache 
24.9.12 
To 
2.11.12 
BT 9600 59 32 10 6 22 11 120 18 175 NIL NIL PCS 200  
 Good 
 AT 9400 57 40 3 4 9 13 110 20 157 NIL NIL NIL 250 
22. 6181 Jarina  
31/Female 
Cough,expectoration,sn
eezing,dyspnoea,wheez
ing 
28.9.12 
To 
4.11.12 
BT 9800 52 39 9 6 12 12 110 21 163 NIL NIL FPC 150 
 
Good 
 
AT 9500 57 39 3 14 24 12 110 19 158 NIL NIL NIL 250 
 
 
23. 7280 Pazhani 
40/Male 
Cough,,sneezing, 
dyspnoea,wheezing, 
headache 
30.9.12 
To 
28.10.1
2 
BT 9400 58 38 4 12 10 12.
8 
102 20 173 NIL NIL FPC 100 
 
Good 
 
AT 8900 54 45 4 8 11 13 98 18 169 NIL NIL NIL 220 
 24. 9010 Pavvalakodi 
48/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing,head ache 
2.10.12 
To 
22.11.1
2 
BT 9600 57 39 4 15 26 9 87 23 169 NIL NIL FPC 100 
 
Good 
 
AT 9300 54 44 2 3 8 10 87 19 155 NIL NIL NIL 200 
25. 729 Suganya 
28/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing, 
6.10.12 
To 
20.11.1
2 
BT 9500 55 39 6 12 25 11.
2 
93 21 210 NIL NIL FPS 120 
 
 
   Good  
 
                   
AT 9000 58 39 3 8 13 12 81 23 159 NIL NIL NIL 250 
      
 STUDY ON ORITHAZHTHAMARAI CHOORANAM IN OP DEPT ON MANAGEMENT OF BRONCHIAL ASTHMA 
SL
N
O 
Op. 
No 
Name/ Age/ 
Sex Complaints 
Duratio
n of 
Days 
B
T 
& 
A
T 
INVESTIGATION  
 
Results 
BLOOD    
Blo
od 
CL 
Urine Peak 
Flow 
Meter 
Reading 
L/S 
TC 
cells/
cum
m 
DC (%) ESR(mm) Hb 
gm 
Sgr 
mg/
dl 
Ur 
m
g/
dl 
  
Sgr 
  
Alb 
   
Dep      
P 
     
L 
   
E 
½ 
hr 
 1 
hr 
26. 831 Parveen 
10/Female 
Cough,expectoration,sn
eezing,dyspnoea, 
wheezing,head ache 
13.10.1
2 
To 
1.12.12 
B
T
9000 45 48 7 8 20 10 85 18 149 NIL NIL FPC 250 
 Good 
 A
T 
9300 57 40 3 4 9 11 88 20 152 NIL NIL NIL 340 
27. 1299 Bala 
45/Male 
Cough,expectoration, 
sneezing,dyspnoea, 
head ache,rhinitis 
15.9.12 
To 
2.11.12 
B
T 
8800 65 31 4 12 28 14 119 21 179 NIL NIL FPC 200 
 
Good 
 
A
T 
8500 59 39 3 14 26 14 85 19 155 NIL NIL NIL 280 
28. 1757 Mohan 
36/Male 
Cough,expectoration,sn
eezing,dyspnoea,wheez
ing,head ache 
28.9.11 
To 
7.12.11 
B
T 
8400 56 38 6 10 15 14 90 20 173 NIL NIL FPC 100 
 
   poor 
 
A
T 
8300 56 41 3 8 12 15.
2 
87 18 168 NIL NIL NIL 160 
29. 2345 Suganthi 
32/Female 
Cough,expectoration,sn
eezing,dyspnoea,wheez
ing,head ache 
30.9.11 
To 
7.12.11 
B
T
9700 54 42 4 8 16 9.4 87 23 164 NIL NIL FPC 150 Good 
 
A
T 
8800 54 44 2 3 6 12.
6 
82 19 153 NIL NIL NIL 250 
30. 2844 Malathi 
29/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing,head ache 
2.10.12 
To 
7.12.11 
B
T 
9600 58 36 3 28 53 11.
2 
91 21 160 NIL NIL NIL 150 
 
 
   poor 
                 A
T 
9000 56 39 2 26 49 11 95 23 163 NIL NIL NIL 180 
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31. 5237  Madassamy 
39/Male 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing,head ache 
5.10.1
2 
To 
7.11.1
2 
B
T 
9800 45 48 7 8 20 10 85 18 143 NIL NIL PCS 250 
 Good 
 A
T 
9400 58 40 3 4 9 11 90 20 152 NIL NIL NIL 350 
32. 7455 Sharmila 
34/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
head ache,rhinitis 
8.10.1
2 
To 
17.11.
12 
B
T 
8300 60 31 4 12 28 15.2 12
3 
21 173 NIL NIL FPC 200 
 
300 
Good 
 
A
T 
8500 59 39 3 14 24 15 85 19 154 NIL NIL NIL 
33. 9034 Alamelu 
60/Female 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing,head ache 
10.10.
12 
To 
7.10.1
2 
B
T 
8900 56 37 6 10 15 14 90 20 173 NIL NIL FPC 100 
 
160 
Mild 
 
A
T 
8300 56 41 3 8 12 14 87 18 169 NIL NIL NIL 
34. 213 Selvaraj 
25/Male 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing,head ache 
12.10.
12 
To 
25.11.
11 
B
T 
9600 54 42 4 8 16 10 87 23 164 NIL NIL FPC 150 
 
220 
Good 
 
A
T 
8800 56 46 2 3 6 12 82 19 155 NIL NIL NIL 
35. 934 Abdhul 
58/Male 
Cough,expectoration, 
sneezing,dyspnoea, 
wheezing,head ache 
15.10.
12 
To 
17.11.
12 
B
T 
9300 58 39 3 28 53 11.2 91 21 160 NIL NIL NIL 250 
 
350 
Good  
 
              A
T 
9000 56 39 2 19 32 12 88 23 150 NIL NIL NIL 
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36. 2400  Kanmani 
29/Female 
Cough,expectoration,
sneezing,dyspnoea, 
wheezing,head ache 
20.10.1
2 To 
31.11.1
2 
B
T 
8800 55 34 6 21 42 12 99 18 141 NIL NIL PC
S 
200  
 Good 
 A
T 
8400 57 40 3 14 19 13 83 20 152 NIL NIL NIL  340 
37. 4238 Raja 
35/Male 
Cough,expectoration,
sneezing,dyspnoea, 
wheezing 
23.10.1
2 
To 
28.11.12 
B
T 
9500 59 40 3 15 25 12 85 21 159 NIL NIL FP
C 
180 
 
Good 
 
A
T 
9300 58 39 2 8 12 13 90 19 155 NIL NIL NIL 250 
38. 5108 Kanaga 
32/Female 
Cough,expectoration,
sneezing,dyspnoea, 
wheezing,head ache 
25.10.1
2 To 
28.11.1
2 
B
T 
8900 56 38 6 10 14 13 98 20 174 NIL NIL FP
C 
150 
 
Good 
 
A
T 
8500 54 42 5 9 12 13 82 18 167 NIL NIL NIL 260 
39. 6125 Sivakumar 
37/Male 
Cough,expectoration,
sneezing,dyspnoea, 
wheezing 
29.10.1
1 To 
31.11.1
2 
B
T 
1000
0 
64 31 5 2 5 15 87 23 164 NIL NIL FP
C 
240 
 
Good 
 
A
T 
9800 54 42 4 3 6 15 83 19 153 NIL NIL NIL 380 
40. 7892 Bhathmaja 
46/Female 
Cough,expectoration,
sneezing,dyspnoea, 
wheezing,head ache 
31.11.1
2 To 
28.12.1
2 
B
T 
8700 55 39 6 10 26 9 110 29 170 NIL NIL NIL 280 
 
 
Moderat
e  
 
                
A
T 
8400 58 39 3 5 14 12 98 23 154 NIL NIL NIL 320 
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1. 1438  Pazhani 
40/Male 
Cough,expectoration,
sneezing,dyspnoea, 
wheezing,head ache 
15.9.12 
To 
21.10.1
2 
B
T 
8900 55 39 6 20 44 11 85 18 143 NIL NIL PC
S 
220  
 Good 
 A
T 
8400 57 40 3 14 19 12 89 20 155 NIL NIL NIL  320 
2. 1480  Ganesan 
27/Male 
Cough,expectoration,
sneezing,dyspnoea, 
wheezing 
17.9.12 
To 
29.10.1
2 
B
T
8600 59 40 3 15 25 11 85 21 159 NIL NIL FP
C
180 Good 
 
A
T 
8300 58 36 2 8 13 12 80 19 159 NIL NIL NIL 260 
3. 58  Abubakar 
50/Male 
Cough,expectoration,
sneezing,dyspnoea, 
wheezing,head ache 
22.9.12 
To 
5.10.12 
B
T 
8600 56 38 6 10 14 13 90 20 174 NIL NIL FP
C 
150 
 
Moderat
e 
 A
T 
8100 52 42 4 8 15 13.
8 
88 18 169 NIL NIL NIL 220 
4. 71  Thoudasetiyar 
65/Male 
Cough,expectoration,
sneezing,dyspnoea, 
wheezing 
24.9.12 
To 
12.10.1
2 
B
T 
1000
0 
65 31 5 2 5 14 90 23 164 NIL NIL FP
C 
220 
 
Good 
 
A
T 
9800 54 44 4 3 6 15 92 19 158 NIL NIL NIL 350 
5. 1483 Anjalai Cough,expectoration,
sneezing,dyspnoea, 
wheezing,head ache 
12.9.12 
To 
22.10.1
2 
B
T 
8600 55 39 6 10 28 9 110 29 170 NIL NIL NIL 250 
 
 
Moderat
e  
 
                
A
T 
8100 58 38 3 5 14 10 115 23 158 NIL NIL NIL 320 
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6. 130 Krishnaveni 
60/Female 
Cough,expectoration,
sneezing,dyspnoea, 
;wheezing,head ache 
1.910.1
2 To 
7.11.12 
B
T 
8700 55 39 6 2
0 
44 11 85 18 143 NI
L 
NI
L  
PCS 200  
 Good 
 A
T 
8400 57 40 3 1
4 
19 13 83 20 152 NI
L 
NI
L 
NIL  320 
7. 135 Sarojimi 
41/Female 
Cough,expectoration,
sneezing,dyspnoea, 
wheezing 
1.10.12 
To 
22.10.1
2 
B
T 
8500 59 40 3 1
5 
25 12 85 20 159 NI
L 
NI
L  
FPC 180 
 
Good 
 
A
T 
8800 58 39 2 8 3 12 85 19 155 NI
L 
NI
L 
NIL 260 
8. 191 Vasantha 
45/Female 
Cough,expectoration,
sneezing,dyspnoea, 
wheezing,head ache 
8.10.12 
To 
31.10.1
2 
B
T
8400 56 38 6 1
0
14 12 90 20 183 NI
L
NI
L
FPC 150 Mild 
 
A
T 
8100 54 42 4 8 12 13 85 18 168 NI
L 
NI
L 
NIL 220 
9. 325 Knagarani 
40/Female 
Cough,expectoration,
sneezing,dyspnoea, 
wheezing 
26.10.1
2 To 
2.11.12 
B
T 
1000
0 
66 31 5 2 5 12 87 23 164 NI
L 
NI
L  
FPC 220 
 
Good 
 
A
T 
9800 56 42 4 3 6 13 88 20 154 NI
L 
NI
L 
NIL 350 
10.  462 Savithri 
40/Female 
Cough,expectoration,
sneezing,dyspnoea, 
wheezing,head ache 
21.11.1
2 To 
5.12.12 
B
T 
8900 55 39 6 1
0 
28 9 110 29 170 NI
L 
NI
L 
NIL 280 
 
 
Moderat
e  
 
                
A
T 
8200 58 39 3 5 14 12 100 23 159 NI
L 
NI
L 
NIL 350 
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SL 
N
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OP 
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TC 
Cells/cu.mm 
Blood investigation Urine analysis  
 
USG 
abdomen 
 
 
Result DC(%) ESR(hr)  
Hb 
 
Sgr 
 
UR 
 
CR 
 
CL 
 
alb 
 
sgr 
 
Dep 
P L E 1/2 1 
1 
 
 
5959 
 
 
Anbuvendan /40/M 
 
 
BT 8400 54 38 5 10 10 12 90 21 0.7 160 Nil Nil PCS Bilateral 
calculi 
Good  
AT 8600 54 48 3 4 8 13 99 20 0.3 155 Nil Nil Nil 
2 
 
 
6590 
 
 
Bavani/40/F 
 
BT 8500 54 46 2 10 20 10 112 23 0.6 154 Nil Nil FPC Bilateral 
calculi 
Good 
AT 
 
8600 59 46 1 5 10 11 100 19 0.3 150 Nil Nil Nil 
3 7123 Sarasvathi/42/F BT 8400 58 44 2 10 22 11 78 26 0.7 174 Nil Nil FEC Uretric 
calculi 
Good 
AT 8500 62 38 1 7 14 12 70 23 0.3 166 Nil Nil Nil 
4 6905 Manokar/44/M BT 8200 52 38 10 10 20 9.4 88 20 0.6 150 Nil Nil FPC Bilateral 
Calculi  
Good 
AT 8500 55 36 7 5 10 10 80 15 0.4 144 Nil Nil Nil 
5 8354 Maheshwari/43/F BT 9300 55 45 5 15 33 12 120 27 0.7 164 Nil Nil FPC Bilateral 
calculi 
Good 
AT 9600 60 40 3 11 20 13 118 25 0.4 155 Nil Nil Nil 
6 8768 Vembuli/38/F BT 9600 49 37 8 7 15 9.7 110 20 0.7 151 Nil Nil FPC Bilateral 
calculi 
Moderate 
AT 9800 52 30 5 5 10 11 100 19 0.6 146 Nil Nil Nil 
7 9308 kesavan/69/M BT 9500 58 34 6 10 25 10 88 22 0.6 175 Nil Nil Nil Bilateral 
calculi 
Good 
AT 9700 62 30 4 4 8 11.3 80 20 0.3 169 Nil Nil Nil 
8 4456 Balaji /26/M BT 8400 32 39 5 7 12 12 110 22 0.7 158 Nil Nil FEC Bilateral 
Calculi 
Good 
AT 8500 38 35 3 5 10 13 100 18 0.4 151 Nil Nil Nil 
9 4832 Saleem/50/M BT 8500 53 40 5 10 23 9.5 102 28 0.7 165 Nil Nil Nil unilateral 
Calculi 
Good 
AT 8800 59 31 2 7 14 10 99 25 0.5 160 Nil Nil Nil 
10 6500 Kodeeswaran/49/M BT 9000 60 37 3 10 20 13 159 33 0.8 185 Nil Nil FPC Bilateral 
calculi  
Good 
AT 9400 64 35 1 5 10 13 152 30 0.4 179 Nil Nil Nil 
 
  
SL 
N
O 
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CR 
 
CL 
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Dep 
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11 9381 Thiyagarajan/49/M BT 9600 59 36 5 20 55 12 82 33 0.5 150 Nil Nil FEC Bilateral 
calculi 
Good 
AT 9800 62 32 2 10 20 13.1 75 26 0.3 145 Nil Nil Nil 
12 3411 Sankar/35/M BT 8500 55 35 3 20 40 13 109 31 0.7 156 Nil Nil FPC unilateral 
Calculi 
Good 
AT 8700 60 31 1 10 20 14 103 28 0.3 145 Nil Nil Nil 
13 1915 Sundari/45/F BT 9800 59 38 3 7 15 15 81 29 0.7 188 Nil Nil FPC unilateral 
calculi 
Good 
AT 10000 63 35 1 5 10 14 75 25 0.4 180 Nil Nil Nil 
14 1937 Muthu /42/M BT 9700 54 41 5 5 10 12 92 23 0.4 184 Nil Nil FPC Bilateral 
calculi 
Poor  
AT 9800 61 35 2 3 9 13 86 22 0.4 176 Nil Nil Nil 
15 2546 Saradha/38/F BT 9000 54 42 4 12 45 12 110 30 0.5 183 Nil Nil FPC Vesical 
calculi 
Good 
AT 9800 62 39 2 5 10 13 105 25 0.3 175 Nil Nil Nil 
16 3125 Pachaiyappan/58/M BT 8600 57 36 7 7 12 12 160 30 0.7 176 Nil Nil FPC unilateral 
calculi 
Good 
AT 8900 60 30 4 3 9 13 140 26 0.4 166 Nil Nil Nil 
17 1767 Kokila/49/F BT 9800 59 37 4 3 4 12 88 31 0.7 176 Nil Nil FPC Bilateral 
Calculi 
Good 
AT 10000 63 32 2 1 2 13 76 26 0.5 168 Nil Nil Nil 
18 2890 Venkat/41/M BT 9800 57 38 6 20 42 9.5 172 28 0.4 114 Nil Nil FEC Bilateral 
Calculi 
Good 
AT 11000 62 35 3 10 20 10 162 24 0.2 102 Nil Nil Nil 
19 2704 Vetrivel/35/M BT 9000 55 39 6 2 5 15 109 31 0.6 166 Nil Nil FPC Bilateral 
Calculi 
Good 
AT 9200 60 32 4 1 3 15 100 25 0.4 154 Nil Nil Nil 
20 3287 Manikandan/54/M BT 9000 58 34 6 10 22 9.5 173 30 0.7 187 Nil Nil FPC unilateral 
calculi 
Moderate  
AT 9200 64 31 4 7 14 10 165 27 0.6 179 Nil Nil Nil 
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O 
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21 3991 Geethanjali/32/F BT 8600 52 36 4 11 25 10 154 25 0.7 126 Nil Nil FPC Bilateral 
calculi 
Good 
AT 8950 56 32 2 5 10 10.5 148 22 0.5 111 Nil Nil Nil 
22 4960 Iyasamy/47/M BT 9400 61 38 1 10 20 12 102 27 0.6 162 Nil Nil FPC Unilateral 
calculi 
Good 
AT 9700 65 31 1 6 12 13 99 23 0.4 156 Nil Nil Nil 
23 5851 Revathi/40/F BT 8800 50 36 4 15 20 10.8 110 23 0.6 156 Nil Nil FPC unilateral 
calculi 
Mild  
AT 9100 56 31 2 12 20 11 102 22 0.5 152 Nil Nil Nil 
24 6904 Jagan/26/M BT 9200 57 39 4 2 3 13 90 25 0.7 168 Nil Nil FPC Bilateral 
calculi 
Good 
AT 9600 60 33 2 1 2 14 85 22 0.4 154 Nil Nil Nil 
25 5243 Senthamarai/38/F BT 9400 55 42 3 4 8 10 117 26 0.8 155 Nil Nil FEC Uretric 
calculi 
Good 
AT 9600 58 45 1 3 9 10 100 22 0.5 145 Nil Nil Nil 
26 6783 Kannammal/49/F BT 8800 57 36 7 12 20 10 105 25 0.8 156 Nil Nil FPC Bilateral 
calculi 
Good 
AT 8900 62 30 5 10 22 11 95 22 0.4 144 Nil Nil Nil 
27 7456 Thamayanthi/56/F BT 9500 65 35 3 5 12 12 168 26 0.7 167 Nil Nil Nil Bilateral 
calculi 
Moderate  
AT 9800 69 31 1 4 8 13 156 25 0.5 158 Nil Nil Nil 
28 8736 Manimaran/50/M BT 10700 67 28 5 23 60 12 118 31 0.7 178 Nil Nil FPC Bilateral 
calculi 
Good 
AT 10800 70 23 2 10 30 13 88 24 0.5 162 Nil Nil Nil 
29 9990 Venkatesh/37/M BT 10200 60 34 6 8 21 10.8 88 34 0.4 179 Nil Nil FPC Bilateral 
calculi 
Good 
AT 10600 65 30 3 5 10 11 80 31 0.3 166 Nil Nil Nil 
30 1194 Malliga/34/F BT 9400 57 38 5 23 54 8 99 29 0.6 165 Nil Nil FEC unilateral 
calculi 
Good 
AT 9700 61 32 2 10 20 10 100 25 0.4 157 Nil Nil Nil 
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31 3981 Azhagan/37/M BT 9200 62 35 3 12 34 12.5 119 33 0.7 130 Nil Nil FPC Bilateral 
calculi 
Good 
AT 9600 65 31 1 10 32 12 97 30 0.4 122 Nil Nil Nil 
32 6198 Meiyappan/42/M BT 9400 52 38 2 15 30 12 126 30 0.8 176 Nil Nil FEC Bilateral 
calculi 
Good 
AT 9600 54 34 1 10 22 12.9 120 24 0.6 171 Nil Nil Nil 
33 7123 Sugunya/44/F BT 10600 63 32 5 25 56 10 99 30 0.7 184 Nil Nil FPC unilateral 
calculi 
Good 
AT 10900 66 27 2 23 60 11 80 24 0.5 175 Nil Nil Nil 
34 8795 Santhanam/30/M BT 10200 63 31 6 12 30 11 97 29 0.7 162 Nil Nil FPC Bilateral 
calculi 
Poor  
AT 10600 65 25 4 9 20 10 90 28 0.7 153 Nil Nil Nil 
35 9853 Guna /48/M BT 9200 52 36 7 12 20 12 126 30 0.6 180 Nil Nil FPC Bilateral 
calculi 
Good 
AT 9600 59 31 5 5 10 12 120 24 0.3 174 Nil Nil Nil 
36 9747 Kurinji/50/F BT 8400 52 43 5 13 20 12 130 20 0.8 158 Nil Nil Nil Bilateral 
calculi 
Good 
AT 8900 56 41 2 8 15 13 115 15 0.4 147 Nil Nil Nil 
37 2433 Vennilla/39/F BT 8200 59 36 5 20 40 9.5 82 27 0.6 140 Nil Nil FPC unilateral 
calculi 
Good 
AT 8400 64 34 2 15 30 10 76 24 0.3 131 Nil Nil Nil 
38 4562 Kaliraj/60/M BT 10000 58 36 5 7 12 13.2 99 25 0.5 170 Nil Nil FPC unilateral 
calculi 
Moderate  
AT 10300 62 32 2 6 10 14 100 22 0.3 162 Nil Nil Nil 
39 5500 Chinnadhurai/36/M BT 8200 53 40 8 7 16 12 128 25 0.4 170 Nil Nil FPC Bilateral 
Calculi 
Good 
AT 8400 61 35 5 4 8 13 115 20 0.3 161 Nil Nil Nil 
40 8010 Kannan/36/M BT 7300 53 44 4 20 40 8.6 83 19 0.6 165 Nil Nil Nil Bilateral 
calculi 
 
Good 
AT 7900 62 36 3 10 20 9 75 15 0.3 156 Nil Nil Nil 
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41 946/
3611 
Kalaivani/53/F BT 8600 52 42 5 10 20 11 123 27 0.5 155 Nil Nil FPC Bilateral 
calculi 
Good 
AT 9300 54 45 3 4 10 12 120 20 0.3 157 Nil Nil Nil 
42 995/
4945 
Selvaraj/55/M BT 9600 53 38 3 7 14 10.8 126 24 0.6 166 Nil Nil FPC Bilateral 
calculi 
Good 
AT 9900 50 35 1 5 10 11 133 24 0.5 177 Nil Nil Nil 
43 1073
/669
3 
Pattammal/51/F BT 8800 57 44 2 8 16 10 88 29 0.7 174 Nil Nil FPC unilateral 
calculi 
Good 
AT 9200 56 35 4 5 10 11 89 25 0.4 176 Nil Nil Nil 
44 1107
/776
3 
Charles/29/M BT 10200 63 31 6 12 30 11 97 29 0.7 162 Nil Nil FPC Bilateral 
calculi 
Good 
AT 10300 65 25 4 12 20 12 90 22 0.4 155 Nil Nil Nil 
45 1244
/171
9 
Panneerselvan/45/
M 
BT 8200 55 38 7 12 24 9.8 136 30 0.5 188 Nil Nil FPC Bilateral 
calculi 
Mild  
AT 8800 52 43 6 12 32 12 120 28 0.4 175 Nil Nil Nil 
46 1299
/343
2 
Chandhrammal/45/
F 
BT 8600 61 36 2 8 16 11.2 143 24 0.7 156 Nil Nil Nil Bilateral 
calculi 
Good 
AT 8900 56 41 2 4 8 12 115 16 0.4 159 Nil Nil Nil 
47 1295
/328
2 
Prabakaran/33/M BT 8500 58 42 4 10 20 9.5 88 26 0.3 144 Nil Nil FPC unilateral 
calculi 
Good 
AT 9200 61 35 2 2 4 12.6 77 24 0.3 179 Nil Nil Nil 
48 1262
/122
4 
Padmanaban/55/M BT 10000 53 37 4 7 14 12 99 25 0.4 170 Nil Nil FPC unilateral 
calculi 
Good 
AT 10200 62 32 2 5 10 14 90 21 0.3 162 Nil Nil Nil 
49 150/
4077 
Narasimaprasath/37
/M 
BT 8200 52 40 8 7 3 6 140 26 0.5 177 Nil Nil FPC Bilateral 
Calculi 
Good 
AT 8600 61 36 4 4 8 7.6 135 25 0.8 166 Nil Nil Nil 
50 212/
6186 
Kannan/38/M BT 8400 63 42 2 10 20 9 122 19 0.6 166 Nil Nil Nil Bilateral 
calculi 
 
Good 
AT 8600 65 45 3 11 28 10 130 18 0.4 171  Nil   Nil   Nil 
 
